MeSH term
Frequency | Condition_Probility | *Cleavage Stage, Ovum | 5 | 4.0 |
Embryo Transfer/*standards | 5 | 4.0 |
Female | 2254 | 2.0 |
Humans | 4856 | 2.0 |
Meta-Analysis | 5 | 3.0 |
Pregnancy | 191 | 3.0 |
Pregnancy Outcome | 9 | 3.0 |
Pregnancy Rate | 5 | 3.0 |
Pregnancy, Multiple | 7 | 4.0 |
Randomized Controlled Trials | 12 | 2.0 |
Review Literature | 5 | 3.0 |
Acute Disease | 56 | 2.0 |
Adult | 1256 | 2.0 |
Bone Marrow Transplantation/*statistics & numerical data | 3 | 3.0 |
Comparative Study | 441 | 1.0 |
Cord Blood Stem Cell Transplantation/*statistics & numerical data | 3 | 3.0 |
Fetal Blood/transplantation | 3 | 3.0 |
Leukemia/*therapy | 3 | 2.0 |
Patient Selection | 7 | 3.0 |
Animals | 1652 | 2.0 |
*Computational Biology | 2 | 3.0 |
Oligonucleotide Array Sequence Analysis | 32 | 3.0 |
Adolescent | 202 | 1.0 |
Empyema, Tuberculous/*diagnosis/radiography | 2 | 25.0 |
Lung/radiography | 3 | 11.0 |
Male | 1735 | 2.0 |
Mycobacterium tuberculosis/isolation & purification | 2 | 9.0 |
Pleural Effusion/microbiology | 2 | 25.0 |
Tomography, X-Ray Computed | 25 | 3.0 |
*Stem Cells | 2 | 15.0 |
Cell Culture Techniques | 23 | 5.0 |
Cell Differentiation/*physiology | 5 | 2.0 |
Stem Cells/*physiology | 4 | 6.0 |
Antihypertensive Agents/therapeutic use | 3 | 3.0 |
Blood Glucose/metabolism | 6 | 0.0 |
Diabetes Mellitus, Type 2/*epidemiology/prevention & control | 2 | 7.0 |
*Diet, Reducing | 2 | 2.0 |
*Exercise | 7 | 5.0 |
Incidence | 7 | 0.0 |
Middle Aged | 1416 | 2.0 |
Reference Values | 111 | 2.0 |
Risk Factors | 70 | 1.0 |
Smoking/adverse effects | 2 | 0.0 |
*Smoking Cessation | 4 | 10.0 |
United States/epidemiology | 8 | 2.0 |
Weight Loss | 4 | 2.0 |
Albumins/metabolism | 5 | 3.0 |
Albuminuria/*prevention & control | 3 | 3.0 |
Antihypertensive Agents/*therapeutic use | 7 | 3.0 |
Diabetes Mellitus, Type 2/complications/*drug therapy | 3 | 3.0 |
Hypertension/complications/*drug therapy | 3 | 2.0 |
Indoles/*therapeutic use | 13 | 9.0 |
Renin-Angiotensin System/*drug effects | 3 | 2.0 |
Aged | 1131 | 3.0 |
Cardiac Output, Low/*mortality | 2 | 3.0 |
Coronary Arteriosclerosis/mortality | 2 | 3.0 |
Risk | 15 | 1.0 |
Surgical Procedures, Elective/*mortality | 2 | 3.0 |
Time Factors | 315 | 3.0 |
Aged, 80 and over | 444 | 4.0 |
Fatal Outcome | 7 | 1.0 |
Magnetic Resonance Imaging | 28 | 2.0 |
Mutation | 62 | 0.0 |
Child | 117 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 939 | 1.0 |
*Colorectal Neoplasms/diagnosis/metabolism/pathology/therapy | 2 | 3.0 |
Biopsy | 45 | 2.0 |
*Gene Expression | 41 | 3.0 |
*Aging | 5 | 3.0 |
Cohort Studies | 44 | 1.0 |
Confounding Factors (Epidemiology) | 2 | 3.0 |
Epidemiologic Methods | 2 | 3.0 |
*War | 2 | 6.0 |
Cooperative Behavior | 2 | 15.0 |
History, 20th Century | 5 | 3.0 |
United States | 10 | 1.0 |
Chloramphenicol O-Acetyltransferase/metabolism | 3 | 2.0 |
Disease Susceptibility | 2 | 0.0 |
Genes, Reporter | 36 | 1.0 |
Genotype | 22 | 0.0 |
Luciferases/metabolism | 22 | 3.0 |
Models, Biological | 79 | 2.0 |
Odds Ratio | 10 | 0.0 |
Phenotype | 45 | 0.0 |
Polymorphism, Genetic | 7 | 0.0 |
*Smoking | 2 | 2.0 |
*Tumor Markers, Biological | 10 | 5.0 |
Ultraviolet Rays | 6 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 373 | 9.0 |
Vascular Endothelial Growth Factor A/*blood | 102 | 99.0 |
Bronchoalveolar Lavage Fluid/*chemistry | 8 | 14.0 |
Epithelium/metabolism | 13 | 3.0 |
Research Support, Non-U.S. Gov't | 2801 | 2.0 |
Reverse Transcriptase Polymerase Chain Reaction | 370 | 5.0 |
Vascular Endothelial Growth Factor A/*metabolism | 126 | 94.0 |
Vascular Endothelial Growth Factor Receptor-1/*metabolism | 11 | 91.0 |
Forced Expiratory Volume/physiology | 3 | 8.0 |
Immunohistochemistry | 801 | 6.0 |
Muscle, Smooth, Vascular/metabolism | 9 | 15.0 |
Neovascularization, Pathologic | 226 | 58.0 |
Vascular Endothelial Growth Factor Receptor-2/*metabolism | 16 | 76.0 |
Vital Capacity/physiology | 2 | 10.0 |
Breast Neoplasms/*metabolism/pathology | 11 | 5.0 |
Cell Movement | 61 | 7.0 |
Down-Regulation | 61 | 3.0 |
Enzyme Inhibitors/pharmacology | 120 | 4.0 |
Gelatinase B/*metabolism | 6 | 18.0 |
Mice | 836 | 2.0 |
Mice, Inbred BALB C | 147 | 5.0 |
Neoplasm Invasiveness | 124 | 10.0 |
Phosphorylation | 152 | 1.0 |
Signal Transduction | 149 | 2.0 |
Transforming Growth Factor beta/pharmacology | 15 | 4.0 |
Tumor Cells, Cultured | 575 | 3.0 |
Urinary Plasminogen Activator/metabolism | 6 | 13.0 |
Vascular Endothelial Growth Factor A/metabolism | 93 | 77.0 |
*Catheter Ablation | 3 | 6.0 |
Prospective Studies | 96 | 2.0 |
Anoxia/*physiopathology | 11 | 26.0 |
Neovascularization, Pathologic/*genetics | 23 | 52.0 |
Signal Transduction/*physiology | 28 | 2.0 |
Ascites/metabolism | 3 | 42.0 |
Base Sequence | 217 | 0.0 |
Cell Line, Tumor | 141 | 5.0 |
Disease Models, Animal | 105 | 4.0 |
Mice, Nude | 270 | 14.0 |
Microcirculation/pathology | 55 | 58.0 |
Neoplasm Transplantation | 168 | 14.0 |
Transplantation, Heterologous | 104 | 11.0 |
Vascular Endothelial Growth Factor A/*antagonists & | 8 | 100.0 |
Genes, Dominant | 13 | 1.0 |
Heterozygote | 5 | 0.0 |
Fibroblast Growth Factor 2/*metabolism | 20 | 37.0 |
Glucuronidase/*metabolism | 2 | 33.0 |
Immunoenzyme Techniques | 181 | 5.0 |
Interleukin-8/genetics/metabolism | 2 | 9.0 |
RNA, Messenger/genetics/metabolism | 80 | 3.0 |
Receptors, Vascular Endothelial Growth Factor/genetics/metabolism | 5 | 100.0 |
Vascular Endothelial Growth Factor A/genetics/metabolism | 23 | 92.0 |
Cell Movement/*drug effects | 18 | 19.0 |
Cell Proliferation/*drug effects | 3 | 16.0 |
Cells, Cultured | 706 | 4.0 |
Endothelial Cells/*drug effects | 5 | 62.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 25 | 6.0 |
Mitogen-Activated Protein Kinase 3/metabolism | 2 | 5.0 |
Vascular Endothelial Growth Factor A/metabolism/*pharmacology | 4 | 100.0 |
p38 Mitogen-Activated Protein Kinases/metabolism | 3 | 10.0 |
Cell Survival/*physiology | 3 | 5.0 |
Flow Cytometry | 70 | 1.0 |
Stem Cells/*cytology | 5 | 5.0 |
Transfection/methods | 7 | 5.0 |
*Persistent Vegetative State/rehabilitation | 2 | 16.0 |
Diagnosis, Differential | 25 | 1.0 |
Aging/metabolism | 4 | 2.0 |
Alcohol Drinking | 2 | 1.0 |
Antioxidants/pharmacology | 9 | 4.0 |
Sex Factors | 14 | 0.0 |
*Genome | 2 | 1.0 |
DNA Primers/chemistry | 39 | 3.0 |
Menstrual Cycle/metabolism | 5 | 22.0 |
RNA, Messenger/metabolism | 268 | 6.0 |
Vascular Endothelial Growth Factor A/*genetics/metabolism | 11 | 100.0 |
Vascular Endothelial Growth Factor C/*genetics/metabolism | 2 | 100.0 |
*Adaptation, Physiological | 2 | 3.0 |
Anemia, Sickle Cell/*metabolism/pathology | 2 | 100.0 |
Anoxia/*metabolism/physiopathology | 2 | 66.0 |
Antigens, CD31/metabolism | 35 | 47.0 |
Biological Markers/analysis | 38 | 4.0 |
Endothelium, Vascular/metabolism/pathology | 13 | 25.0 |
Fetal Blood/metabolism | 3 | 4.0 |
Homeostasis | 8 | 2.0 |
Umbilical Cord/blood supply | 2 | 40.0 |
Proto-Oncogene Proteins c-myc/*metabolism | 4 | 4.0 |
Tumor Markers, Biological/*metabolism | 36 | 8.0 |
Phylogeny | 5 | 0.0 |
Angiogenesis Inhibitors/therapeutic use | 24 | 77.0 |
Neoplasms/blood supply/drug therapy | 4 | 66.0 |
Neovascularization, Physiologic/*physiology | 82 | 68.0 |
Blood Vessels/pathology | 13 | 32.0 |
Cell Count | 41 | 4.0 |
Child, Preschool | 77 | 0.0 |
Infant | 56 | 0.0 |
Microcirculation | 108 | 41.0 |
Mitosis | 4 | 0.0 |
Multivariate Analysis | 83 | 6.0 |
Neovascularization, Pathologic/metabolism/*pathology | 19 | 51.0 |
Prognosis | 497 | 7.0 |
Retrospective Studies | 119 | 3.0 |
Survival Analysis | 155 | 7.0 |
Blood Vessels/enzymology | 2 | 40.0 |
Gene Expression Regulation, Neoplastic/physiology | 8 | 5.0 |
Isoenzymes/*biosynthesis | 13 | 20.0 |
Prostaglandin-Endoperoxide Synthase/*biosynthesis | 13 | 30.0 |
Antigens, CD34/metabolism | 23 | 8.0 |
Carcinoma, Hepatocellular/*blood supply/metabolism | 2 | 66.0 |
Endothelium, Vascular/pathology | 31 | 28.0 |
Fibroblast Growth Factor 2/metabolism | 42 | 42.0 |
Liver Neoplasms/*blood supply/metabolism | 2 | 66.0 |
Proliferating Cell Nuclear Antigen/metabolism | 18 | 8.0 |
Analysis of Variance | 88 | 4.0 |
Cadherins/*analysis | 2 | 9.0 |
Disease-Free Survival | 84 | 9.0 |
Gene Expression Regulation, Neoplastic | 125 | 5.0 |
Logistic Models | 14 | 1.0 |
Lymphatic Metastasis | 119 | 11.0 |
Protein p53/analysis | 21 | 7.0 |
Receptor, erbB-2/analysis | 4 | 4.0 |
Receptors, Estrogen/analysis | 9 | 2.0 |
Receptors, Progesterone/analysis | 4 | 1.0 |
Risk Assessment | 18 | 2.0 |
Transcription Factors/analysis | 5 | 6.0 |
Tumor Markers, Biological/*analysis | 62 | 6.0 |
Vascular Endothelial Growth Factor A/analysis | 35 | 94.0 |
Cell Line | 225 | 1.0 |
Cyclooxygenase Inhibitors/pharmacology | 12 | 17.0 |
Cytosol/enzymology | 2 | 1.0 |
Gene Expression | 155 | 2.0 |
Indoles/pharmacology | 19 | 8.0 |
Interleukin-1/pharmacology | 23 | 3.0 |
Nitrobenzenes/pharmacology | 6 | 24.0 |
Prostaglandin-Endoperoxide Synthase/*metabolism | 19 | 30.0 |
Pyrazoles/pharmacology | 4 | 8.0 |
Sulfonamides/pharmacology | 12 | 11.0 |
Antigens, CD34/analysis | 31 | 4.0 |
Bone Marrow/blood supply/chemistry/pathology | 2 | 100.0 |
L-Lactate Dehydrogenase/blood | 2 | 1.0 |
Multiple Myeloma/*metabolism | 3 | 11.0 |
Neovascularization, Pathologic/pathology | 37 | 62.0 |
Plasma Cells/pathology | 4 | 10.0 |
Survival Rate | 138 | 6.0 |
Vascular Endothelial Growth Factor A/*analysis | 34 | 94.0 |
Astrocytoma/blood supply/*pathology | 2 | 100.0 |
Brain Neoplasms/blood supply/*pathology | 3 | 75.0 |
Neovascularization, Pathologic/*metabolism/*pathology | 4 | 100.0 |
Chronic Disease | 39 | 2.0 |
Neovascularization, Pathologic/*metabolism/pathology | 31 | 75.0 |
Phosphoric Monoester Hydrolases/*metabolism | 4 | 4.0 |
Stomach Neoplasms/blood supply/*metabolism/pathology | 5 | 83.0 |
Tumor Suppressor Proteins/*metabolism | 5 | 5.0 |
Adenocarcinoma/blood/pathology | 2 | 33.0 |
Carcinoma, Squamous Cell/blood/pathology | 2 | 33.0 |
Fibroblast Growth Factor 2/*blood | 48 | 94.0 |
Immunoassay | 5 | 2.0 |
Neoplasm Staging | 206 | 8.0 |
Aorta/pathology | 2 | 5.0 |
Bone Morphogenetic Proteins/metabolism | 3 | 5.0 |
Cattle | 123 | 4.0 |
Cell Proliferation | 14 | 8.0 |
Collagen/chemistry | 4 | 23.0 |
Dose-Response Relationship, Drug | 219 | 3.0 |
Drug Combinations | 48 | 9.0 |
Endothelial Cells/*metabolism | 8 | 26.0 |
Extracellular Matrix Proteins/metabolism/*physiology | 2 | 100.0 |
Immunoblotting | 44 | 1.0 |
Immunoprecipitation | 6 | 2.0 |
Laminin/chemistry | 4 | 33.0 |
Plasmids/metabolism | 19 | 1.0 |
Proteoglycans/chemistry | 4 | 33.0 |
Transfection | 257 | 2.0 |
Transforming Growth Factor beta/*metabolism | 12 | 5.0 |
Angiogenesis Inhibitors/*therapeutic use | 50 | 73.0 |
Neoplasms/*blood supply/drug therapy | 6 | 66.0 |
Neovascularization, Pathologic/*drug therapy | 31 | 75.0 |
Platelet-Derived Growth Factor/*antagonists & inhibitors | 2 | 50.0 |
Tumor Markers, Biological/blood | 27 | 17.0 |
Vascular Endothelial Growth Factor A/*antagonists & inhibitors | 13 | 100.0 |
Anti-Inflammatory Agents/therapeutic use | 4 | 4.0 |
English Abstract | 307 | 2.0 |
Follow-Up Studies | 88 | 2.0 |
Pilot Projects | 15 | 2.0 |
Ultrasonography, Doppler | 5 | 18.0 |
Adenosine Triphosphate/metabolism | 3 | 0.0 |
Binding Sites/genetics | 6 | 0.0 |
Hydrolysis | 4 | 0.0 |
Ki-67 Antigen/analysis | 15 | 5.0 |
Endothelial Growth Factors/*biosynthesis/genetics | 122 | 97.0 |
Lymphokines/*biosynthesis/genetics | 115 | 89.0 |
Neuroblastoma/*metabolism | 2 | 3.0 |
Receptor Protein-Tyrosine Kinases/*biosynthesis/genetics | 10 | 28.0 |
Receptors, Growth Factor/*biosynthesis/genetics | 9 | 60.0 |
Receptors, Vascular Endothelial Growth Factor | 482 | 89.0 |
Vascular Endothelial Growth Factor A | 3172 | 93.0 |
Vascular Endothelial Growth Factors | 3158 | 93.0 |
Carcinoma, Squamous Cell/*blood supply | 2 | 50.0 |
Endothelial Growth Factors/secretion | 9 | 75.0 |
Interleukin-8/secretion | 3 | 7.0 |
Lymphokines/secretion | 9 | 23.0 |
Macrophage Activation | 4 | 2.0 |
Monocytes/physiology | 4 | 3.0 |
Neovascularization, Pathologic/*etiology | 30 | 73.0 |
Tretinoin/*pharmacology | 2 | 0.0 |
Cytokines/*blood | 11 | 3.0 |
Statistics | 27 | 5.0 |
Flavonoids/*pharmacology | 2 | 2.0 |
Gene Expression/drug effects | 33 | 4.0 |
Iron Chelating Agents/pharmacology | 5 | 20.0 |
Lymphokines/antagonists & inhibitors/*biosynthesis/genetics | 3 | 100.0 |
Piperidines/*pharmacology | 6 | 10.0 |
RNA, Messenger/analysis | 208 | 6.0 |
Anti-Inflammatory Agents/*pharmacology | 2 | 2.0 |
Biocompatible Materials | 4 | 6.0 |
Dexamethasone/*pharmacology | 3 | 1.0 |
Endothelial Growth Factors/metabolism | 164 | 84.0 |
Gelatinase A/metabolism | 14 | 23.0 |
Gelatinase B/metabolism | 9 | 15.0 |
Hyaluronic Acid/*pharmacology | 3 | 9.0 |
Intercellular Signaling Peptides and Proteins/metabolism | 46 | 59.0 |
Interleukin-6/metabolism | 7 | 3.0 |
Lipopolysaccharides/pharmacology | 14 | 1.0 |
Lymphokines/metabolism | 162 | 72.0 |
Nitric Oxide/metabolism | 16 | 9.0 |
Nitrites/metabolism | 4 | 9.0 |
Peritoneum | 2 | 22.0 |
Wound Healing/physiology | 9 | 15.0 |
Endothelial Growth Factors/*metabolism | 363 | 97.0 |
Lymph Nodes/pathology | 17 | 5.0 |
Receptor, erbB-2/*metabolism | 7 | 4.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 150 | 1.0 |
Vascular Endothelial Growth Factor C | 63 | 88.0 |
Vascular Endothelial Growth Factor D | 13 | 81.0 |
Carcinoma, Renal Cell/*genetics | 2 | 2.0 |
Endothelial Growth Factors/*genetics | 162 | 95.0 |
Kidney Neoplasms/*genetics | 2 | 0.0 |
Ligases/*genetics | 3 | 2.0 |
Lymphokines/*genetics | 158 | 76.0 |
RNA, Messenger/*analysis | 31 | 7.0 |
*Tumor Suppressor Proteins | 20 | 1.0 |
*Ubiquitin-Protein Ligases | 17 | 3.0 |
Antirheumatic Agents/*pharmacology | 3 | 21.0 |
Cyclic AMP/metabolism | 12 | 2.0 |
Cyclosporine/*pharmacology | 2 | 1.0 |
Down-Regulation/drug effects | 9 | 3.0 |
Immunosuppressive Agents/pharmacology | 2 | 1.0 |
Protein Binding/drug effects | 8 | 2.0 |
Synovial Membrane/*cytology | 2 | 25.0 |
Transcription Factor AP-1/metabolism | 17 | 6.0 |
Intercellular Signaling Peptides and Proteins/*metabolism | 64 | 64.0 |
Lymphokines/*metabolism | 347 | 85.0 |
Receptors, Vascular Endothelial Growth Factor/*metabolism | 13 | 100.0 |
*Drosophila Proteins | 2 | 0.0 |
Proto-Oncogene Proteins/*genetics | 14 | 1.0 |
Receptor Protein-Tyrosine Kinases/*genetics | 30 | 7.0 |
Aorta/cytology | 13 | 16.0 |
Binding Sites | 58 | 0.0 |
Collagenases/metabolism | 3 | 8.0 |
DNA, Complementary/metabolism | 25 | 1.0 |
Endothelium, Vascular/cytology | 75 | 31.0 |
Interstitial Collagenase/metabolism | 4 | 16.0 |
Matrilysin/metabolism | 2 | 40.0 |
Matrix Metalloproteinases/*metabolism | 4 | 10.0 |
*Neovascularization, Pathologic | 255 | 67.0 |
*Neovascularization, Physiologic | 124 | 70.0 |
Plasmin/metabolism | 3 | 3.0 |
Protein Binding | 95 | 1.0 |
Recombinant Proteins/metabolism | 44 | 1.0 |
Alternative Splicing | 30 | 2.0 |
Cell Differentiation | 55 | 1.0 |
Disease Progression | 181 | 6.0 |
Endothelial Growth Factors/*genetics/metabolism | 42 | 95.0 |
In Vitro | 87 | 1.0 |
Intercellular Signaling Peptides and Proteins/*genetics/metabolism | 8 | 53.0 |
Lymphokines/*genetics/metabolism | 39 | 90.0 |
Protein Isoforms | 51 | 7.0 |
RNA, Neoplasm/metabolism | 7 | 7.0 |
Tumor Cells, Cultured/metabolism | 4 | 2.0 |
Blood Platelets/drug effects/metabolism | 2 | 4.0 |
Cell Movement/drug effects | 61 | 16.0 |
Endothelial Growth Factors/chemistry/*metabolism | 4 | 100.0 |
Endothelium, Vascular/cytology/drug effects/*metabolism | 14 | 15.0 |
Enzyme Activation | 59 | 1.0 |
Lymphokines/chemistry/*metabolism | 4 | 66.0 |
Mitogen-Activated Protein Kinases/metabolism | 59 | 5.0 |
Peptide Fragments/pharmacology | 4 | 1.0 |
Proto-Oncogene Proteins/metabolism | 65 | 5.0 |
Receptor Protein-Tyrosine Kinases/metabolism | 81 | 32.0 |
Receptors, Vitronectin/metabolism | 5 | 27.0 |
Thrombin/pharmacology | 12 | 5.0 |
Vascular Endothelial Growth Factor Receptor-1 | 188 | 89.0 |
Vitronectin/pharmacology | 2 | 20.0 |
Endothelial Growth Factors/*biosynthesis | 170 | 96.0 |
Fibroblast Growth Factor 2/biosynthesis | 18 | 66.0 |
Lymphokines/*biosynthesis | 163 | 61.0 |
Endothelial Growth Factors/*blood | 283 | 99.0 |
Intercellular Signaling Peptides and Proteins/*blood | 61 | 93.0 |
Lymphokines/*blood | 278 | 94.0 |
*Platelet Count | 6 | 18.0 |
Angiogenesis Inhibitors/adverse effects/*therapeutic use | 7 | 100.0 |
Clinical Trials | 34 | 3.0 |
Neoplasms/blood supply/*drug therapy | 2 | 66.0 |
Capillary Permeability | 48 | 55.0 |
Cell Hypoxia | 62 | 40.0 |
Glucose/*metabolism | 4 | 2.0 |
Glycosylation End Products, Advanced/metabolism | 5 | 31.0 |
Rats | 357 | 2.0 |
Reactive Oxygen Species/metabolism | 20 | 6.0 |
Sorbitol/metabolism | 3 | 25.0 |
Case-Control Studies | 159 | 3.0 |
Endothelium, Vascular/physiology | 10 | 15.0 |
Leg/*blood supply | 8 | 25.0 |
Protein Isoforms/blood | 7 | 30.0 |
Neovascularization, Physiologic/drug effects/*physiology | 21 | 51.0 |
Actins/analysis | 10 | 5.0 |
Angiogenesis Inducing Agents/analysis | 6 | 100.0 |
Bone Marrow/pathology | 12 | 3.0 |
Endothelial Growth Factors/analysis | 67 | 83.0 |
Lymphokines/analysis | 68 | 71.0 |
Mouth Mucosa/pathology | 2 | 8.0 |
Muscle, Smooth/pathology | 2 | 9.0 |
Neoplasm Proteins/analysis | 8 | 2.0 |
Proliferating Cell Nuclear Antigen/analysis | 25 | 10.0 |
Protein Isoforms/analysis | 12 | 28.0 |
Ribonuclease, Pancreatic/analysis | 2 | 100.0 |
von Willebrand Factor/analysis | 30 | 9.0 |
Interleukins/*physiology | 2 | 6.0 |
Dinoprostone/biosynthesis | 6 | 10.0 |
Endothelial Growth Factors/*pharmacology | 136 | 93.0 |
Endothelium, Vascular/cytology/*metabolism | 27 | 15.0 |
Isoenzymes/genetics/*metabolism | 3 | 3.0 |
Lymphokines/*pharmacology | 134 | 51.0 |
Promoter Regions (Genetics)/drug effects/genetics | 2 | 6.0 |
Prostaglandin-Endoperoxide Synthase/genetics/*metabolism | 3 | 13.0 |
Up-Regulation | 170 | 7.0 |
Endothelial Growth Factors/blood/genetics/*metabolism | 3 | 100.0 |
Estradiol/blood/metabolism | 2 | 20.0 |
Follicular Fluid/metabolism | 5 | 38.0 |
Insulin-Like Growth Factor II/metabolism | 2 | 7.0 |
Lymphokines/blood/genetics/*metabolism | 3 | 100.0 |
Anti-Inflammatory Agents/pharmacology | 5 | 8.0 |
Cycloheximide/pharmacology | 18 | 2.0 |
Deferoxamine/pharmacology | 7 | 16.0 |
Dexamethasone/pharmacology | 17 | 3.0 |
Endothelial Growth Factors/*genetics/*metabolism | 12 | 85.0 |
Gene Expression Regulation/drug effects/physiology | 4 | 6.0 |
Protein Synthesis Inhibitors/pharmacology | 14 | 3.0 |
RNA, Messenger/drug effects/metabolism | 11 | 7.0 |
Apoptosis | 57 | 3.0 |
Breast Neoplasms/metabolism | 6 | 4.0 |
Cell Survival | 34 | 3.0 |
Cytoplasm/metabolism | 10 | 1.0 |
Eukaryotic Initiation Factor-4E | 7 | 5.0 |
*Gene Expression Regulation, Neoplastic | 76 | 5.0 |
Integrins/*metabolism | 5 | 3.0 |
Oligonucleotides, Antisense/pharmacology | 12 | 4.0 |
Protein Structure, Tertiary | 33 | 0.0 |
Protein Transport | 8 | 1.0 |
Endothelial Growth Factors/metabolism/*secretion | 2 | 100.0 |
Epidermal Growth Factor/pharmacology | 17 | 2.0 |
Infant, Newborn | 74 | 1.0 |
Intercellular Signaling Peptides and Proteins/metabolism/*secretion | 2 | 100.0 |
Interferon Type II/*pharmacology | 6 | 1.0 |
Interleukin-4/*pharmacology | 3 | 1.0 |
Kinetics | 83 | 1.0 |
Endothelial Growth Factors | 6 | 60.0 |
Enzyme Inhibitors/therapeutic use | 16 | 21.0 |
Intercellular Signaling Peptides and Proteins | 7 | 58.0 |
Lymphokines | 4 | 36.0 |
Protein-Tyrosine Kinase/drug effects | 2 | 50.0 |
Endothelial Growth Factors/*analysis | 148 | 97.0 |
Intercellular Signaling Peptides and Proteins/*analysis | 19 | 67.0 |
Lymphatic Metastasis/*diagnosis | 4 | 21.0 |
Lymphokines/*analysis | 139 | 85.0 |
Capillaries/drug effects/growth & development | 2 | 100.0 |
Cell Adhesion/drug effects | 21 | 4.0 |
Cell Division | 196 | 4.0 |
Chemotaxis | 10 | 5.0 |
Culture Media, Conditioned/chemistry/pharmacology | 4 | 44.0 |
Culture Techniques | 22 | 4.0 |
Endothelium, Vascular/cytology/drug effects/physiology | 8 | 57.0 |
Laminin/metabolism | 8 | 7.0 |
Neoplasms/*blood supply/metabolism/pathology | 4 | 80.0 |
Xenograft Model Antitumor Assays | 53 | 24.0 |
*Apoptosis | 25 | 1.0 |
Multiple Myeloma/blood supply/metabolism/*pathology | 2 | 66.0 |
Endothelial Growth Factors/*physiology | 94 | 94.0 |
Neoplasms/*metabolism/*pathology | 2 | 15.0 |
Neovascularization, Pathologic/*pathology | 55 | 52.0 |
Receptor Protein-Tyrosine Kinases/physiology | 18 | 40.0 |
Proportional Hazards Models | 34 | 5.0 |
Proto-Oncogene Proteins/*analysis | 7 | 4.0 |
Receptor Protein-Tyrosine Kinases/*analysis | 18 | 38.0 |
Receptors, Growth Factor/*analysis | 14 | 70.0 |
Angiopoietin-1 | 52 | 75.0 |
Cadherins/metabolism | 8 | 6.0 |
Cytoskeletal Proteins/metabolism | 9 | 3.0 |
Endothelium, Vascular/metabolism/*physiology | 2 | 25.0 |
Membrane Glycoproteins/analysis | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/analysis | 23 | 46.0 |
Receptors, Growth Factor/analysis | 20 | 74.0 |
*Trans-Activators | 5 | 0.0 |
Biocompatible Materials/pharmacology | 2 | 16.0 |
Blood Cell Count | 6 | 2.0 |
Body Weight/drug effects | 11 | 5.0 |
Collagen/pharmacology | 10 | 7.0 |
DNA/biosynthesis | 22 | 3.0 |
Laminin/pharmacology | 7 | 16.0 |
Lung Neoplasms/blood supply/*pathology | 3 | 60.0 |
Mice, Inbred C57BL | 113 | 3.0 |
Neoplasm Metastasis/prevention & control | 7 | 41.0 |
Neovascularization, Pathologic/prevention & control | 21 | 72.0 |
Organ Size/drug effects | 4 | 4.0 |
Proteoglycans/pharmacology | 9 | 22.0 |
Blotting, Northern | 155 | 3.0 |
Carcinoma, Renal Cell/genetics | 3 | 8.0 |
Gene Expression Profiling | 23 | 2.0 |
*Genes, Tumor Suppressor | 13 | 1.0 |
Hippel-Lindau Disease/*genetics | 6 | 4.0 |
Kidney Neoplasms/genetics | 3 | 4.0 |
Oxygen/pharmacology | 11 | 28.0 |
Endometriosis/*metabolism | 9 | 31.0 |
Endometrium/metabolism | 2 | 3.0 |
Thrombospondin 1/*genetics | 5 | 50.0 |
Adenoviridae/genetics/metabolism | 3 | 10.0 |
Angiography, Digital Subtraction | 2 | 18.0 |
Angioplasty, Balloon | 3 | 27.0 |
*Gene Therapy | 51 | 13.0 |
Ischemia/*therapy | 12 | 63.0 |
Neovascularization, Physiologic/drug effects | 46 | 64.0 |
Adrenal Cortex Hormones/therapeutic use | 5 | 7.0 |
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use | 4 | 8.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 23 | 4.0 |
Remission Induction | 10 | 1.0 |
Endothelial Growth Factors/pharmacology | 71 | 70.0 |
Hematopoietic Stem Cells/drug effects | 2 | 3.0 |
Hindlimb/blood supply | 11 | 44.0 |
Joints/pathology | 3 | 13.0 |
Lymphokines/pharmacology | 72 | 39.0 |
*Neovascularization, Physiologic/drug effects | 11 | 78.0 |
Receptor Protein-Tyrosine Kinases/*immunology/metabolism | 2 | 100.0 |
Receptors, Growth Factor/immunology/metabolism | 3 | 100.0 |
Recombinant Fusion Proteins/genetics/metabolism | 7 | 0.0 |
Immunohistochemistry/methods | 42 | 6.0 |
In Situ Hybridization | 163 | 5.0 |
Lymphatic Metastasis/diagnosis | 2 | 11.0 |
Neoplasm Proteins/*metabolism | 32 | 6.0 |
Receptor Protein-Tyrosine Kinases/*metabolism | 78 | 29.0 |
Receptors, Growth Factor/*metabolism | 70 | 65.0 |
Stomach Neoplasms/*metabolism/*pathology | 3 | 23.0 |
Vascular Endothelial Growth Factor Receptor-3 | 31 | 53.0 |
Adenocarcinoma/blood supply/metabolism/*pathology | 3 | 75.0 |
Gelatinase A/biosynthesis | 3 | 18.0 |
Gelatinase B/biosynthesis | 4 | 19.0 |
Lymphatic System/*pathology | 2 | 40.0 |
Receptor Protein-Tyrosine Kinases/biosynthesis | 14 | 45.0 |
Receptors, Growth Factor/biosynthesis | 18 | 64.0 |
Angiogenesis Inducing Agents/*analysis | 7 | 100.0 |
Capillaries/chemistry | 2 | 25.0 |
Endometrium/*blood supply | 5 | 83.0 |
Neovascularization, Physiologic | 101 | 66.0 |
*Vascular Endothelial Growth Factor A | 12 | 92.0 |
Vascular Endothelial Growth Factor B | 23 | 92.0 |
Vascular Endothelial Growth Factor Receptor-1/analysis | 8 | 88.0 |
Vascular Endothelial Growth Factor Receptor-2/analysis | 10 | 71.0 |
Vascular Endothelial Growth Factor Receptor-3/analysis | 2 | 66.0 |
Solubility | 45 | 3.0 |
Transduction, Genetic | 13 | 3.0 |
Animals, Newborn | 25 | 4.0 |
Neovascularization, Physiologic/*drug effects | 73 | 73.0 |
Platelet-Derived Growth Factor/*pharmacology | 12 | 12.0 |
RNA, Messenger/*genetics | 12 | 3.0 |
Rats, Sprague-Dawley | 112 | 4.0 |
Recombinant Proteins/pharmacology | 75 | 4.0 |
Transcription, Genetic/drug effects | 21 | 3.0 |
Lymphatic Metastasis/*physiopathology | 3 | 100.0 |
Lymphokines/*physiology | 90 | 71.0 |
Angiogenesis Inducing Agents/*physiology | 2 | 50.0 |
Angiogenesis Inducing Agents/physiology | 4 | 66.0 |
Gene Expression/physiology | 16 | 5.0 |
Inositol Phosphates/metabolism | 2 | 1.0 |
Plasmids | 16 | 1.0 |
Pregnancy Proteins/*physiology | 5 | 71.0 |
Receptors, Growth Factor/metabolism | 74 | 62.0 |
Retroviridae/genetics | 10 | 2.0 |
Signal Transduction/physiology | 32 | 3.0 |
3T3 Cells | 43 | 2.0 |
DNA-Binding Proteins/genetics/metabolism | 8 | 1.0 |
Dependovirus/*genetics | 6 | 7.0 |
Endothelial Growth Factors/genetics | 66 | 80.0 |
Erythropoietin/genetics | 5 | 35.0 |
Gene Therapy | 29 | 8.0 |
*Genetic Vectors | 21 | 6.0 |
Hela Cells | 19 | 0.0 |
Lac Operon | 10 | 8.0 |
Lymphokines/genetics | 64 | 74.0 |
Nuclear Proteins/genetics/metabolism | 5 | 2.0 |
*Transcription Factors | 66 | 4.0 |
Cholesterol/blood | 2 | 0.0 |
Coronary Disease/*blood | 2 | 3.0 |
Lipoproteins, LDL Cholesterol/blood | 2 | 0.0 |
Pyrroles/*pharmacology | 10 | 20.0 |
Cadherins/*biosynthesis | 4 | 12.0 |
Cell Communication | 8 | 2.0 |
Intercellular Signaling Peptides and Proteins/*biosynthesis | 27 | 84.0 |
Ovarian Neoplasms/*metabolism | 11 | 18.0 |
Antigens, CD31/genetics/metabolism | 2 | 66.0 |
Cell Survival/drug effects | 40 | 3.0 |
Endothelium, Vascular/cytology/drug effects | 37 | 56.0 |
Fibroblast Growth Factor 2/*pharmacology | 22 | 18.0 |
Intercellular Signaling Peptides and Proteins/*pharmacology | 18 | 62.0 |
Plasmids/genetics | 11 | 2.0 |
Liver Neoplasms/*metabolism/secondary | 2 | 33.0 |
Lymph Nodes/*pathology | 8 | 8.0 |
Macrophages/*pathology | 4 | 7.0 |
Blotting, Western | 231 | 3.0 |
Capillaries | 16 | 28.0 |
Coronary Vessels | 9 | 32.0 |
Endothelial Growth Factors/genetics/*metabolism | 90 | 96.0 |
Mice, Knockout | 42 | 1.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 20 | 7.0 |
*MAP Kinase Kinase Kinase 1 | 7 | 4.0 |
Prostatic Neoplasms | 3 | 5.0 |
Protein-Serine-Threonine Kinases/*metabolism | 11 | 1.0 |
Protein-Tyrosine Kinase/*metabolism | 12 | 1.0 |
Proto-Oncogene Proteins/*metabolism | 31 | 3.0 |
Reactive Oxygen Species/*metabolism | 4 | 2.0 |
Age Factors | 24 | 0.0 |
Biological Markers/blood | 42 | 3.0 |
Body Mass Index | 13 | 1.0 |
Positive-Pressure Respiration | 2 | 12.0 |
Predictive Value of Tests | 124 | 6.0 |
Severity of Illness Index | 44 | 3.0 |
Treatment Outcome | 126 | 3.0 |
Antineoplastic Agents/*pharmacology | 35 | 3.0 |
Antioxidants/*pharmacology | 4 | 3.0 |
Cell Division/drug effects | 206 | 5.0 |
Angiogenesis Inhibitors/*pharmacology | 58 | 65.0 |
Endothelial Growth Factors/antagonists & inhibitors/*metabolism | 2 | 66.0 |
Indoles/*pharmacology | 10 | 10.0 |
Lymphokines/antagonists & inhibitors/*metabolism | 2 | 66.0 |
Models, Animal | 25 | 10.0 |
Pneumonectomy | 4 | 21.0 |
Regional Blood Flow/drug effects | 6 | 5.0 |
Wound Healing/*drug effects | 5 | 11.0 |
Amino Acid Sequence | 136 | 0.0 |
Cloning, Molecular | 66 | 0.0 |
Endothelial Growth Factors/chemistry/*genetics | 3 | 100.0 |
*Gene Expression Profiling | 12 | 2.0 |
Intercellular Signaling Peptides and Proteins/chemistry/*genetics | 2 | 100.0 |
Lymphokines/chemistry/*genetics | 2 | 50.0 |
Molecular Sequence Data | 231 | 0.0 |
Sequence Alignment | 30 | 0.0 |
Sequence Homology, Amino Acid | 44 | 0.0 |
Multigene Family | 10 | 1.0 |
*Oligonucleotide Array Sequence Analysis | 5 | 2.0 |
Proliferating Cell Nuclear Antigen/genetics | 2 | 6.0 |
Protein-Tyrosine Kinase/*genetics/metabolism | 2 | 4.0 |
Tumor Markers, Biological | 25 | 5.0 |
Collagen/metabolism | 13 | 4.0 |
Gene Deletion | 14 | 0.0 |
Gene Transfer Techniques | 42 | 8.0 |
Green Fluorescent Proteins | 22 | 2.0 |
Hydrogen Peroxide/*pharmacology | 4 | 6.0 |
Keratinocytes/*metabolism | 5 | 5.0 |
Luminescent Proteins/metabolism | 8 | 2.0 |
Microscopy, Fluorescence | 31 | 1.0 |
NADPH Oxidase/metabolism | 5 | 10.0 |
Oxidants/*pharmacology | 2 | 8.0 |
Oxidation-Reduction | 16 | 1.0 |
Phosphotyrosine/metabolism | 9 | 2.0 |
Precipitin Tests | 30 | 1.0 |
Promoter Regions (Genetics) | 73 | 1.0 |
Ribonucleases/metabolism | 5 | 3.0 |
Skin/pathology | 4 | 1.0 |
*Skin Physiology | 2 | 5.0 |
Trans-Activation (Genetics) | 29 | 1.0 |
*Wound Healing | 9 | 17.0 |
rac1 GTP-Binding Protein/metabolism | 4 | 4.0 |
Cytokines/biosynthesis/*genetics | 2 | 11.0 |
Endothelial Growth Factors/biosynthesis/genetics | 20 | 80.0 |
Lymphokines/biosynthesis/genetics | 21 | 72.0 |
*Polymorphism, Single Nucleotide | 7 | 1.0 |
Tumor Necrosis Factor-alpha/biosynthesis/genetics | 2 | 3.0 |
Capillary Permeability/drug effects/*physiology | 6 | 60.0 |
Cornea/blood supply | 7 | 50.0 |
Endothelial Growth Factors/*antagonists & inhibitors/*physiology | 2 | 100.0 |
Endothelium, Vascular/cytology/drug effects/enzymology | 2 | 25.0 |
Lymphokines/*antagonists & inhibitors/*physiology | 2 | 100.0 |
Nitric Oxide/*metabolism | 24 | 18.0 |
Nitric-Oxide Synthase/physiology | 3 | 37.0 |
Umbilical Veins/cytology | 79 | 27.0 |
Isoenzymes/*metabolism | 22 | 7.0 |
Choroidal Neovascularization/etiology/*metabolism | 3 | 100.0 |
Endothelium, Vascular/metabolism | 58 | 24.0 |
Macular Degeneration/*complications | 2 | 66.0 |
Nitric-Oxide Synthase/*metabolism | 13 | 15.0 |
*Anoxia | 12 | 42.0 |
Carcinoma, Hepatocellular/pathology | 3 | 6.0 |
Endothelial Growth Factors/analysis/*biosynthesis | 21 | 100.0 |
Forensic Medicine/methods | 2 | 5.0 |
Ischemia | 4 | 23.0 |
Liver Neoplasms/pathology | 4 | 8.0 |
Lymphokines/analysis/*biosynthesis | 19 | 73.0 |
Regional Blood Flow | 16 | 13.0 |
Tissue Distribution | 46 | 1.0 |
Diabetic Retinopathy/etiology/*metabolism | 3 | 75.0 |
Gene Expression Regulation/*physiology | 11 | 3.0 |
Carcinoma, Squamous Cell/metabolism/*pathology | 2 | 7.0 |
Endothelium, Vascular/metabolism/*pathology | 5 | 27.0 |
Head and Neck Neoplasms/metabolism/*pathology | 2 | 28.0 |
Oligonucleotides, Antisense/*pharmacology | 5 | 5.0 |
Receptor, Epidermal Growth Factor/*genetics | 4 | 1.0 |
Angiogenesis Inhibitors/pharmacology | 21 | 58.0 |
Fluorescent Antibody Technique | 25 | 0.0 |
Mice, Inbred C3H | 13 | 2.0 |
Neoplasms, Experimental/*blood supply/pathology | 4 | 100.0 |
Phthalazines/pharmacology | 2 | 28.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 22 | 10.0 |
*Pyridines | 12 | 75.0 |
Coculture Techniques | 30 | 4.0 |
Endothelium, Vascular/*enzymology | 6 | 12.0 |
Muscle, Smooth, Vascular/*enzymology | 2 | 15.0 |
Nitric Oxide/*physiology | 14 | 18.0 |
Pulmonary Artery | 2 | 10.0 |
Lymphokines/genetics/*metabolism/pharmacology | 6 | 85.0 |
Anoxia | 28 | 36.0 |
Endothelium/*cytology | 6 | 28.0 |
*Eye Proteins | 18 | 11.0 |
MAP Kinase Signaling System | 10 | 3.0 |
Mitogen-Activated Protein Kinase 3 | 46 | 7.0 |
*Nerve Growth Factors | 20 | 10.0 |
Retina/metabolism | 10 | 15.0 |
Aorta, Thoracic | 2 | 22.0 |
Cell Survival/*drug effects | 4 | 5.0 |
DNA Primers | 88 | 1.0 |
*Endothelial Growth Factors | 2 | 100.0 |
Endothelium, Vascular/cytology/drug effects/*physiology | 13 | 28.0 |
Polymerase Chain Reaction | 130 | 1.0 |
Rabbits | 96 | 3.0 |
Coculture Techniques/methods | 2 | 10.0 |
Membrane Glycoproteins/pharmacology | 3 | 5.0 |
Morphogenesis | 10 | 4.0 |
Cadherins/genetics/metabolism | 3 | 21.0 |
Endothelial Growth Factors/genetics/metabolism | 35 | 83.0 |
Fibroblast Growth Factor 2/genetics/metabolism | 7 | 53.0 |
Gelatinase A/genetics/metabolism | 5 | 55.0 |
Gelatinase B/genetics/metabolism | 4 | 33.0 |
Intercellular Signaling Peptides and Proteins/genetics/metabolism | 11 | 52.0 |
Interleukin-8/metabolism | 11 | 9.0 |
Kidney Neoplasms/*blood supply/pathology | 3 | 100.0 |
Lymphokines/genetics/metabolism | 31 | 81.0 |
Neoadjuvant Therapy | 2 | 5.0 |
Haplotypes | 4 | 0.0 |
Intercellular Signaling Peptides and Proteins/*genetics | 24 | 40.0 |
Cell Division/*drug effects | 10 | 3.0 |
Endothelium, Vascular/*cytology/drug effects | 16 | 38.0 |
Fibroblasts/cytology/drug effects | 2 | 5.0 |
Intercellular Signaling Peptides and Proteins/pharmacology | 16 | 57.0 |
Lung/blood supply | 5 | 25.0 |
RNA, Messenger/genetics | 82 | 3.0 |
Skin/blood supply | 13 | 20.0 |
Transcription, Genetic | 93 | 1.0 |
Umbilical Veins | 65 | 15.0 |
Cell Adhesion | 18 | 1.0 |
*Cell Movement | 2 | 1.0 |
Complement 5a/metabolism | 2 | 14.0 |
E-Selectin/metabolism | 5 | 10.0 |
Fibroblast Growth Factor 1/*physiology | 2 | 50.0 |
Fibroblast Growth Factor 2/*physiology | 8 | 38.0 |
Intercellular Adhesion Molecule-1/metabolism | 6 | 3.0 |
Macrophage Inflammatory Protein-1/metabolism | 3 | 5.0 |
Monocyte Chemoattractant Protein-1/metabolism | 4 | 6.0 |
RANTES/metabolism | 3 | 4.0 |
Vascular Cell Adhesion Molecule-1/metabolism | 3 | 3.0 |
Wound Healing | 21 | 18.0 |
Carcinoma, Non-Small-Cell Lung/*pathology | 3 | 12.0 |
Lung Neoplasms/*pathology | 7 | 10.0 |
*Neoplasm Recurrence, Local | 4 | 8.0 |
Platelet Count | 30 | 6.0 |
Survival | 7 | 20.0 |
Biological Markers | 46 | 2.0 |
Cell Membrane Permeability | 4 | 2.0 |
Probability | 26 | 4.0 |
Sampling Studies | 5 | 2.0 |
Sensitivity and Specificity | 102 | 3.0 |
Synovial Fluid/metabolism | 4 | 12.0 |
Extremities/*blood supply | 4 | 100.0 |
Myocardial Ischemia/*drug therapy | 4 | 36.0 |
Peripheral Vascular Diseases/*drug therapy | 2 | 100.0 |
Blood Vessels/*physiology | 2 | 16.0 |
Extremities/blood supply | 3 | 60.0 |
Hypertrophy | 5 | 4.0 |
Ischemia/physiopathology | 4 | 25.0 |
Protein-Serine-Threonine Kinases/genetics/*metabolism | 3 | 1.0 |
*Proto-Oncogene Proteins | 23 | 1.0 |
Proto-Oncogene Proteins/physiology | 10 | 7.0 |
Receptor Protein-Tyrosine Kinases/*physiology | 19 | 29.0 |
Receptors, Growth Factor/*physiology | 16 | 55.0 |
Vasodilation/drug effects | 4 | 7.0 |
Estradiol/pharmacology | 14 | 5.0 |
Estrogen Receptor Modulators/pharmacology | 2 | 9.0 |
Estrogen Receptor alpha | 9 | 3.0 |
Estrogen Receptor beta | 7 | 9.0 |
Receptor, Epidermal Growth Factor/biosynthesis/genetics | 2 | 8.0 |
Tamoxifen/pharmacology | 5 | 5.0 |
Adenocarcinoma/blood supply/*metabolism | 2 | 100.0 |
Protein p53/*biosynthesis | 21 | 17.0 |
Receptor, erbB-2/*biosynthesis | 5 | 10.0 |
*Contrast Media | 4 | 14.0 |
Regression Analysis | 33 | 2.0 |
Tumor Markers, Biological/*blood | 63 | 13.0 |
Ultrasonography, Doppler/*methods | 2 | 66.0 |
Neoplasm Proteins/metabolism | 12 | 3.0 |
Endothelial Growth Factors/*analysis/*blood | 3 | 100.0 |
Immunoglobulin G/analysis | 2 | 0.0 |
Lymphokines/*analysis/*blood | 3 | 100.0 |
Synovial Fluid/*chemistry | 3 | 13.0 |
Tumor Necrosis Factor-alpha/metabolism | 16 | 2.0 |
Intercellular Signaling Peptides and Proteins/analysis | 14 | 70.0 |
Lung Neoplasms/*blood supply/chemistry/mortality | 2 | 100.0 |
Cell Nucleus/pathology | 3 | 4.0 |
Extracellular Matrix/metabolism | 10 | 5.0 |
Genes, p53 | 8 | 1.0 |
Ploidies | 3 | 1.0 |
Telomerase/metabolism | 4 | 7.0 |
Tumor Markers, Biological/*analysis/genetics | 5 | 14.0 |
Capillaries/cytology | 4 | 25.0 |
Cell Hypoxia/*physiology | 25 | 47.0 |
Dactinomycin/pharmacology | 9 | 2.0 |
Endothelium, Vascular/*metabolism | 46 | 17.0 |
Histocytochemistry | 4 | 0.0 |
Microcirculation/cytology | 4 | 21.0 |
Nucleic Acid Synthesis Inhibitors/pharmacology | 4 | 3.0 |
RNA, Messenger/*biosynthesis/genetics | 8 | 13.0 |
*Transforming Growth Factor beta | 3 | 2.0 |
Endothelium, Vascular/secretion | 2 | 40.0 |
Gelatinase A/*blood | 5 | 62.0 |
Pre-Eclampsia/*blood | 7 | 14.0 |
Clinical Protocols | 2 | 3.0 |
Ovulation Induction/adverse effects | 2 | 50.0 |
alpha-Macroglobulins/*metabolism | 2 | 6.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 12 | 2.0 |
Endothelial Growth Factors/*antagonists & inhibitors | 15 | 88.0 |
Ligands | 35 | 1.0 |
Lymphokines/*antagonists & inhibitors | 15 | 78.0 |
MAP Kinase Signaling System/drug effects | 5 | 5.0 |
Membrane Proteins/*pharmacology | 2 | 4.0 |
Mitogen-Activated Protein Kinases/*metabolism | 21 | 3.0 |
Proto-Oncogene Protein p21(ras)/*metabolism | 3 | 6.0 |
Receptor, EphB4 | 2 | 16.0 |
Receptors, Eph Family | 2 | 15.0 |
Umbilical Veins/cytology/physiology | 2 | 33.0 |
Gene Expression Regulation | 89 | 2.0 |
Hyperplasia | 13 | 3.0 |
Neovascularization, Pathologic/etiology/metabolism/pathology | 2 | 100.0 |
Ophthalmoscopy | 2 | 8.0 |
Protein p16/genetics/metabolism | 3 | 11.0 |
Calcium/*metabolism | 9 | 1.0 |
Insulin-Like Growth Factor I/*metabolism | 3 | 2.0 |
Macular Degeneration/complications/*metabolism | 2 | 100.0 |
Cell Size/drug effects | 2 | 2.0 |
Drug Implants | 3 | 7.0 |
Mice, Inbred CBA | 4 | 1.0 |
Adenocarcinoma | 3 | 2.0 |
Endometrial Neoplasms | 2 | 14.0 |
Epithelial Cells | 8 | 1.0 |
Estradiol/administration & dosage/pharmacology | 2 | 40.0 |
Gene Expression/*drug effects | 11 | 5.0 |
Hormone Antagonists/pharmacology | 4 | 6.0 |
Vascular Endothelial Growth Factor A/*genetics | 46 | 95.0 |
Estrogens/administration & dosage | 3 | 27.0 |
Progestins/administration & dosage | 2 | 16.0 |
Fibroblasts/metabolism | 23 | 2.0 |
Interleukin-1/*pharmacology | 14 | 3.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 10 | 0.0 |
Vascular Endothelial Growth Factor A/*biosynthesis/genetics | 27 | 93.0 |
Cell Division/physiology | 49 | 5.0 |
Endothelial Cells/metabolism | 9 | 30.0 |
Exons | 18 | 0.0 |
Neovascularization, Pathologic/*metabolism | 85 | 73.0 |
Carcinoma, Renal Cell/blood supply/*drug therapy | 2 | 100.0 |
Kidney Neoplasms/blood supply/*drug therapy | 2 | 100.0 |
Matrix Metalloproteinases/antagonists & inhibitors | 3 | 33.0 |
Thalidomide/therapeutic use | 3 | 21.0 |
Vascular Endothelial Growth Factor A/antagonists & inhibitors | 9 | 81.0 |
Brain/pathology | 3 | 0.0 |
Necrosis | 20 | 5.0 |
Neoplasm Metastasis | 129 | 12.0 |
Piperidines/pharmacology | 4 | 6.0 |
Placebos | 6 | 2.0 |
Quinazolines/pharmacology | 5 | 6.0 |
RNA/metabolism | 23 | 4.0 |
Mutation/genetics | 6 | 0.0 |
Superoxide Dismutase/genetics | 2 | 2.0 |
Doxycycline/pharmacology | 4 | 7.0 |
Mice, Transgenic | 49 | 1.0 |
Pigment Epithelium of Eye/drug effects/*metabolism | 2 | 18.0 |
Promoter Regions (Genetics)/genetics | 12 | 1.0 |
Retina/drug effects/*metabolism | 2 | 66.0 |
Tetracycline/pharmacology | 5 | 6.0 |
Vascular Endothelial Growth Factor A/genetics/*metabolism | 23 | 95.0 |
Angiogenesis Inhibitors/*metabolism | 6 | 75.0 |
Antineoplastic Agents/metabolism | 2 | 11.0 |
Endothelium, Vascular/cytology/metabolism | 35 | 29.0 |
Heat-Shock Proteins 90/metabolism | 2 | 6.0 |
Transcription Factors/*metabolism | 36 | 2.0 |
Angiogenic Proteins/blood | 2 | 100.0 |
Biological Markers/*blood | 7 | 4.0 |
Cell Adhesion Molecules/*blood | 4 | 6.0 |
Colitis, Ulcerative/*blood | 3 | 27.0 |
Crohn Disease/*blood | 5 | 25.0 |
Cross-Sectional Studies | 24 | 1.0 |
E-Selectin/blood | 7 | 12.0 |
Intercellular Adhesion Molecule-1/blood | 6 | 7.0 |
P-Selectin/blood | 4 | 6.0 |
Pregnancy Proteins/blood | 3 | 50.0 |
Vascular Cell Adhesion Molecule-1/blood | 8 | 14.0 |
Vascular Endothelial Growth Factor A/blood | 40 | 93.0 |
Carcinoma/pathology | 4 | 9.0 |
Culture Media, Serum-Free | 18 | 4.0 |
Dogs | 12 | 1.0 |
Epithelial Cells/physiology | 3 | 4.0 |
Prostatic Neoplasms/pathology | 6 | 25.0 |
Protein-Tyrosine Kinase/metabolism | 19 | 2.0 |
Tyrosine/metabolism | 27 | 2.0 |
Vascular Endothelial Growth Factor Receptor-1/genetics/*metabolism | 6 | 85.0 |
Culture Media/pharmacology | 4 | 4.0 |
Macrophages, Peritoneal/physiology | 2 | 22.0 |
Remission, Spontaneous | 3 | 4.0 |
Interleukin-6/*blood | 12 | 4.0 |
Anoxia/*metabolism/pathology | 5 | 71.0 |
Endothelium, Vascular/*drug effects/metabolism/pathology | 3 | 75.0 |
Estrogens/*pharmacology | 4 | 4.0 |
Gene Expression Regulation/drug effects | 40 | 4.0 |
Retinal Neovascularization/*metabolism/pathology | 4 | 80.0 |
Retinopathy of Prematurity/*metabolism/pathology | 3 | 75.0 |
Cell Hypoxia/physiology | 30 | 44.0 |
Cell Nucleus/metabolism | 21 | 1.0 |
Endothelin-1/*pharmacology | 3 | 25.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 15 | 5.0 |
Transcription Factors/*genetics/metabolism | 5 | 1.0 |
*Transcription, Genetic | 29 | 1.0 |
Cell Adhesion/physiology | 6 | 2.0 |
Endothelial Growth Factors/physiology | 46 | 79.0 |
Intercellular Signaling Peptides and Proteins/physiology | 10 | 55.0 |
Lymphokines/physiology | 46 | 54.0 |
Receptors, Vascular Endothelial Growth Factor/genetics | 4 | 80.0 |
Receptors, Vitronectin/physiology | 2 | 25.0 |
Antigens, Helminth/*immunology | 2 | 3.0 |
Schistosoma mansoni/*immunology | 2 | 2.0 |
Apoptosis/*drug effects | 14 | 1.0 |
Caspases/metabolism | 12 | 1.0 |
Endothelium, Vascular/cytology/*drug effects | 19 | 26.0 |
Enzyme Activation/drug effects | 30 | 3.0 |
Lipopolysaccharides/*toxicity | 2 | 3.0 |
Colorectal Neoplasms/*blood/pathology/surgery | 3 | 60.0 |
Macaca fascicularis | 13 | 4.0 |
Organ Specificity | 23 | 1.0 |
Species Specificity | 6 | 0.0 |
Blood Vessels/drug effects/growth & development | 2 | 100.0 |
Gene Therapy/methods | 10 | 10.0 |
Genetic Vectors/administration & dosage/genetics | 3 | 12.0 |
Liposomes | 11 | 4.0 |
Cell Survival/physiology | 14 | 7.0 |
*Microtubule-Associated Proteins | 3 | 3.0 |
*Dietary Supplements | 2 | 3.0 |
Drug Administration Schedule | 22 | 2.0 |
Smoking/blood | 3 | 7.0 |
Blood Vessels/growth & development | 2 | 66.0 |
Fibroblast Growth Factor 2/genetics | 21 | 65.0 |
Genetic Vectors/genetics | 10 | 4.0 |
Regeneration | 8 | 13.0 |
Sendai virus/genetics | 2 | 28.0 |
Colonic Neoplasms/*metabolism/pathology | 2 | 5.0 |
Endothelial Growth Factors/*biosynthesis/metabolism | 7 | 100.0 |
HT29 Cells | 6 | 3.0 |
Lymphokines/*biosynthesis/metabolism | 7 | 77.0 |
Transcription Factors/*biosynthesis/metabolism | 2 | 18.0 |
Autocrine Communication/physiology | 5 | 19.0 |
Colon/*blood supply | 3 | 75.0 |
Iodine Radioisotopes/diagnostic use | 2 | 0.0 |
Microcirculation/physiology | 10 | 30.0 |
Neovascularization, Physiologic/physiology | 33 | 64.0 |
Paracrine Communication/physiology | 6 | 24.0 |
Receptor Protein-Tyrosine Kinases/genetics/*metabolism | 24 | 19.0 |
Receptors, Growth Factor/genetics/*metabolism | 22 | 68.0 |
Eye Enucleation | 3 | 23.0 |
Retinal Vessels/pathology | 3 | 23.0 |
Capillary Permeability/*drug effects | 12 | 50.0 |
Molecular Weight | 24 | 0.0 |
*Signal Transduction | 44 | 2.0 |
In Situ Hybridization, Fluorescence | 10 | 0.0 |
Interleukin-6/*metabolism | 7 | 6.0 |
Karyotyping | 4 | 0.0 |
Keratin/analysis | 6 | 2.0 |
Lung Neoplasms/blood/*pathology | 2 | 66.0 |
Apoptosis/physiology | 20 | 5.0 |
Neovascularization, Pathologic/metabolism | 52 | 68.0 |
Chorionic Gonadotropin/*pharmacology | 7 | 12.0 |
Circadian Rhythm | 4 | 1.0 |
Endothelial Growth Factors/*blood/secretion | 3 | 100.0 |
Lymphokines/*blood/secretion | 3 | 100.0 |
*Ovulation Induction | 6 | 14.0 |
Interleukin-6/*biosynthesis | 3 | 2.0 |
Carrier Proteins/genetics/*metabolism | 2 | 0.0 |
Endothelial Growth Factors/administration & dosage/*pharmacology | 6 | 100.0 |
Injections | 14 | 12.0 |
Nitric-Oxide Synthase/genetics/*metabolism | 2 | 11.0 |
Peptide Fragments/metabolism | 7 | 1.0 |
Aging/*metabolism | 6 | 2.0 |
Gene Expression Regulation, Developmental/*physiology | 2 | 1.0 |
Protein Isoforms/genetics | 13 | 4.0 |
Receptor Protein-Tyrosine Kinases/genetics | 27 | 18.0 |
Receptors, Growth Factor/genetics | 26 | 60.0 |
Myocardial Ischemia/*therapy | 6 | 85.0 |
Neovascularization, Pathologic/*physiopathology/prevention & control | 2 | 50.0 |
Signal Transduction/drug effects/*physiology | 12 | 5.0 |
Angiopoietin-2 | 41 | 70.0 |
Neovascularization, Pathologic/metabolism/*physiopathology | 5 | 83.0 |
Proteins/analysis | 11 | 7.0 |
Receptor, TIE-2 | 42 | 72.0 |
Angiogenesis Inducing Agents/blood | 5 | 100.0 |
Antineoplastic Agents/*pharmacology/therapeutic use | 5 | 5.0 |
Endothelial Growth Factors/blood | 45 | 88.0 |
Interleukin-6/blood | 14 | 2.0 |
Interleukin-8/blood | 8 | 8.0 |
Linear Models | 15 | 3.0 |
Lymphokines/blood/drug effects | 6 | 100.0 |
Bronchoalveolar Lavage Fluid/chemistry | 5 | 7.0 |
Endothelial Growth Factors/*analysis/blood | 12 | 100.0 |
Lymphokines/*analysis/blood | 12 | 92.0 |
Neovascularization, Pathologic/*diagnosis | 9 | 60.0 |
Tumor Markers, Biological/analysis | 18 | 2.0 |
Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors/physiology | 4 | 80.0 |
Receptors, Growth Factor/*antagonists & inhibitors/physiology | 4 | 80.0 |
Random Allocation | 16 | 3.0 |
Single-Blind Method | 3 | 1.0 |
Endothelin-1/*metabolism | 5 | 31.0 |
Angiogenesis Inhibitors/*pharmacology/therapeutic use | 3 | 50.0 |
Drug Evaluation | 3 | 1.0 |
Fibroblast Growth Factor 2/blood/drug effects | 3 | 100.0 |
Growth Substances/*blood | 6 | 23.0 |
Intercellular Signaling Peptides and Proteins/blood | 20 | 74.0 |
Multiple Myeloma/blood/*drug therapy | 3 | 50.0 |
Endothelial Growth Factors/metabolism/physiology | 3 | 100.0 |
Lymphokines/metabolism/physiology | 3 | 75.0 |
Antineoplastic Agents/*therapeutic use | 30 | 7.0 |
*Immune Tolerance | 2 | 1.0 |
Interleukin-12/*blood | 5 | 38.0 |
Interleukin-2/*therapeutic use | 2 | 1.0 |
Neovascularization, Physiologic/*immunology | 3 | 50.0 |
Collagen/analysis | 6 | 8.0 |
Culture Media, Conditioned/chemistry | 11 | 23.0 |
Endostatins | 29 | 67.0 |
Fibroblast Growth Factor 2/analysis | 22 | 62.0 |
Neovascularization, Pathologic/*etiology/metabolism/pathology | 2 | 66.0 |
Peptide Fragments/analysis | 3 | 1.0 |
Interleukin-1/metabolism | 7 | 3.0 |
Ovarian Hyperstimulation Syndrome/*metabolism/pathology | 2 | 100.0 |
Proto-Oncogene Proteins/drug effects/genetics/metabolism | 2 | 28.0 |
Receptor Protein-Tyrosine Kinases/drug effects/genetics/metabolism | 2 | 50.0 |
Diphtheria Toxin/*pharmacology | 2 | 28.0 |
Neovascularization, Pathologic/*drug therapy/prevention & control | 2 | 100.0 |
Statistics, Nonparametric | 56 | 5.0 |
Interleukin-8/*biosynthesis | 7 | 11.0 |
NF-kappa B/*metabolism | 11 | 1.0 |
Transcription Factor AP-1/*metabolism | 6 | 3.0 |
Antigens, CD34/biosynthesis | 10 | 12.0 |
Breast Neoplasms/*metabolism | 15 | 5.0 |
Cell Separation | 8 | 0.0 |
Endothelium/*metabolism | 2 | 11.0 |
Genetic Vectors | 61 | 3.0 |
Membrane Glycoproteins/metabolism | 13 | 2.0 |
Proto-Oncogene Proteins/biosynthesis | 13 | 7.0 |
Tumor Necrosis Factor-alpha/*metabolism | 7 | 1.0 |
Adenoviridae/genetics | 41 | 8.0 |
*Gene Transfer Techniques | 32 | 8.0 |
Epithelial Cells/metabolism | 11 | 3.0 |
Glucose/pharmacology | 4 | 3.0 |
Peptide Fragments/secretion | 2 | 33.0 |
*Peritoneal Dialysis | 8 | 13.0 |
Angiogenesis Inducing Agents/genetics/*metabolism | 4 | 66.0 |
Endothelium, Vascular/cytology/*physiology | 16 | 26.0 |
Hematopoiesis/physiology | 3 | 6.0 |
Membrane Glycoproteins/genetics/*metabolism | 5 | 3.0 |
Metalloendopeptidases/genetics/*metabolism | 2 | 5.0 |
Nucleic Acid Hybridization | 6 | 0.0 |
Ovarian Neoplasms/*metabolism/pathology | 7 | 10.0 |
RNA, Messenger/analysis/genetics | 6 | 1.0 |
Tissue Inhibitor of Metalloproteinase-2/genetics/metabolism | 3 | 27.0 |
Radioimmunoassay | 7 | 0.0 |
Autocrine Communication | 9 | 12.0 |
Endothelial Growth Factors/analysis/secretion | 2 | 100.0 |
Germ-Line Mutation | 2 | 0.0 |
Growth Substances/*biosynthesis | 6 | 13.0 |
Lymphokines/analysis/secretion | 2 | 66.0 |
Proto-Oncogene Proteins/genetics | 11 | 2.0 |
Receptors, Growth Factor/biosynthesis/genetics | 7 | 58.0 |
Receptors, Thrombin/genetics | 2 | 66.0 |
Vascular Cell Adhesion Molecule-1/genetics | 3 | 17.0 |
Interferon Type II/pharmacology | 3 | 0.0 |
Interferon-alpha/pharmacology | 2 | 2.0 |
Tumor Necrosis Factor-alpha/pharmacology | 34 | 2.0 |
Breast Neoplasms | 7 | 2.0 |
Neuropilin-1 | 31 | 60.0 |
Pregnancy Proteins/chemistry/*metabolism | 2 | 50.0 |
Hematocrit | 6 | 1.0 |
Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors | 23 | 53.0 |
Receptors, Growth Factor/*antagonists & inhibitors | 16 | 94.0 |
Microscopy, Immunoelectron | 5 | 0.0 |
Culture Media/metabolism | 5 | 21.0 |
Culture Media, Conditioned/metabolism | 6 | 20.0 |
Vascular Endothelial Growth Factor A/blood/metabolism | 3 | 100.0 |
Adenocarcinoma/*blood/complications | 2 | 100.0 |
Carcinoma, Squamous Cell/*blood/complications | 2 | 100.0 |
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use | 5 | 2.0 |
Neoplasms/blood supply/*drug therapy/metabolism | 2 | 100.0 |
Endothelial Growth Factors/*cerebrospinal fluid | 3 | 100.0 |
Lymphokines/*cerebrospinal fluid | 3 | 100.0 |
1-Phosphatidylinositol 3-Kinase/physiology | 4 | 3.0 |
Bladder Neoplasms/*metabolism | 3 | 17.0 |
Culture Media, Conditioned | 45 | 13.0 |
Endothelial Growth Factors/analysis/*genetics | 35 | 97.0 |
Lymphokines/analysis/*genetics | 34 | 97.0 |
Mitogen-Activated Protein Kinases/physiology | 7 | 6.0 |
*Neoplasm Proteins | 9 | 1.0 |
Transcription Factors/genetics/*physiology | 2 | 1.0 |
p38 Mitogen-Activated Protein Kinases | 39 | 6.0 |
Glucocorticoids/pharmacology | 4 | 3.0 |
Hyperoxia/*metabolism | 2 | 66.0 |
Proto-Oncogene Proteins/*genetics/metabolism | 4 | 2.0 |
Receptor Protein-Tyrosine Kinases/*genetics/metabolism | 7 | 11.0 |
Receptors, Growth Factor/*genetics/metabolism | 6 | 54.0 |
Quinazolines/*pharmacology | 9 | 9.0 |
Antigens, CD/metabolism | 8 | 0.0 |
Antigens, Differentiation, Myelomonocytic/metabolism | 2 | 1.0 |
Choroidal Neovascularization/*metabolism/pathology | 2 | 66.0 |
Cytokines/*metabolism | 12 | 4.0 |
Endothelium, Vascular/*metabolism/pathology | 9 | 25.0 |
Factor VIII/metabolism | 11 | 11.0 |
Keratin/metabolism | 4 | 2.0 |
Macrophages/*metabolism/pathology | 2 | 14.0 |
Microscopy, Confocal | 24 | 2.0 |
Thromboplastin/metabolism | 3 | 3.0 |
Collagen/*pharmacology | 2 | 7.0 |
Endothelial Growth Factors/antagonists & inhibitors | 15 | 93.0 |
Lymphokines/antagonists & inhibitors | 15 | 93.0 |
Nitric-Oxide Synthase/chemistry/*metabolism | 3 | 60.0 |
Peptide Fragments/*pharmacology | 7 | 4.0 |
*Protein-Serine-Threonine Kinases | 35 | 4.0 |
Signal Transduction/drug effects | 28 | 4.0 |
Carcinoma, Squamous Cell/*metabolism | 11 | 10.0 |
Electrophoretic Mobility Shift Assay | 17 | 3.0 |
Enzyme Induction | 7 | 1.0 |
Head and Neck Neoplasms/*metabolism | 9 | 42.0 |
Imidazoles/pharmacology | 10 | 4.0 |
Mitogen-Activated Protein Kinase 8 | 2 | 2.0 |
Pyridines/pharmacology | 13 | 4.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 19 | 3.0 |
Chemotherapy, Adjuvant | 14 | 6.0 |
Colorectal Neoplasms/*drug therapy | 5 | 41.0 |
Drug Design | 7 | 2.0 |
Genes, APC | 2 | 2.0 |
Immunotherapy/methods | 4 | 4.0 |
Infusions, Intravenous | 11 | 1.0 |
Isoenzymes/antagonists & inhibitors | 2 | 4.0 |
Prostaglandin-Endoperoxide Synthase | 6 | 20.0 |
Receptor, Epidermal Growth Factor/antagonists & inhibitors | 4 | 10.0 |
Angiogenesis Inducing Agents/*biosynthesis/genetics | 3 | 60.0 |
Intercellular Signaling Peptides and Proteins/*biosynthesis/genetics | 24 | 75.0 |
Membrane Glycoproteins/biosynthesis/genetics | 3 | 6.0 |
Neoplasm Proteins/biosynthesis/genetics | 7 | 5.0 |
RNA, Messenger/biosynthesis/genetics | 52 | 9.0 |
Receptor Protein-Tyrosine Kinases/biosynthesis/genetics | 8 | 50.0 |
Receptor, TIE-1 | 12 | 85.0 |
Receptors, TIE | 18 | 58.0 |
Endothelial Growth Factors/immunology/*metabolism | 6 | 85.0 |
Lymphokines/immunology/*metabolism | 6 | 75.0 |
Esophageal Neoplasms/*metabolism | 3 | 15.0 |
Oxygen/*metabolism | 17 | 13.0 |
RNA, Messenger/biosynthesis | 106 | 5.0 |
Antigens, Polyomavirus Transforming/genetics/*metabolism | 2 | 18.0 |
Endothelial Growth Factors/biosynthesis/*genetics | 25 | 96.0 |
*Gene Expression Regulation | 44 | 2.0 |
Lymphokines/biosynthesis/*genetics | 26 | 78.0 |
Protein p53/metabolism | 28 | 4.0 |
Up-Regulation/immunology | 2 | 1.0 |
Endothelial Growth Factors/*chemistry/metabolism | 3 | 100.0 |
Lymphokines/*chemistry/metabolism | 3 | 100.0 |
Menstrual Cycle | 6 | 5.0 |
Uterus/*metabolism | 3 | 6.0 |
Ovarian Neoplasms/enzymology/*metabolism/pathology | 2 | 66.0 |
Paraffin Embedding | 13 | 5.0 |
Vascular Endothelial Growth Factor A/*biosynthesis | 55 | 96.0 |
Biological Transport | 6 | 0.0 |
Interleukin-6/*analysis/blood | 2 | 20.0 |
Peritoneum/*metabolism | 2 | 16.0 |
Vascular Endothelial Growth Factor A/*analysis/blood | 3 | 100.0 |
Gelatinase B/*blood | 5 | 50.0 |
Vascular Endothelial Growth Factor C/*blood | 2 | 100.0 |
Diterpenes/*pharmacology | 3 | 10.0 |
Drugs, Chinese Herbal/pharmacology | 2 | 18.0 |
Endothelial Cells/cytology/drug effects/metabolism | 2 | 66.0 |
Extracellular Signal-Regulated MAP Kinases/metabolism | 2 | 11.0 |
In Situ Nick-End Labeling | 41 | 6.0 |
Phosphorylation/drug effects | 46 | 5.0 |
Protein-Serine-Threonine Kinases/metabolism | 14 | 1.0 |
Umbilical Veins/cytology/drug effects | 3 | 33.0 |
Vascular Endothelial Growth Factor A/*pharmacology | 33 | 86.0 |
Vascular Endothelial Growth Factor Receptor-2/metabolism | 40 | 86.0 |
Gene Therapy/*methods | 35 | 8.0 |
Rats, Inbred Strains | 4 | 0.0 |
Structure-Activity Relationship | 20 | 0.0 |
Octreotide/pharmacology | 3 | 12.0 |
Receptor, IGF Type 1/biosynthesis/genetics | 2 | 66.0 |
Neoplasm Recurrence, Local/metabolism | 3 | 23.0 |
Cell Lineage | 7 | 1.0 |
Cytokines/physiology | 6 | 3.0 |
Gene Expression Regulation, Developmental | 16 | 1.0 |
Transcription Factors/physiology | 5 | 2.0 |
Dendritic Cells/immunology | 2 | 1.0 |
Microscopy, Electron | 27 | 1.0 |
Vascular Endothelial Growth Factor A/immunology/*metabolism | 2 | 100.0 |
1-Phosphatidylinositol 3-Kinase/*antagonists & inhibitors | 2 | 10.0 |
Endothelial Growth Factors/*metabolism/pharmacology | 16 | 80.0 |
Lymphokines/*metabolism/pharmacology | 16 | 61.0 |
Mitogen-Activated Protein Kinases/*antagonists & inhibitors | 3 | 16.0 |
Nitric-Oxide Synthase/*genetics/metabolism | 3 | 15.0 |
Apoptosis/drug effects | 54 | 8.0 |
Neovascularization, Pathologic/drug therapy | 16 | 57.0 |
Brain Neoplasms/enzymology/*metabolism/pathology | 2 | 100.0 |
COS Cells | 22 | 0.0 |
DNA-Binding Proteins/*metabolism | 26 | 1.0 |
Trans-Activators/*metabolism | 9 | 0.0 |
Cell Line, Transformed | 22 | 1.0 |
Collagen | 21 | 12.0 |
Laminin | 15 | 16.0 |
Lymphokines/genetics/*metabolism | 80 | 91.0 |
Mutagenesis, Site-Directed | 27 | 0.0 |
Proteoglycans | 15 | 17.0 |
*Up-Regulation | 20 | 8.0 |
Hydrogen Peroxide/pharmacology | 8 | 3.0 |
Keratinocytes/drug effects/metabolism | 4 | 30.0 |
DNA, Complementary/analysis | 5 | 1.0 |
Escherichia coli | 7 | 1.0 |
Microcirculation/*pathology | 10 | 50.0 |
Thymidine Phosphorylase/analysis/*genetics | 2 | 100.0 |
Colonic Neoplasms/*blood supply/metabolism | 2 | 100.0 |
Cytokines/metabolism | 11 | 2.0 |
Glioma/*metabolism | 11 | 22.0 |
Hirudins/pharmacology | 3 | 15.0 |
Protease Inhibitors/pharmacology | 5 | 2.0 |
Coronary Vessels/*physiopathology | 2 | 28.0 |
Endothelial Growth Factors/analysis/*blood | 8 | 100.0 |
Hepatocyte Growth Factor/analysis/*blood | 2 | 40.0 |
Japan | 12 | 0.0 |
Lymphokines/analysis/*blood | 7 | 100.0 |
NF-kappa B/metabolism | 17 | 2.0 |
Antineoplastic Agents, Hormonal/*therapeutic use | 5 | 6.0 |
Factor VIII/biosynthesis | 3 | 42.0 |
Proto-Oncogene Proteins/*biosynthesis | 11 | 7.0 |
Receptor Protein-Tyrosine Kinases/*biosynthesis | 21 | 37.0 |
Receptors, Growth Factor/*biosynthesis | 20 | 80.0 |
Endothelial Growth Factors/*biosynthesis/physiology | 4 | 80.0 |
Hypertension/*metabolism | 3 | 9.0 |
Lymphokines/*biosynthesis/physiology | 4 | 66.0 |
Pregnancy Complications, Cardiovascular/*metabolism | 3 | 42.0 |
Aging | 3 | 0.0 |
Oxidative Stress | 9 | 2.0 |
Lymphokines/blood | 40 | 70.0 |
*Adaptor Proteins, Signal Transducing | 8 | 0.0 |
*Adaptor Proteins, Vesicular Transport | 2 | 0.0 |
Cadherins/genetics/*metabolism | 4 | 16.0 |
Proteins/*metabolism | 16 | 1.0 |
src Homology Domains/physiology | 2 | 4.0 |
*Altitude | 6 | 10.0 |
Anoxia/metabolism | 20 | 52.0 |
Exercise/physiology | 2 | 3.0 |
Anoxia/*metabolism | 22 | 42.0 |
Muscle, Skeletal/*metabolism | 3 | 1.0 |
Nitric Oxide/metabolism/*physiology | 2 | 33.0 |
*DNA-Binding Proteins | 11 | 0.0 |
*Receptors, Aryl Hydrocarbon | 4 | 14.0 |
Transcription Factors/metabolism | 39 | 2.0 |
Macaca | 2 | 2.0 |
*Menstruation | 2 | 5.0 |
Biocompatible Materials/metabolism | 2 | 50.0 |
Cell Transplantation | 9 | 9.0 |
Intercellular Signaling Peptides and Proteins/*metabolism/pharmacology | 3 | 75.0 |
Mice, SCID | 60 | 7.0 |
Capillary Permeability/drug effects | 21 | 48.0 |
Endothelial Growth Factors/metabolism/*pharmacology | 8 | 88.0 |
Endothelium, Vascular/cytology/*drug effects/metabolism | 18 | 20.0 |
Lymphokines/metabolism/*pharmacology | 8 | 57.0 |
Tissue Extracts/*pharmacology | 2 | 8.0 |
Carcinoembryonic Antigen/metabolism | 2 | 10.0 |
Growth Substances/genetics/*metabolism | 3 | 7.0 |
Pregnancy Proteins/genetics/metabolism | 3 | 100.0 |
Proteins/metabolism | 20 | 2.0 |
Radioimmunotherapy | 2 | 18.0 |
Blood Vessels/*physiopathology | 2 | 40.0 |
Capillary Permeability/physiology | 8 | 42.0 |
Hemodynamic Processes/physiology | 2 | 3.0 |
Membrane Glycoproteins/genetics | 5 | 2.0 |
Neovascularization, Pathologic/genetics/*pathology | 5 | 71.0 |
Ovariectomy | 4 | 3.0 |
Acetylcysteine/pharmacology | 4 | 5.0 |
Antibodies, Monoclonal/pharmacology | 13 | 1.0 |
Endothelium, Vascular/*cytology/*metabolism | 2 | 16.0 |
Genetic Vectors/drug effects | 2 | 100.0 |
Muscle, Smooth, Vascular/cytology/metabolism | 3 | 9.0 |
RNA, Messenger/biosynthesis/drug effects | 10 | 17.0 |
Gestational Age | 32 | 3.0 |
Placenta/*metabolism | 16 | 10.0 |
Proteins/genetics/*metabolism | 7 | 1.0 |
Cell Differentiation/physiology | 12 | 2.0 |
Pre-Eclampsia/*physiopathology | 3 | 37.0 |
Receptor Protein-Tyrosine Kinases/metabolism/*physiology | 5 | 33.0 |
Trophoblasts/cytology/*physiology | 2 | 11.0 |
Endothelial Growth Factors/*metabolism/physiology | 6 | 100.0 |
Lymphokines/*metabolism/physiology | 5 | 62.0 |
Macrophages/physiology | 4 | 5.0 |
Regeneration/*physiology | 4 | 15.0 |
Colon | 2 | 7.0 |
Intestinal Mucosa/*metabolism | 2 | 2.0 |
Membrane Potentials/physiology | 2 | 2.0 |
Recombinant Fusion Proteins/metabolism | 15 | 0.0 |
Maximum Tolerated Dose | 8 | 21.0 |
Salvage Therapy | 5 | 6.0 |
DNA-Binding Proteins/antagonists & inhibitors/*physiology | 2 | 20.0 |
Endothelial Growth Factors/antagonists & inhibitors/genetics/*physiology | 2 | 100.0 |
Lymphokines/antagonists & inhibitors/genetics/*physiology | 2 | 100.0 |
DNA, Complementary | 22 | 1.0 |
Glycosylation End Products, Advanced/*metabolism | 3 | 7.0 |
Macrophages/*drug effects | 2 | 9.0 |
Receptor Protein-Tyrosine Kinases/antagonists & inhibitors/metabolism | 4 | 40.0 |
Serum Albumin | 2 | 6.0 |
Transcription Factor AP-1/genetics/metabolism | 2 | 9.0 |
Age of Onset | 3 | 0.0 |
Blood Pressure/drug effects | 7 | 1.0 |
Diabetes Mellitus, Type 1/physiopathology | 2 | 18.0 |
Diabetes Mellitus, Type 2/physiopathology | 2 | 16.0 |
Diabetic Retinopathy/*physiopathology | 4 | 30.0 |
Endothelial Growth Factors/genetics/metabolism/*pharmacology | 5 | 100.0 |
Extracellular Matrix Proteins/metabolism | 13 | 13.0 |
Lymphokines/genetics/metabolism/*pharmacology | 3 | 100.0 |
Monosaccharide Transport Proteins/metabolism | 5 | 12.0 |
Neovascularization, Physiologic/*drug effects/physiology | 11 | 64.0 |
Protein Isoforms/genetics/metabolism | 15 | 7.0 |
Rats, Wistar | 41 | 3.0 |
Serum Albumin/metabolism | 7 | 4.0 |
*Disease Models, Animal | 5 | 1.0 |
Oocytes/cytology/*growth & development | 2 | 100.0 |
Receptors, Growth Factor/*genetics | 23 | 48.0 |
Thyrotropin/*pharmacology | 3 | 10.0 |
Antibodies/immunology | 9 | 2.0 |
Antigens, Nuclear | 11 | 7.0 |
Endothelial Growth Factors/biosynthesis | 53 | 82.0 |
Ki-67 Antigen | 9 | 4.0 |
Lymphokines/biosynthesis | 51 | 45.0 |
Nuclear Proteins/biosynthesis | 7 | 14.0 |
Preoperative Care | 9 | 5.0 |
Radiotherapy, Adjuvant | 5 | 5.0 |
Autopsy | 5 | 2.0 |
Interleukins/biosynthesis | 2 | 4.0 |
Angiotensin II/*metabolism | 3 | 6.0 |
Blood-Retinal Barrier | 7 | 77.0 |
Diabetic Retinopathy/*metabolism/surgery | 8 | 88.0 |
Macular Edema, Cystoid/*metabolism/surgery | 2 | 100.0 |
Vitreous Body | 3 | 21.0 |
Granulosa Cells/metabolism | 5 | 14.0 |
RNA, Messenger | 12 | 2.0 |
Dinoprostone/metabolism | 14 | 18.0 |
Endothelial Growth Factors/blood/*metabolism | 16 | 100.0 |
Lymphokines/blood/*metabolism | 16 | 100.0 |
Ovarian Hyperstimulation Syndrome/blood/*metabolism | 3 | 75.0 |
Antibiotics, Antineoplastic/*pharmacology | 6 | 5.0 |
Antibodies, Monoclonal/*pharmacology | 5 | 2.0 |
Combined Modality Therapy | 36 | 3.0 |
Doxorubicin/*pharmacology | 5 | 7.0 |
Drug Synergism | 35 | 2.0 |
Endothelium, Vascular/*drug effects/pathology | 3 | 37.0 |
Receptor Protein-Tyrosine Kinases/*immunology | 6 | 35.0 |
Receptors, Growth Factor/*immunology | 6 | 75.0 |
Neovascularization, Pathologic/metabolism/pathology | 19 | 79.0 |
Proto-Oncogene Proteins/*biosynthesis/genetics | 3 | 3.0 |
Antineoplastic Combined Chemotherapy Protocols/*pharmacology | 4 | 8.0 |
Endothelium, Vascular/drug effects/pathology | 4 | 36.0 |
Neovascularization, Pathologic/drug therapy/pathology | 4 | 66.0 |
Pancreatic Neoplasms/blood supply/*drug therapy/pathology | 4 | 100.0 |
Receptor, Epidermal Growth Factor/*antagonists & inhibitors | 7 | 5.0 |
Signal Transduction/*drug effects/physiology | 4 | 6.0 |
Antineoplastic Agents, Hormonal/pharmacology | 5 | 11.0 |
Breast Neoplasms/*blood supply/*metabolism | 4 | 100.0 |
Contrast Media | 12 | 21.0 |
Estrogen Antagonists/*pharmacology | 4 | 5.0 |
Gadolinium DTPA/diagnostic use | 4 | 33.0 |
Tamoxifen/*pharmacology | 5 | 7.0 |
Autocrine Communication/drug effects | 2 | 28.0 |
Endothelium, Vascular/*cytology/drug effects/metabolism | 5 | 25.0 |
Extracellular Matrix/physiology | 8 | 9.0 |
Fibroblast Growth Factor 2/pharmacology | 49 | 22.0 |
Gene Expression Regulation/physiology | 10 | 3.0 |
Umbilical Cord/cytology | 4 | 21.0 |
Ascitic Fluid/*chemistry | 4 | 26.0 |
Interleukin-6/*analysis | 2 | 5.0 |
Retinal Neovascularization/drug therapy | 2 | 100.0 |
Skin Neoplasms/drug therapy | 2 | 33.0 |
Vitreous Body/metabolism | 7 | 58.0 |
Chick Embryo | 43 | 8.0 |
Kidney/cytology | 3 | 1.0 |
Endothelium, Vascular/cytology/*drug effects/enzymology | 5 | 50.0 |
Genistein/pharmacology | 8 | 7.0 |
Protein-Tyrosine Kinase/*physiology | 3 | 2.0 |
Staurosporine/pharmacology | 6 | 3.0 |
Pain Measurement | 3 | 4.0 |
Leptin/*blood | 4 | 5.0 |
Neovascularization, Pathologic/*blood | 9 | 81.0 |
*Collateral Circulation | 6 | 75.0 |
Endothelial Growth Factors/genetics/*physiology | 35 | 100.0 |
Hemodynamic Processes | 3 | 1.0 |
Ischemia/physiopathology/*therapy | 7 | 100.0 |
Lymphokines/genetics/*physiology | 27 | 93.0 |
Muscle, Skeletal/*blood supply | 6 | 85.0 |
Liver Neoplasms/secondary | 10 | 15.0 |
Thromboplastin/*analysis | 3 | 6.0 |
Stromal Cells/metabolism | 12 | 13.0 |
Thymidine Phosphorylase/*metabolism | 14 | 60.0 |
Sialoglycoproteins/*physiology | 2 | 20.0 |
Apoptosis/drug effects/physiology | 4 | 4.0 |
Drug Resistance, Multiple | 2 | 1.0 |
Drug Resistance, Neoplasm | 17 | 3.0 |
Enzyme Inhibitors/*therapeutic use | 7 | 7.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors/metabolism | 3 | 7.0 |
Receptor, Epidermal Growth Factor/*metabolism | 6 | 0.0 |
*Taxoids | 3 | 5.0 |
Transforming Growth Factor alpha/metabolism | 5 | 6.0 |
Tumor Cells, Cultured/drug effects/metabolism | 14 | 7.0 |
Adenocarcinoma/*genetics/metabolism/pathology | 2 | 6.0 |
Cervix Neoplasms/*genetics/metabolism/pathology | 2 | 66.0 |
DNA, Neoplasm/analysis | 12 | 1.0 |
Macrophages | 3 | 3.0 |
Thymidine Phosphorylase/*biosynthesis | 4 | 36.0 |
Acetylcholine/pharmacology | 2 | 2.0 |
Body Weight | 9 | 1.0 |
Indomethacin/pharmacology | 7 | 3.0 |
NG-Nitroarginine Methyl Ester/pharmacology | 14 | 28.0 |
Vasodilation/*drug effects | 3 | 7.0 |
Vasodilator Agents/pharmacology | 4 | 6.0 |
Angiogenesis Inducing Agents/biosynthesis | 4 | 80.0 |
Endothelium/metabolism | 7 | 13.0 |
*Drug Resistance, Neoplasm | 4 | 2.0 |
Endothelium, Vascular/*drug effects | 9 | 16.0 |
Bone Marrow Cells/*physiology | 3 | 16.0 |
*Cell Differentiation | 3 | 1.0 |
Collagen/genetics | 4 | 4.0 |
Stromal Cells/physiology | 3 | 5.0 |
Administration, Inhalation | 4 | 2.0 |
DNA/administration & dosage | 2 | 28.0 |
*Drug Delivery Systems | 3 | 9.0 |
Genes, p53/*genetics | 12 | 3.0 |
Thrombospondin 1/metabolism | 3 | 27.0 |
Up-Regulation/physiology | 9 | 7.0 |
Antimetabolites, Antineoplastic/*pharmacology | 2 | 2.0 |
Fluorouracil/*pharmacology | 2 | 5.0 |
Pancreatic Neoplasms/genetics/pathology/*therapy | 2 | 100.0 |
China | 2 | 0.0 |
Endothelial Growth Factors/*genetics/physiology | 5 | 83.0 |
Luminescent Proteins/genetics/metabolism | 4 | 2.0 |
Lymphokines/*genetics/physiology | 5 | 71.0 |
Adaptation, Physiological/physiology | 2 | 11.0 |
Electric Stimulation | 4 | 1.0 |
Leg | 5 | 12.0 |
Regional Blood Flow/physiology | 6 | 12.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/metabolism | 7 | 8.0 |
Diabetic Retinopathy/physiopathology | 2 | 15.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/metabolism | 10 | 10.0 |
Nuclear Proteins/*metabolism | 22 | 3.0 |
Proto-Oncogene Proteins/genetics/metabolism | 11 | 6.0 |
Rats, Long-Evans | 4 | 8.0 |
Receptor Protein-Tyrosine Kinases/genetics/metabolism | 13 | 22.0 |
Retina/cytology/*metabolism | 2 | 18.0 |
Trans-Activation (Genetics)/physiology | 4 | 4.0 |
Endothelium, Vascular/*physiology | 15 | 10.0 |
Nitric Oxide/physiology | 4 | 8.0 |
Nitroglycerin/pharmacology | 3 | 16.0 |
Vasodilation/*physiology | 5 | 27.0 |
Blood Platelets/*chemistry | 4 | 10.0 |
Discriminant Analysis | 4 | 5.0 |
Gene Expression Regulation, Neoplastic/genetics | 9 | 4.0 |
Kidney/chemistry/pathology | 2 | 20.0 |
Endothelial Growth Factors/analysis/*metabolism | 13 | 100.0 |
Lymphokines/analysis/*metabolism | 11 | 100.0 |
Antibodies, Monoclonal/diagnostic use | 9 | 1.0 |
Endothelial Growth Factors/*analysis/genetics | 26 | 100.0 |
Epithelial Cells/pathology | 6 | 7.0 |
Lymphokines/*analysis/genetics | 26 | 100.0 |
Paracrine Communication | 10 | 26.0 |
Protein Isoforms/*analysis/genetics | 3 | 100.0 |
Embryonic and Fetal Development | 12 | 3.0 |
Image Processing, Computer-Assisted | 16 | 4.0 |
von Willebrand Factor/metabolism | 20 | 7.0 |
Gene Expression Regulation, Neoplastic/drug effects | 24 | 5.0 |
HL-60 Cells | 15 | 2.0 |
Protein Isoforms/pharmacology | 5 | 25.0 |
Proto-Oncogene Proteins c-bcl-2/*genetics | 2 | 2.0 |
Quinones/pharmacology | 7 | 5.0 |
Receptor Protein-Tyrosine Kinases/drug effects/physiology | 3 | 42.0 |
Receptors, Growth Factor/drug effects/physiology | 3 | 75.0 |
Carbonic Anhydrases/biosynthesis | 2 | 100.0 |
DNA-Binding Proteins/biosynthesis | 6 | 6.0 |
Neoplasm Proteins/biosynthesis | 3 | 3.0 |
Thymidine Phosphorylase/biosynthesis | 9 | 81.0 |
Tumor Markers, Biological/*biosynthesis | 10 | 12.0 |
Neoplasm Proteins/*physiology | 3 | 3.0 |
Gene Expression Regulation, Neoplastic/*physiology | 9 | 5.0 |
Kidney Neoplasms/*genetics/pathology | 3 | 4.0 |
Proteins/genetics/metabolism | 4 | 2.0 |
Thrombospondin 1/genetics/metabolism | 3 | 60.0 |
Receptors, Estrogen/metabolism | 13 | 4.0 |
Embryo Transfer | 15 | 20.0 |
Fertilization in Vitro | 21 | 16.0 |
Follicular Fluid/*metabolism | 12 | 46.0 |
Antibodies, Monoclonal/*therapeutic use | 21 | 6.0 |
Endothelial Growth Factors/*immunology | 19 | 100.0 |
Magnetic Resonance Imaging/*methods | 10 | 14.0 |
Rats, Nude | 8 | 16.0 |
Cell Hypoxia/drug effects/physiology | 5 | 62.0 |
Chemotherapy, Adjuvant/methods | 5 | 55.0 |
*Trans-Activation (Genetics) | 7 | 0.0 |
Capillaries/anatomy & histology | 2 | 40.0 |
Nitric-Oxide Synthase/metabolism | 15 | 12.0 |
Transcription Factors/*biosynthesis | 10 | 8.0 |
Injections, Intramuscular | 10 | 6.0 |
Dialysis Solutions/*chemistry | 2 | 22.0 |
*Lactic Acid | 2 | 40.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 4 | 3.0 |
Peritoneum/metabolism | 2 | 22.0 |
Tumor Necrosis Factor-alpha/analysis | 12 | 2.0 |
*Cell Transformation, Neoplastic | 8 | 1.0 |
DNA, Complementary/genetics | 27 | 1.0 |
Endothelial Cells/*pathology | 3 | 42.0 |
Point Mutation/*genetics | 3 | 1.0 |
Algorithms | 3 | 0.0 |
Endothelial Cells/*cytology | 4 | 25.0 |
*Models, Biological | 6 | 3.0 |
Actins/metabolism | 8 | 1.0 |
Enzyme Precursors/*metabolism | 3 | 2.0 |
Gelatinases/*metabolism | 3 | 12.0 |
Glial Fibrillary Acidic Protein/metabolism | 7 | 3.0 |
Metalloendopeptidases/*metabolism | 6 | 6.0 |
Vimentin/metabolism | 5 | 4.0 |
Germany | 2 | 0.0 |
Breast Neoplasms/*genetics/pathology | 2 | 0.0 |
Lasers | 3 | 2.0 |
Cell Cycle Proteins/biosynthesis/genetics | 2 | 10.0 |
DNA-Binding Proteins/physiology | 7 | 2.0 |
Pancreatic Neoplasms/genetics/*metabolism/pathology | 2 | 16.0 |
Transcription Factor, Sp1/physiology | 2 | 5.0 |
Transcription Factors/*physiology | 9 | 1.0 |
Angiogenesis Inhibitors/administration & dosage/*pharmacology | 3 | 75.0 |
Enzyme Inhibitors/administration & dosage/pharmacology | 2 | 33.0 |
Histone Deacetylases/*antagonists & inhibitors | 3 | 6.0 |
Neovascularization, Pathologic/drug therapy/enzymology/genetics | 2 | 100.0 |
Transcription Factors/biosynthesis | 7 | 7.0 |
Vascular Endothelial Growth Factor A/biosynthesis | 22 | 95.0 |
Vascular Endothelial Growth Factor Receptor-2/*antagonists & inhibitors | 7 | 87.0 |
Angiogenesis Inhibitors/*administration & dosage | 4 | 100.0 |
Antineoplastic Combined Chemotherapy Protocols/administration & dosage | 2 | 6.0 |
Blood Platelets/metabolism | 5 | 2.0 |
Vascular Endothelial Growth Factor Receptor-2/*immunology | 3 | 100.0 |
Chorionic Gonadotropin/blood | 3 | 3.0 |
Embryo Implantation | 3 | 8.0 |
Estradiol/blood | 20 | 3.0 |
Gene Expression Regulation/genetics | 4 | 2.0 |
Progesterone/blood | 18 | 7.0 |
Receptors, Vascular Endothelial Growth Factor/*genetics | 3 | 100.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 19 | 6.0 |
*Embryo Transfer | 2 | 8.0 |
*Fertilization in Vitro | 16 | 15.0 |
Follicular Fluid/*chemistry | 6 | 24.0 |
Nitric Oxide/*analysis | 3 | 30.0 |
Ovarian Follicle/*blood supply | 2 | 66.0 |
Cell Movement/*physiology | 5 | 2.0 |
Focal Adhesions/metabolism | 2 | 10.0 |
p38 Mitogen-Activated Protein Kinases/*metabolism | 2 | 10.0 |
Capillaries/drug effects/metabolism | 2 | 100.0 |
Down-Regulation/drug effects/physiology | 4 | 10.0 |
Endothelial Cells/drug effects/*metabolism | 3 | 37.0 |
Growth Substances/pharmacology | 9 | 4.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology | 4 | 6.0 |
Neovascularization, Physiologic/drug effects/physiology | 5 | 83.0 |
Up-Regulation/drug effects/physiology | 6 | 12.0 |
Cell Differentiation/drug effects/*physiology | 4 | 6.0 |
Cell Movement/drug effects/physiology | 10 | 16.0 |
Intercellular Junctions/drug effects/metabolism | 2 | 66.0 |
Microscopy, Electron, Transmission | 4 | 9.0 |
*Oxidative Stress | 4 | 1.0 |
Transcription Factors/genetics/metabolism | 6 | 1.0 |
Neoplasm Recurrence, Local | 32 | 7.0 |
Vascular Endothelial Growth Factor C/*metabolism | 4 | 66.0 |
Enzyme-Linked Immunosorbent Assay/methods | 29 | 10.0 |
Treatment Failure | 3 | 1.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 37 | 7.0 |
Calcitriol/pharmacology | 2 | 1.0 |
Cobalt/pharmacology | 18 | 36.0 |
Dinoprostone/pharmacology | 5 | 6.0 |
Endothelial Growth Factors/*biosynthesis/chemistry | 3 | 100.0 |
Free Radical Scavengers/pharmacology | 5 | 8.0 |
Lymphokines/*biosynthesis/chemistry | 3 | 100.0 |
Osteoblasts/*metabolism | 3 | 5.0 |
Reactive Oxygen Species | 4 | 3.0 |
Response Elements | 9 | 3.0 |
Angiogenesis Inhibitors/pharmacology/therapeutic use | 7 | 77.0 |
Cell Division/drug effects/physiology | 24 | 8.0 |
Chemotaxis/drug effects/*physiology | 3 | 20.0 |
Endothelial Growth Factors/pharmacology/*physiology | 10 | 100.0 |
Fibroblast Growth Factor 2/pharmacology/physiology | 2 | 100.0 |
Osteoblasts/cytology/drug effects/*physiology | 2 | 50.0 |
Endothelial Growth Factors/analysis/genetics/*metabolism | 5 | 100.0 |
Endothelium, Vascular/chemistry/metabolism | 3 | 75.0 |
Estrogens/pharmacology | 3 | 3.0 |
Extracellular Matrix Proteins/analysis/genetics/metabolism | 2 | 100.0 |
Lymphokines/analysis/genetics/*metabolism | 5 | 71.0 |
Medroxyprogesterone 17-Acetate/pharmacology | 6 | 18.0 |
Menstrual Cycle/*metabolism | 9 | 30.0 |
Pregnancy/*metabolism | 3 | 5.0 |
Receptor Protein-Tyrosine Kinases/analysis/genetics/*metabolism | 3 | 42.0 |
Receptors, Growth Factor/analysis/genetics/*metabolism | 3 | 100.0 |
Administration, Oral | 13 | 1.0 |
Angiogenesis Inhibitors/*chemical synthesis/pharmacology | 2 | 66.0 |
Antineoplastic Agents/*chemical synthesis/pharmacology | 2 | 14.0 |
Biological Availability | 3 | 1.0 |
Proto-Oncogene Proteins/*antagonists & inhibitors | 2 | 8.0 |
Antigens, CD31/analysis/genetics | 2 | 100.0 |
Extracellular Matrix Proteins/*genetics | 2 | 2.0 |
Infant, Premature | 4 | 3.0 |
Papio | 4 | 2.0 |
Transplantation, Heterologous/*pathology | 2 | 28.0 |
Antigens, CD31/analysis | 21 | 23.0 |
Endothelial Growth Factors/analysis/physiology | 3 | 100.0 |
Lymphokines/analysis/physiology | 3 | 75.0 |
Neoplasms, Experimental | 4 | 11.0 |
Apoptosis/*physiology | 6 | 0.0 |
Immunologic Techniques | 5 | 1.0 |
Up-Regulation/*physiology | 5 | 11.0 |
Bone Marrow/metabolism/pathology | 3 | 13.0 |
Leukemia, Myeloid, Chronic/diagnosis/*metabolism/pathology | 2 | 100.0 |
Endothelial Growth Factors/metabolism/pharmacology/*physiology | 2 | 100.0 |
Receptors, Growth Factor/metabolism/*physiology | 4 | 80.0 |
Tumor Cells, Cultured/secretion | 3 | 42.0 |
Umbilical Cord | 2 | 15.0 |
CD8-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Estradiol/*pharmacology | 12 | 5.0 |
Intracellular Membranes/metabolism | 4 | 2.0 |
Progesterone/pharmacology | 9 | 7.0 |
Magnetic Resonance Imaging/methods | 3 | 3.0 |
Metabolic Clearance Rate | 2 | 0.0 |
Vasodilation | 5 | 14.0 |
Cryopreservation | 4 | 3.0 |
Oocytes/cytology | 2 | 14.0 |
*Ovulation | 2 | 10.0 |
Ovulation Induction | 10 | 25.0 |
Angiogenesis Inducing Agents/*genetics | 2 | 66.0 |
Epidermal Growth Factor/analysis | 5 | 8.0 |
Intercellular Signaling Peptides and Proteins/genetics | 13 | 46.0 |
Nitric-Oxide Synthase/analysis | 3 | 20.0 |
Receptor, Epidermal Growth Factor/analysis | 7 | 3.0 |
Bone Remodeling/physiology | 2 | 15.0 |
Chondrocytes/*metabolism | 2 | 6.0 |
Hindlimb | 5 | 20.0 |
Recurrence/prevention & control | 2 | 5.0 |
Renal Dialysis | 3 | 0.0 |
Antibodies, Monoclonal | 17 | 0.0 |
Diabetic Retinopathy/chemically induced/*metabolism/pathology | 2 | 100.0 |
Retinal Vessels/*metabolism/pathology | 2 | 100.0 |
Electrophoresis, Polyacrylamide Gel | 23 | 0.0 |
Endothelium, Vascular/*pathology | 9 | 14.0 |
Recombinant Proteins | 22 | 2.0 |
Brain Neoplasms/metabolism/*pathology | 3 | 12.0 |
Antigens, CD34/*metabolism | 3 | 2.0 |
Neovascularization, Pathologic/physiopathology | 21 | 70.0 |
Breast Neoplasms/blood supply/*metabolism/pathology | 9 | 69.0 |
Endothelial Cells/*physiology | 6 | 40.0 |
Glioblastoma/metabolism/*pathology | 2 | 25.0 |
Drug Evaluation, Preclinical | 6 | 3.0 |
Enzyme Inhibitors/*pharmacology | 17 | 2.0 |
Escherichia coli/genetics/metabolism | 2 | 3.0 |
Recombinant Proteins/biosynthesis/genetics | 2 | 2.0 |
Vascular Endothelial Growth Factor Receptor-1/*antagonists & | 2 | 66.0 |
DNA/metabolism | 12 | 0.0 |
Receptors, Cell Surface/*metabolism | 14 | 2.0 |
Solutions | 4 | 2.0 |
DNA-Binding Proteins/genetics/*metabolism | 13 | 1.0 |
Half-Life | 5 | 0.0 |
Nuclear Proteins/genetics/*metabolism | 5 | 1.0 |
*RNA Stability | 2 | 8.0 |
Cell Cycle Proteins/metabolism | 8 | 2.0 |
Fibroblasts/cytology/metabolism | 4 | 2.0 |
Gene Expression Regulation/drug effects/*physiology | 5 | 6.0 |
Ionophores/pharmacology | 4 | 2.0 |
Promoter Regions (Genetics)/physiology | 4 | 2.0 |
Vitreous Body/*metabolism | 15 | 51.0 |
Neoplasm Metastasis/drug therapy | 3 | 50.0 |
Chorionic Gonadotropin/therapeutic use | 7 | 23.0 |
Oocytes | 2 | 1.0 |
Capillaries/pathology | 18 | 38.0 |
Reproducibility of Results | 21 | 1.0 |
1-Phosphatidylinositol 3-Kinase/*physiology | 4 | 7.0 |
Fibroblast Growth Factor 2/*antagonists & inhibitors | 2 | 40.0 |
Proto-Oncogene Proteins/*physiology | 9 | 4.0 |
*Neoplasm Invasiveness | 2 | 2.0 |
Carcinoma/*pathology/secondary | 2 | 100.0 |
Colorectal Neoplasms/*pathology | 12 | 20.0 |
Gelatinase A/*analysis | 2 | 28.0 |
Insulin-Like Growth Factor II/*analysis | 2 | 18.0 |
Transforming Growth Factor alpha/*analysis | 2 | 3.0 |
Neovascularization, Pathologic/*prevention & control | 33 | 62.0 |
Stomach Neoplasms/*blood supply/metabolism/pathology | 3 | 100.0 |
Prostatic Hyperplasia/*metabolism | 3 | 6.0 |
Protein p53/*metabolism | 14 | 2.0 |
Thrombospondin 1/*metabolism | 5 | 38.0 |
Liver Neoplasms/metabolism/*secondary | 3 | 75.0 |
Neoplasm Invasiveness/pathology | 6 | 10.0 |
Brain Ischemia/*physiopathology | 2 | 12.0 |
Lymphokines/pharmacology/*physiology | 9 | 60.0 |
Membrane Glycoproteins/*physiology | 4 | 1.0 |
Platelet Activation | 4 | 2.0 |
Laser Coagulation | 11 | 68.0 |
Macaca mulatta | 12 | 2.0 |
Antineoplastic Agents/pharmacology | 17 | 3.0 |
Gene Expression/drug effects/physiology | 3 | 6.0 |
Glucose/metabolism | 6 | 2.0 |
Hemostatics/pharmacology | 2 | 8.0 |
Peritoneal Dialysis | 2 | 5.0 |
Fibroblast Growth Factor 2/blood | 31 | 93.0 |
Intercellular Signaling Peptides and Proteins/*blood/secretion | 2 | 100.0 |
Ribonuclease, Pancreatic/*blood | 7 | 77.0 |
Kidney/metabolism/pathology | 2 | 6.0 |
DNA, Neoplasm/*analysis | 4 | 2.0 |
Staining and Labeling/methods | 4 | 3.0 |
DNA, Neoplasm/genetics | 4 | 0.0 |
Interleukin-8/*biosynthesis/genetics | 6 | 14.0 |
Lung Neoplasms/*genetics/*pathology | 2 | 15.0 |
Chi-Square Distribution | 11 | 1.0 |
Prevalence | 5 | 0.0 |
Protein Isoforms/*analysis | 6 | 85.0 |
*Radiation Tolerance | 2 | 3.0 |
Cytokines/*analysis/blood | 2 | 20.0 |
Hemoglobins/analysis | 9 | 3.0 |
Immunosuppressive Agents/*therapeutic use | 3 | 2.0 |
Thalidomide/*therapeutic use | 8 | 50.0 |
Transforming Growth Factor beta/analysis | 9 | 20.0 |
Evans Blue/pharmacokinetics | 3 | 75.0 |
Permeability | 12 | 7.0 |
Endothelial Growth Factors/metabolism/pharmacology | 10 | 100.0 |
Endothelium, Vascular/cytology/drug effects/metabolism | 13 | 34.0 |
Lymphokines/metabolism/pharmacology | 10 | 76.0 |
Microscopy, Electron, Scanning | 8 | 2.0 |
Oligopeptides/*pharmacology | 3 | 3.0 |
Protease Inhibitors/*pharmacology | 2 | 4.0 |
Tissue Inhibitor of Metalloproteinases/metabolism | 4 | 30.0 |
Tumor Cells, Cultured/drug effects | 15 | 2.0 |
Chromosome Aberrations | 5 | 0.0 |
Immunophenotyping | 5 | 0.0 |
Collagen Type I/metabolism | 6 | 16.0 |
DNA-Binding Proteins/metabolism | 25 | 1.0 |
Growth Substances/metabolism | 12 | 9.0 |
*Immediate-Early Proteins | 9 | 3.0 |
*Intercellular Signaling Peptides and Proteins | 4 | 0.0 |
*Membrane Proteins | 2 | 0.0 |
S100 Proteins/metabolism | 3 | 2.0 |
Transcription, Genetic/physiology | 5 | 2.0 |
Blood Cells/pathology | 2 | 10.0 |
Bone Marrow Cells/pathology | 2 | 3.0 |
Cell Cycle | 5 | 0.0 |
Cells, Cultured/metabolism | 2 | 5.0 |
Membrane Glycoproteins/*biosynthesis/genetics | 2 | 3.0 |
Neoplasm Proteins/*biosynthesis/genetics | 15 | 9.0 |
*Protein Biosynthesis | 12 | 2.0 |
Proteins/genetics | 11 | 1.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Cell Differentiation/drug effects/physiology | 3 | 3.0 |
Cell Survival/drug effects/physiology | 5 | 6.0 |
Endothelial Growth Factors/antagonists & inhibitors/metabolism | 2 | 100.0 |
Lymphokines/antagonists & inhibitors/metabolism | 2 | 66.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
Blood Vessels/metabolism/pathology | 6 | 46.0 |
Coronary Vessels/metabolism/pathology | 2 | 33.0 |
Endothelial Growth Factors/*biosynthesis/blood | 8 | 100.0 |
Fibrin/metabolism | 4 | 6.0 |
Fibrinogen/metabolism | 5 | 2.0 |
Lymphokines/*biosynthesis/blood | 8 | 57.0 |
Gene Transfer, Horizontal | 2 | 11.0 |
Transgenes | 12 | 3.0 |
Anti-Bacterial Agents/pharmacology | 2 | 1.0 |
Retina/drug effects/*metabolism/pathology | 2 | 100.0 |
Macrophages/*physiology | 2 | 2.0 |
*Transplantation, Heterologous | 2 | 2.0 |
Bone Marrow/metabolism | 2 | 1.0 |
Mesothelioma/*drug therapy | 2 | 50.0 |
Menopause | 4 | 1.0 |
Recurrence | 28 | 2.0 |
Blood Glucose/analysis | 2 | 0.0 |
Brain/physiology | 3 | 4.0 |
Insulin/blood | 3 | 0.0 |
Osmolar Concentration | 18 | 2.0 |
Anticoagulants/*pharmacology | 4 | 4.0 |
Cross-Linking Reagents | 7 | 1.0 |
Dextrans/*pharmacology | 2 | 16.0 |
Fibroblast Growth Factors/pharmacology | 4 | 6.0 |
Heparin/*pharmacology | 6 | 4.0 |
Hydrogels | 3 | 75.0 |
Diabetic Retinopathy/*metabolism | 12 | 50.0 |
Hepatocyte Growth Factor/*metabolism | 9 | 8.0 |
Iris/*blood supply | 3 | 60.0 |
Retinal Neovascularization/*metabolism | 3 | 100.0 |
3' Untranslated Regions | 6 | 4.0 |
*Antigens, Surface | 3 | 4.0 |
Glutathione Transferase/metabolism | 6 | 0.0 |
RNA, Messenger/*metabolism | 34 | 5.0 |
RNA-Binding Proteins/metabolism | 5 | 6.0 |
Diabetes Mellitus, Type 2/*blood/complications | 2 | 10.0 |
Receptor Protein-Tyrosine Kinases/*blood | 5 | 71.0 |
Receptors, Growth Factor/*blood | 2 | 100.0 |
Oximetry | 4 | 30.0 |
Oxygen/metabolism | 26 | 12.0 |
*Cytoprotection | 2 | 18.0 |
Protein Kinase C/antagonists & inhibitors | 11 | 8.0 |
Liver Cirrhosis/metabolism | 4 | 18.0 |
Liver Neoplasms/blood supply/*metabolism/pathology | 4 | 100.0 |
Vascular Endothelial Growth Factor Receptor-2/*biosynthesis | 9 | 100.0 |
Angiogenesis Inducing Agents/metabolism | 14 | 82.0 |
Meningioma/*metabolism | 2 | 10.0 |
Ki-67 Antigen/*analysis | 5 | 7.0 |
Protein p53/*analysis | 7 | 3.0 |
Thymidine Phosphorylase/*analysis | 9 | 69.0 |
DNA, Neoplasm/biosynthesis | 2 | 1.0 |
Prostatic Neoplasms/blood supply/*metabolism/pathology | 2 | 66.0 |
Proto-Oncogene Proteins/biosynthesis/metabolism | 2 | 22.0 |
Receptor Protein-Tyrosine Kinases/biosynthesis/metabolism | 2 | 50.0 |
Receptors, Growth Factor/biosynthesis/metabolism | 2 | 100.0 |
Antigens, CD40/*metabolism/pharmacology/physiology | 2 | 100.0 |
Endothelial Growth Factors/*secretion | 18 | 85.0 |
Promoter Regions (Genetics)/drug effects | 3 | 2.0 |
Fibroblasts/physiology | 8 | 6.0 |
Particle Size | 4 | 1.0 |
Prosthesis Failure | 5 | 9.0 |
Immune System/physiology | 2 | 8.0 |
*Surgical Flaps | 4 | 28.0 |
Neovascularization, Pathologic/*chemically induced | 5 | 83.0 |
Models, Cardiovascular | 6 | 12.0 |
Receptor Protein-Tyrosine Kinases/antagonists & inhibitors/*physiology | 3 | 75.0 |
Receptors, Growth Factor/antagonists & inhibitors/*physiology | 3 | 100.0 |
Breast Neoplasms/*blood | 4 | 9.0 |
Endothelial Growth Factors/*blood/physiology | 4 | 100.0 |
Liver Neoplasms/blood/secondary | 2 | 28.0 |
Lymphokines/*blood/physiology | 4 | 100.0 |
Organ Culture Techniques | 12 | 3.0 |
Calcium/metabolism/pharmacology | 3 | 10.0 |
Chemotaxis/drug effects/physiology | 6 | 28.0 |
Endothelium, Vascular/*cytology/*drug effects/physiology | 3 | 100.0 |
Oligomycins/pharmacology | 2 | 25.0 |
Surface Properties | 2 | 1.0 |
Fibronectins/genetics/metabolism | 2 | 25.0 |
Membrane Proteins/genetics/metabolism | 2 | 1.0 |
RNA, Neoplasm/analysis | 14 | 4.0 |
Receptors, Growth Factor/genetics/metabolism | 9 | 42.0 |
Stromal Cells/metabolism/pathology | 6 | 13.0 |
Aorta/drug effects | 5 | 55.0 |
Carrier Proteins/genetics | 2 | 0.0 |
Chorion/blood supply/drug effects | 7 | 87.0 |
Endothelium, Vascular/drug effects/metabolism | 17 | 30.0 |
Microscopy, Phase-Contrast | 3 | 3.0 |
Nerve Tissue Proteins/genetics | 3 | 1.0 |
Signal Transduction/*drug effects | 6 | 1.0 |
Umbilical Veins/cytology/drug effects/metabolism | 3 | 27.0 |
Up-Regulation/drug effects | 19 | 5.0 |
Pregnancy, Ectopic/*blood | 2 | 40.0 |
Drug Interactions | 13 | 1.0 |
Growth Substances/*pharmacology | 10 | 2.0 |
Peptides/*pharmacology | 2 | 0.0 |
Lung Neoplasms/*metabolism/mortality/pathology | 2 | 12.0 |
Receptor Protein-Tyrosine Kinases/analysis/*biosynthesis | 2 | 28.0 |
DNA, Antisense | 3 | 8.0 |
Neovascularization, Pathologic/pathology/physiopathology | 6 | 85.0 |
Gene Therapy/*trends | 2 | 16.0 |
Apyrase/metabolism | 2 | 28.0 |
Hyperoxia/metabolism | 4 | 66.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/immunology/*metabolism | 6 | 60.0 |
Receptors, Growth Factor/immunology/*metabolism | 6 | 100.0 |
Retina/*metabolism | 9 | 15.0 |
Glioblastoma/pathology | 3 | 16.0 |
Lymphokines/*immunology | 18 | 54.0 |
Macrophages/pathology | 8 | 6.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors | 8 | 5.0 |
Kidney Neoplasms/*blood supply/metabolism/pathology | 2 | 100.0 |
Nerve Tissue Proteins/genetics/*metabolism | 4 | 2.0 |
Growth Substances/metabolism/physiology | 3 | 60.0 |
Bone Marrow/blood supply/pathology | 3 | 75.0 |
Leukemia, Myeloid/metabolism/*pathology | 4 | 21.0 |
Antibodies, Monoclonal/therapeutic use | 12 | 6.0 |
Endothelial Growth Factors/immunology/metabolism/*physiology | 2 | 100.0 |
Lymphokines/immunology/metabolism/*physiology | 2 | 100.0 |
Receptors, Growth Factor/physiology | 20 | 46.0 |
Microcirculation/anatomy & histology | 2 | 100.0 |
Antineoplastic Agents/pharmacology/*therapeutic use | 2 | 5.0 |
Capillaries/drug effects | 4 | 66.0 |
Cell Proliferation/drug effects | 9 | 10.0 |
Endothelial Cells/drug effects | 4 | 66.0 |
Cell Cycle/drug effects | 7 | 1.0 |
Insulin-Like Growth Factor I/pharmacology | 10 | 5.0 |
Interleukin-6/pharmacology | 8 | 2.0 |
Leukocytes, Mononuclear/cytology/drug effects | 2 | 13.0 |
Multiple Myeloma/*pathology | 5 | 8.0 |
Angiopoietin-1/*blood | 3 | 100.0 |
Blood Platelets/*metabolism | 5 | 1.0 |
Blood Pressure/physiology | 4 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/*biosynthesis | 3 | 2.0 |
Vascular Endothelial Growth Factor C/biosynthesis | 2 | 100.0 |
Vascular Endothelial Growth Factor Receptor-3/*biosynthesis | 3 | 75.0 |
Adenoviridae/*genetics | 17 | 7.0 |
Kidney/cytology/metabolism | 2 | 2.0 |
Neoplasms/therapy | 2 | 4.0 |
Recombination, Genetic | 6 | 0.0 |
Stromelysin 1/*blood | 2 | 20.0 |
Fibrin Fibrinogen Degradation Products/*analysis | 2 | 4.0 |
Liver/pathology | 2 | 1.0 |
Portal Vein/pathology | 3 | 27.0 |
Vascular Endothelial Growth Factor A/analysis/*biosynthesis | 5 | 100.0 |
Antineoplastic Agents/therapeutic use | 11 | 4.0 |
Bone Marrow/*blood supply | 3 | 27.0 |
Angiogenesis Inhibitors/*genetics | 2 | 33.0 |
Endothelial Cells | 5 | 45.0 |
Ovarian Neoplasms/genetics/*pathology | 2 | 9.0 |
Cell Movement/physiology | 21 | 9.0 |
Catechin/*analogs & derivatives/*pharmacology | 5 | 21.0 |
Endothelium, Vascular/drug effects/enzymology | 2 | 40.0 |
Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors/metabolism | 4 | 40.0 |
Receptors, Growth Factor/*antagonists & inhibitors/metabolism | 4 | 80.0 |
Endothelium, Vascular/*cytology/metabolism | 9 | 17.0 |
Hypertension/*blood | 2 | 3.0 |
Placenta/metabolism | 6 | 3.0 |
Pregnancy Trimester, Third | 7 | 3.0 |
Dyes/diagnostic use | 7 | 9.0 |
Factor VIII/analysis/genetics | 2 | 66.0 |
Interleukin-1/*physiology | 3 | 3.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/*metabolism | 5 | 6.0 |
Heparin/pharmacology | 8 | 3.0 |
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology | 6 | 4.0 |
Chemotaxis/drug effects | 16 | 16.0 |
Endothelium, Vascular/*cytology/drug effects/physiology | 2 | 28.0 |
Umbilical Cord/cytology/drug effects | 2 | 100.0 |
Kidney Glomerulus/metabolism | 2 | 10.0 |
Estradiol/*analogs & derivatives/pharmacology | 3 | 6.0 |
Estrogen Antagonists/pharmacology | 3 | 3.0 |
Neoplasm Proteins/genetics | 5 | 1.0 |
Rats, Inbred F344 | 17 | 4.0 |
Rats, Inbred WF | 2 | 9.0 |
Collateral Circulation | 9 | 52.0 |
Coronary Circulation | 6 | 26.0 |
Insulin/pharmacology | 4 | 1.0 |
Myocardium/*metabolism | 8 | 3.0 |
Rats, Zucker | 3 | 12.0 |
Lung Neoplasms/drug therapy/pathology | 2 | 28.0 |
Promoter Regions (Genetics)/*genetics | 4 | 0.0 |
Transcription Factor, Sp1/metabolism | 10 | 2.0 |
Transcription, Genetic/*drug effects | 12 | 3.0 |
Genome, Viral | 3 | 2.0 |
Antigens, CD31/biosynthesis | 10 | 43.0 |
Transcription Factors/*biosynthesis/*genetics | 2 | 6.0 |
Transforming Growth Factor beta/*cerebrospinal fluid | 2 | 66.0 |
Cell Hypoxia/*genetics | 6 | 50.0 |
DNA-Binding Proteins/biosynthesis/*genetics | 2 | 1.0 |
Nuclear Proteins/biosynthesis/*genetics | 2 | 5.0 |
Transcription Factors/genetics | 10 | 1.0 |
Cadaver | 2 | 0.0 |
Genetic Techniques | 2 | 2.0 |
Skin Transplantation/*methods | 2 | 50.0 |
Carcinoma, Squamous Cell/blood supply/*genetics/pathology | 2 | 100.0 |
Neovascularization, Pathologic/genetics/pathology | 6 | 60.0 |
Otorhinolaryngologic Neoplasms/blood supply/*genetics/pathology | 2 | 100.0 |
Diabetic Retinopathy/*drug therapy | 4 | 66.0 |
Thrombolytic Therapy | 3 | 16.0 |
Vitrectomy | 18 | 43.0 |
Angiogenesis Inducing Agents/*biosynthesis | 6 | 75.0 |
In Situ Hybridization/methods | 8 | 6.0 |
Bladder Neoplasms/*pathology | 2 | 9.0 |
Blood Vessels/chemistry/pathology | 3 | 37.0 |
Carcinoma, Hepatocellular/*metabolism/pathology | 6 | 9.0 |
Liver Neoplasms/*metabolism/pathology | 8 | 10.0 |
*Portal Vein | 2 | 14.0 |
Capillaries/*pathology | 4 | 66.0 |
Proliferating Cell Nuclear Antigen/biosynthesis | 2 | 4.0 |
Lung/pathology | 2 | 2.0 |
Pulmonary Fibrosis/*metabolism/pathology | 2 | 28.0 |
Receptor Protein-Tyrosine Kinases/analysis/metabolism | 2 | 40.0 |
Receptors, Growth Factor/analysis/metabolism | 2 | 100.0 |
Antigens, CD/analysis | 10 | 0.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 6 | 1.0 |
Luciferases/genetics | 11 | 3.0 |
Ovarian Neoplasms/chemistry | 2 | 22.0 |
Transcription Factors/analysis/*genetics | 2 | 6.0 |
Tumor Cells, Cultured/*metabolism | 2 | 6.0 |
Heart Transplantation/*immunology/pathology | 2 | 11.0 |
Ascites/*metabolism | 3 | 42.0 |
Ascitic Fluid/chemistry | 9 | 42.0 |
C-Reactive Protein/analysis | 8 | 1.0 |
*Microcirculation | 5 | 62.0 |
Aqueous Humor/*metabolism | 9 | 42.0 |
Thromboplastin/*metabolism | 10 | 6.0 |
Integrin alpha1beta1 | 2 | 14.0 |
Integrins/*physiology | 2 | 2.0 |
Neovascularization, Pathologic/*physiopathology | 58 | 73.0 |
Receptors, Collagen | 2 | 2.0 |
*Cell Transformation, Viral | 2 | 1.0 |
Endothelial Growth Factors/metabolism/*physiology | 10 | 100.0 |
Herpesvirus 8, Human/*physiology | 3 | 27.0 |
Pregnancy Proteins/metabolism | 7 | 43.0 |
Calcium/metabolism | 15 | 0.0 |
Monocyte Chemoattractant Protein-1/biosynthesis | 2 | 8.0 |
Protein Biosynthesis | 26 | 1.0 |
Endothelial Growth Factors/*therapeutic use | 4 | 100.0 |
Luminescent Proteins/genetics | 7 | 3.0 |
Lymphokines/*therapeutic use | 4 | 50.0 |
Surgical Flaps/*blood supply | 4 | 57.0 |
Tissue Survival | 2 | 40.0 |
Endothelial Growth Factors/blood/*physiology | 5 | 100.0 |
Hypertension/*etiology | 3 | 14.0 |
Lymphokines/blood/*physiology | 4 | 100.0 |
Aging/physiology | 2 | 1.0 |
Endothelial Growth Factors/blood/physiology | 3 | 100.0 |
Lymphokines/blood/physiology | 3 | 100.0 |
Lymphokines/antagonists & inhibitors/immunology/*physiology | 2 | 100.0 |
Mice, Inbred ICR | 9 | 3.0 |
Mifepristone/*pharmacology | 3 | 12.0 |
Adaptation, Physiological | 3 | 3.0 |
Forced Expiratory Volume | 2 | 2.0 |
Nuclear Proteins/physiology | 7 | 9.0 |
Obesity/complications | 2 | 4.0 |
Oxygen/blood | 5 | 4.0 |
Polysomnography | 2 | 4.0 |
Vital Capacity | 4 | 10.0 |
Astrocytes/metabolism | 5 | 7.0 |
Blood-Brain Barrier/*physiology | 4 | 10.0 |
Brain/embryology/metabolism | 2 | 3.0 |
Culture Media, Conditioned/metabolism/pharmacology | 2 | 22.0 |
Endothelium/cytology | 4 | 10.0 |
Oxygen/metabolism/*physiology | 2 | 66.0 |
Thrombospondin 1/biosynthesis | 2 | 50.0 |
Clinical Trials, Phase II | 10 | 19.0 |
Endothelium, Vascular/drug effects | 19 | 32.0 |
Indoles/therapeutic use | 8 | 40.0 |
Leukemia, Myeloid/*drug therapy | 2 | 16.0 |
Multicenter Studies | 3 | 2.0 |
Neovascularization, Pathologic/*drug therapy/pathology | 5 | 71.0 |
Pyrroles/therapeutic use | 8 | 42.0 |
Clinical Trials, Phase I | 9 | 15.0 |
Receptor Protein-Tyrosine Kinases/antagonists & inhibitors | 10 | 58.0 |
Receptors, Growth Factor/antagonists & inhibitors | 10 | 100.0 |
*Genes, ras | 7 | 3.0 |
Lung Neoplasms/pathology/*physiopathology | 2 | 28.0 |
MAP Kinase Signaling System/physiology | 4 | 5.0 |
ras Proteins/metabolism | 7 | 4.0 |
Nitric-Oxide Synthase/*biosynthesis | 2 | 7.0 |
Fibroblast Growth Factors/physiology | 4 | 22.0 |
Recombinant Proteins/administration & dosage/therapeutic use | 2 | 5.0 |
Recombinant Fusion Proteins/biosynthesis | 7 | 1.0 |
Deoxycytidine/administration & dosage/*analogs & derivatives | 2 | 10.0 |
Enzyme Inhibitors/administration & dosage/pharmacology/*therapeutic use | 2 | 100.0 |
Phthalazines/administration & dosage/pharmacology/*therapeutic use | 2 | 100.0 |
Antibodies/*chemistry | 2 | 20.0 |
Epitope Mapping | 6 | 2.0 |
Peptide Library | 7 | 5.0 |
Sequence Analysis, DNA | 8 | 0.0 |
Blotting, Southern | 17 | 0.0 |
Ki-67 Antigen/biosynthesis | 7 | 8.0 |
Lymphokines/*secretion | 17 | 40.0 |
Polysaccharide-Lyases/metabolism | 2 | 22.0 |
Transforming Growth Factor beta/metabolism | 15 | 7.0 |
Follicle Stimulating Hormone/*pharmacology | 3 | 10.0 |
Luteinizing Hormone/*pharmacology | 2 | 22.0 |
Cell Transformation, Neoplastic | 10 | 1.0 |
Transforming Growth Factor beta/*physiology | 6 | 4.0 |
Umbilical Veins/metabolism | 9 | 28.0 |
Antigens, CD34/*biosynthesis | 3 | 6.0 |
Glioblastoma/genetics/metabolism/pathology | 3 | 30.0 |
Neoplasm Proteins/biosynthesis/*genetics | 3 | 3.0 |
Cardiovascular Diseases/genetics/*therapy | 3 | 100.0 |
Endothelial Growth Factors/genetics/therapeutic use | 2 | 100.0 |
Graft Occlusion, Vascular/prevention & control | 2 | 50.0 |
Lymphokines/genetics/therapeutic use | 2 | 100.0 |
Muscle, Smooth, Vascular/drug effects/metabolism | 3 | 21.0 |
HIV Infections/complications | 2 | 4.0 |
RNA, Messenger/drug effects/genetics/metabolism | 8 | 9.0 |
Tissue Kallikreins/*blood | 2 | 8.0 |
Carrier Proteins/biosynthesis | 3 | 5.0 |
Intracranial Arteriovenous Malformations/*metabolism | 2 | 100.0 |
Membrane Glycoproteins/*analysis | 3 | 2.0 |
Proteins/*analysis | 5 | 3.0 |
Anti-Inflammatory Agents, Non-Steroidal/pharmacology | 5 | 7.0 |
Carcinogens/pharmacology | 3 | 3.0 |
Endothelial Growth Factors/*biosynthesis/genetics/secretion | 7 | 100.0 |
Endothelium, Vascular/*drug effects/metabolism | 12 | 20.0 |
Lymphokines/*biosynthesis/genetics/secretion | 8 | 88.0 |
*Phenanthrenes | 2 | 33.0 |
Tetradecanoylphorbol Acetate/pharmacology | 33 | 1.0 |
Carcinoma, Renal Cell/blood supply/*metabolism/pathology | 4 | 80.0 |
Gelatinase A/biosynthesis/genetics | 3 | 25.0 |
Gelatinase B/biosynthesis/genetics | 3 | 33.0 |
Kidney Neoplasms/blood supply/*metabolism/pathology | 4 | 80.0 |
Nuclear Proteins/analysis | 2 | 1.0 |
Extracellular Matrix Proteins/genetics/*metabolism | 2 | 15.0 |
Tumor Cells, Cultured/metabolism/pathology | 3 | 6.0 |
Sarcoma/*blood/pathology | 2 | 100.0 |
Epidermal Growth Factor/*analysis | 2 | 1.0 |
Cross-Linking Reagents/pharmacology | 3 | 2.0 |
Immunoglobulin G/metabolism | 4 | 2.0 |
Retina/cytology | 3 | 75.0 |
Eye Proteins/metabolism | 2 | 7.0 |
Receptor, Epidermal Growth Factor/metabolism | 7 | 1.0 |
Collagen/*metabolism | 4 | 2.0 |
Diabetic Retinopathy/*metabolism/pathology | 5 | 71.0 |
Peptide Fragments/*metabolism | 5 | 3.0 |
Platelet Factor 4/metabolism | 3 | 5.0 |
*Capillary Permeability | 7 | 25.0 |
Insulin-Like Growth Factor I/*analysis | 4 | 7.0 |
Cell Communication/physiology | 3 | 3.0 |
Fibroblast Growth Factor 2/secretion | 2 | 66.0 |
Interleukin-6/secretion | 4 | 6.0 |
Thalidomide/pharmacology | 2 | 40.0 |
Doxorubicin/pharmacology | 6 | 2.0 |
Drug Antagonism | 2 | 4.0 |
Neoplasm Proteins/genetics/metabolism | 3 | 2.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Antibodies/pharmacology | 17 | 4.0 |
Leukocyte Count | 19 | 1.0 |
Rats, Inbred Lew | 8 | 3.0 |
Cell Membrane/metabolism | 8 | 0.0 |
Fibronectins/metabolism | 6 | 3.0 |
Microscopy, Video | 4 | 5.0 |
Protein Kinase C/*metabolism | 8 | 2.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
Ovarian Neoplasms/*drug therapy/pathology | 2 | 8.0 |
Prostate/chemistry | 2 | 10.0 |
Prostatectomy | 2 | 2.0 |
Transcription Factors/*analysis | 2 | 3.0 |
Antigens, CD/genetics | 2 | 1.0 |
Apoptosis/drug effects/*physiology | 3 | 1.0 |
Dimerization | 22 | 1.0 |
Receptor Protein-Tyrosine Kinases/genetics/metabolism/*physiology | 2 | 25.0 |
Receptors, Growth Factor/genetics/metabolism/*physiology | 2 | 66.0 |
Swine | 44 | 3.0 |
Adenocarcinoma/*metabolism | 7 | 7.0 |
Luciferases/genetics/metabolism | 2 | 0.0 |
Lung Neoplasms/*metabolism | 5 | 6.0 |
Pyrimidines/pharmacology | 4 | 3.0 |
Epidermal Growth Factor/*pharmacology | 3 | 0.0 |
Pregnancy Proteins/*pharmacology | 5 | 29.0 |
Collagen/*blood | 10 | 45.0 |
Peptide Fragments/*blood | 10 | 12.0 |
Anoxia/genetics/metabolism | 2 | 50.0 |
Ki-67 Antigen/metabolism | 19 | 8.0 |
Interleukin-8/genetics | 9 | 17.0 |
Isoenzymes/*genetics | 3 | 0.0 |
Prostaglandin-Endoperoxide Synthase/*genetics | 3 | 10.0 |
Capillaries/physiology | 10 | 52.0 |
Pigment Epithelium of Eye/drug effects/metabolism/pathology | 2 | 100.0 |
Protein Isoforms/biosynthesis/genetics | 8 | 14.0 |
Colorectal Neoplasms/*blood supply/pathology | 2 | 40.0 |
Interleukin-8/*metabolism | 9 | 16.0 |
Esophageal Neoplasms/blood | 2 | 66.0 |
Angiogenesis Inducing Agents/*metabolism | 21 | 77.0 |
Blood Vessels/*embryology | 4 | 30.0 |
Endothelium, Vascular/*embryology | 3 | 60.0 |
Heart/embryology | 2 | 3.0 |
Kidney/embryology | 2 | 6.0 |
Nervous System/embryology | 2 | 6.0 |
Epithelial Cells/metabolism/secretion | 2 | 66.0 |
Bone Marrow Cells/*metabolism | 3 | 6.0 |
Fibroblasts/metabolism/pathology | 4 | 9.0 |
*Mutation | 9 | 0.0 |
*Blood Vessel Prosthesis | 3 | 9.0 |
Endothelial Growth Factors/chemistry/*physiology | 3 | 100.0 |
Lymphokines/chemistry/*physiology | 2 | 100.0 |
Tissue Engineering | 3 | 27.0 |
Adenocarcinoma/*blood supply/metabolism/pathology | 5 | 83.0 |
Carcinoma, Pancreatic Ductal/blood supply/metabolism/pathology | 2 | 100.0 |
*Neovascularization, Pathologic/metabolism/pathology | 2 | 100.0 |
Pancreatic Neoplasms/*blood supply/metabolism/pathology | 2 | 100.0 |
Endometrial Neoplasms/*pathology | 2 | 18.0 |
Endothelial Growth Factors/genetics/*metabolism/pharmacology | 7 | 100.0 |
Growth Substances/genetics/*metabolism/pharmacology | 2 | 66.0 |
Injections, Subcutaneous | 11 | 3.0 |
Neovascularization, Physiologic/drug effects/genetics/*physiology | 2 | 100.0 |
Skin/blood supply/chemistry/drug effects | 2 | 100.0 |
Two-Hybrid System Techniques | 4 | 0.0 |
Endothelial Growth Factors/*urine | 6 | 100.0 |
Lymphokines/*urine | 6 | 100.0 |
Enzyme Inhibitors | 3 | 3.0 |
Capillary Permeability/*physiology | 5 | 38.0 |
Cell Movement/drug effects/*physiology | 7 | 14.0 |
Ovarian Neoplasms/genetics/*metabolism | 3 | 27.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors | 8 | 13.0 |
Angiogenesis Inducing Agents | 6 | 60.0 |
Lysophosphatidylcholines/*pharmacology | 2 | 16.0 |
Lung Neoplasms/metabolism/*pathology | 2 | 5.0 |
Matrix Metalloproteinases/*biosynthesis | 3 | 27.0 |
Platelet-Derived Growth Factor/biosynthesis | 5 | 50.0 |
Proteins/*physiology | 6 | 3.0 |
*Hydrogen-Ion Concentration | 2 | 7.0 |
*MAP Kinase Signaling System | 6 | 5.0 |
Mitogen-Activated Protein Kinase 1/*metabolism | 9 | 7.0 |
Endothelium, Vascular/*cytology | 39 | 23.0 |
Estrenes/pharmacology | 2 | 5.0 |
Phosphodiesterase Inhibitors/pharmacology | 4 | 3.0 |
Phospholipase C/*metabolism | 5 | 4.0 |
Pyrrolidinones/pharmacology | 3 | 5.0 |
Drug Screening Assays, Antitumor | 14 | 4.0 |
Kidney Neoplasms/drug therapy | 2 | 33.0 |
Multiple Myeloma/*drug therapy/pathology | 2 | 40.0 |
3',5'-Cyclic-Nucleotide Phosphodiesterase/antagonists & inhibitors | 2 | 25.0 |
Adjuvants, Immunologic/therapeutic use | 2 | 4.0 |
Angiogenesis Inhibitors/pharmacology/*therapeutic use | 8 | 100.0 |
Cysteine Endopeptidases | 3 | 6.0 |
Multienzyme Complexes/antagonists & inhibitors | 2 | 7.0 |
Proteasome Endopeptidase Complex | 5 | 0.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors | 3 | 4.0 |
Bone Marrow/*blood supply/pathology | 2 | 66.0 |
Bone Marrow Cells/physiology | 3 | 12.0 |
*Retinal Vessels | 2 | 40.0 |
Breast Neoplasms/*drug therapy/*metabolism | 2 | 10.0 |
Receptor, erbB-2/metabolism | 5 | 3.0 |
Neovascularization, Pathologic/blood/*diagnosis | 2 | 100.0 |
RNA, Messenger/blood | 2 | 3.0 |
*Surgical Procedures, Operative | 2 | 6.0 |
Heart/drug effects | 3 | 6.0 |
Morphine/*pharmacology | 2 | 9.0 |
Narcotics/*pharmacology | 2 | 13.0 |
RNA, Messenger/drug effects | 8 | 12.0 |
Nitric Oxide/*blood | 3 | 11.0 |
Antineoplastic Agents, Hormonal/*pharmacology | 5 | 9.0 |
Endothelium/cytology/drug effects | 3 | 27.0 |
Bradykinin/pharmacology | 2 | 4.0 |
Endothelium, Vascular/cytology/drug effects/*enzymology | 2 | 22.0 |
Guinea Pigs | 17 | 2.0 |
Nitric Oxide/pharmacology | 2 | 12.0 |
Vascular Endothelial Growth Factor A/pharmacology | 22 | 78.0 |
Dinoprostone/*metabolism | 3 | 7.0 |
Colony-Forming Units Assay | 6 | 1.0 |
Fetal Blood/cytology | 2 | 1.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 3 | 1.0 |
Membrane Glycoproteins | 2 | 4.0 |
Polymerase Chain Reaction/methods | 15 | 1.0 |
Recombinant Fusion Proteins/pharmacology | 7 | 7.0 |
Indoles/adverse effects/*therapeutic use | 2 | 28.0 |
Proto-Oncogene Protein c-kit/metabolism | 2 | 4.0 |
Pyrroles/adverse effects/*therapeutic use | 2 | 33.0 |
Receptors, Vascular Endothelial Growth Factor/metabolism | 14 | 87.0 |
Safety | 5 | 3.0 |
Lung Neoplasms/blood supply/drug therapy/secondary | 2 | 100.0 |
Lymphatic Metastasis/pathology | 5 | 7.0 |
Observer Variation | 4 | 3.0 |
Synovial Membrane/blood supply | 2 | 100.0 |
Cell Differentiation/drug effects | 12 | 1.0 |
Macrophages/*drug effects/metabolism | 2 | 5.0 |
Metalloporphyrins/pharmacology | 2 | 22.0 |
Prolactin/*pharmacology | 2 | 2.0 |
Superoxides/metabolism | 6 | 2.0 |
Microtomy | 2 | 13.0 |
Nuclear Proteins/metabolism | 23 | 2.0 |
Angiogenesis Inducing Agents/*pharmacology | 8 | 57.0 |
Ischemia/pathology | 2 | 50.0 |
Neurons/metabolism/pathology | 3 | 4.0 |
Spinal Cord/pathology | 3 | 4.0 |
Vascular Endothelial Growth Factor A/*physiology | 27 | 96.0 |
Epithelial Cells/metabolism/pathology | 4 | 8.0 |
*Milk Proteins | 3 | 0.0 |
Vascular Endothelial Growth Factor Receptor-1/*biosynthesis | 3 | 75.0 |
Transcription, Genetic/genetics | 5 | 1.0 |
Vascular Endothelial Growth Factors/*biosynthesis | 4 | 100.0 |
Inflammation/pathology/physiopathology | 2 | 50.0 |
Lung/*blood supply | 3 | 14.0 |
Research | 2 | 3.0 |
Antigens, CD31/*analysis | 2 | 50.0 |
Birth Weight | 9 | 5.0 |
Cause of Death | 10 | 5.0 |
Extracellular Matrix Proteins/*analysis | 3 | 15.0 |
Drug Resistance | 2 | 0.0 |
Endothelial Growth Factors/*antagonists & inhibitors/metabolism | 7 | 100.0 |
Lymphokines/*antagonists & inhibitors/metabolism | 7 | 87.0 |
Neoplasms/*drug therapy | 7 | 5.0 |
Receptor Protein-Tyrosine Kinases/drug effects | 2 | 100.0 |
Receptors, Growth Factor/drug effects | 2 | 66.0 |
Membrane Glycoproteins/*pharmacology | 3 | 3.0 |
5' Untranslated Regions/genetics | 4 | 3.0 |
Cercopithecus aethiops | 6 | 0.0 |
Ribosomes/*metabolism | 3 | 10.0 |
Sequence Homology, Nucleic Acid | 22 | 0.0 |
Brain Neoplasms/*blood supply/metabolism | 5 | 71.0 |
Glioma/*blood supply/metabolism | 3 | 75.0 |
JNK Mitogen-Activated Protein Kinases | 13 | 2.0 |
Mitogen-Activated Protein Kinases/metabolism/physiology | 2 | 14.0 |
Endometrium/*metabolism | 7 | 8.0 |
Blood Flow Velocity/physiology | 2 | 8.0 |
Embryo Implantation/*physiology | 2 | 5.0 |
Fertilization in Vitro/*methods | 2 | 7.0 |
Ultrasonography, Doppler, Color | 8 | 36.0 |
Serine/*metabolism | 2 | 2.0 |
Colorectal Neoplasms/*blood supply/metabolism/pathology | 2 | 100.0 |
Isoenzymes/*genetics/metabolism | 2 | 3.0 |
Prostaglandin-Endoperoxide Synthase/*genetics/metabolism | 2 | 33.0 |
Endothelium, Vascular/drug effects/*metabolism | 7 | 9.0 |
Aerobiosis | 2 | 8.0 |
Neoplasms/*pathology | 3 | 5.0 |
Proteins/*genetics | 6 | 0.0 |
Serpins/*genetics | 2 | 16.0 |
Endothelial Growth Factors/*antagonists & inhibitors/genetics/metabolism | 2 | 100.0 |
Lymphokines/*antagonists & inhibitors/genetics/metabolism | 2 | 100.0 |
Molecular Structure | 5 | 0.0 |
RNA, Catalytic/therapeutic use | 3 | 100.0 |
Collagen/drug effects/metabolism | 2 | 66.0 |
Extracellular Matrix/drug effects/metabolism | 3 | 17.0 |
Pregnancy Trimester, First | 14 | 5.0 |
Cell Size | 9 | 3.0 |
Endothelium, Vascular/chemistry/cytology | 3 | 25.0 |
Luteal Phase | 4 | 6.0 |
*Menstrual Cycle | 2 | 3.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 8 | 4.0 |
Tumor Cells, Cultured/drug effects/secretion | 3 | 25.0 |
Neoplasm Proteins/*analysis | 10 | 3.0 |
Neoplasm Staging/methods | 8 | 26.0 |
*Drug Design | 2 | 2.0 |
Oligonucleotides, Antisense/therapeutic use | 4 | 50.0 |
Antigens, CD34 | 2 | 0.0 |
Endothelium, Vascular/*cytology/immunology | 2 | 33.0 |
Flow Cytometry/methods | 2 | 0.0 |
DNA Mutational Analysis | 15 | 0.0 |
Endothelin-1/*blood | 4 | 19.0 |
Capillaries/growth & development | 4 | 80.0 |
Cell Culture Techniques/methods | 12 | 5.0 |
Tissue Engineering/*methods | 3 | 17.0 |
Androstadienes/pharmacology | 14 | 5.0 |
Aorta | 11 | 7.0 |
Hydrogen Peroxide/metabolism | 6 | 4.0 |
Phospholipase C/metabolism | 4 | 1.0 |
Receptor Protein-Tyrosine Kinases/genetics/*physiology | 3 | 11.0 |
Receptors, Growth Factor/genetics/*physiology | 2 | 50.0 |
Receptors, Mitogen/physiology | 4 | 80.0 |
Endothelial Growth Factors/antagonists & inhibitors/biosynthesis/genetics | 2 | 100.0 |
Growth Inhibitors/pharmacology | 7 | 4.0 |
Lymphokines/antagonists & inhibitors/biosynthesis/genetics | 2 | 100.0 |
Leukocytes, Mononuclear/metabolism | 5 | 2.0 |
*Lymphatic Metastasis | 5 | 13.0 |
Recombinant Proteins/toxicity | 2 | 9.0 |
Stomach Neoplasms/*pathology | 5 | 10.0 |
Coronary Angiography | 10 | 4.0 |
*Myocardial Revascularization | 2 | 40.0 |
Technetium Tc 99m Sestamibi/diagnostic use | 3 | 20.0 |
Breast Neoplasms/genetics/*pathology | 2 | 4.0 |
Cyclic AMP-Dependent Protein Kinases/metabolism | 7 | 3.0 |
Gene Expression Regulation/*drug effects | 30 | 4.0 |
*Promoter Regions (Genetics) | 13 | 0.0 |
CHO Cells | 13 | 0.0 |
Fibroblast Growth Factor 2/physiology | 13 | 52.0 |
Hamsters | 24 | 0.0 |
Immunoglobulin G/pharmacology | 4 | 6.0 |
Arteriosclerosis/therapy | 2 | 50.0 |
Cardiovascular Diseases/*therapy | 4 | 50.0 |
Forecasting | 9 | 2.0 |
Arthritis, Rheumatoid/*metabolism | 4 | 6.0 |
Fluorescent Antibody Technique, Indirect | 19 | 2.0 |
Neuregulin-1/*metabolism | 2 | 14.0 |
RNA, Neoplasm/genetics/metabolism | 10 | 6.0 |
Angiogenesis Inhibitors/chemistry/*pharmacology | 2 | 66.0 |
Recombinant Proteins/antagonists & inhibitors/metabolism | 2 | 4.0 |
Fibroblast Growth Factor 2/biosynthesis/genetics | 3 | 37.0 |
Genes, Tumor Suppressor | 9 | 1.0 |
Neoplasms, Experimental/blood supply | 3 | 75.0 |
Neovascularization, Pathologic/*genetics/metabolism | 3 | 42.0 |
Ovarian Neoplasms/pathology | 4 | 12.0 |
Protein p53/physiology | 2 | 2.0 |
RNA, Neoplasm/biosynthesis | 12 | 8.0 |
Recombinant Fusion Proteins/physiology | 11 | 4.0 |
Endothelial Growth Factors/*biosynthesis/genetics/immunology | 2 | 100.0 |
RNA/biosynthesis | 2 | 2.0 |
Stents/*adverse effects | 4 | 12.0 |
Adenocarcinoma/metabolism/*pathology | 2 | 3.0 |
Chromatography, High Pressure Liquid | 8 | 0.0 |
Prostatic Neoplasms/metabolism/*pathology | 2 | 2.0 |
Protein p53/genetics/metabolism | 2 | 2.0 |
Endothelial Growth Factors/analysis/genetics | 5 | 100.0 |
Lymphokines/analysis/genetics | 5 | 100.0 |
Serine Endopeptidases/analysis | 4 | 11.0 |
Chromones/pharmacology | 14 | 6.0 |
Morpholines/pharmacology | 16 | 6.0 |
Tyrosine/*metabolism | 6 | 1.0 |
src-Family Kinases/*metabolism | 5 | 3.0 |
Cytoskeletal Proteins/analysis | 2 | 4.0 |
Blood Sedimentation | 3 | 1.0 |
Alleles | 9 | 0.0 |
Bromodeoxyuridine/metabolism | 3 | 4.0 |
Ribonucleoproteins/metabolism | 2 | 6.0 |
Viral Proteins/metabolism | 2 | 2.0 |
Creatine Kinase/blood | 5 | 4.0 |
Electrocardiography | 3 | 0.0 |
Amino Acid Motifs | 2 | 0.0 |
Cell Membrane/*metabolism | 2 | 0.0 |
Chimeric Proteins/chemistry/metabolism | 2 | 3.0 |
Nerve Tissue Proteins/metabolism | 8 | 3.0 |
*Peptide Library | 5 | 8.0 |
DNA-Binding Proteins/genetics/physiology | 2 | 2.0 |
Hematopoietic Stem Cell Transplantation | 2 | 1.0 |
Mice, Mutant Strains | 9 | 1.0 |
*Neovascularization, Pathologic/genetics | 5 | 100.0 |
Neutralization Tests | 10 | 2.0 |
*Repressor Proteins | 8 | 0.0 |
Transcription Factors/genetics/physiology | 5 | 8.0 |
Delayed-Action Preparations | 3 | 2.0 |
Drug Delivery Systems/*methods | 4 | 10.0 |
Mice, Inbred NOD | 6 | 2.0 |
Microspheres | 9 | 4.0 |
Lymph Node Excision | 3 | 4.0 |
Lymph Nodes/metabolism/pathology | 2 | 8.0 |
Gene Expression Regulation, Enzymologic | 13 | 1.0 |
Lymphokines/drug effects/genetics/metabolism | 4 | 100.0 |
Recombinant Fusion Proteins/drug effects/genetics/metabolism | 2 | 10.0 |
Thymidine/metabolism | 7 | 2.0 |
Tritium/diagnostic use | 3 | 2.0 |
Adenocarcinoma/pathology | 6 | 7.0 |
Carcinoma, Squamous Cell/*metabolism/pathology | 9 | 10.0 |
Head and Neck Neoplasms/*metabolism/pathology | 4 | 19.0 |
Lymph Nodes/metabolism | 3 | 5.0 |
Transcription Factors/*genetics | 7 | 0.0 |
*Blood Coagulation | 4 | 1.0 |
Interleukin-6/biosynthesis | 5 | 2.0 |
Interleukin-8/biosynthesis | 7 | 6.0 |
Bone Marrow/chemistry | 2 | 6.0 |
Cytoskeleton/metabolism | 4 | 1.0 |
Capillaries/ultrastructure | 6 | 42.0 |
Blood-Brain Barrier/physiology | 2 | 7.0 |
Fibroblast Growth Factor 2/*cerebrospinal fluid | 2 | 66.0 |
Cell Membrane/physiology | 3 | 2.0 |
Electrophysiology | 2 | 0.0 |
Endothelial Growth Factors/genetics/*pharmacology | 5 | 100.0 |
Lymphokines/genetics/*pharmacology | 4 | 57.0 |
Proto-Oncogene Proteins c-jun/analysis | 2 | 22.0 |
Transforming Growth Factor beta/*pharmacology | 4 | 1.0 |
Platelet-Derived Growth Factor/metabolism | 13 | 20.0 |
DNA, Complementary/*administration & dosage | 2 | 25.0 |
Membrane Glycoproteins/*genetics | 3 | 0.0 |
Recombinant Proteins/genetics | 4 | 3.0 |
Carcinoma, Renal Cell/*blood supply/*metabolism | 2 | 100.0 |
Kidney Neoplasms/*blood supply/*metabolism | 2 | 100.0 |
Actins/genetics | 3 | 2.0 |
Chorionic Villi Sampling | 3 | 6.0 |
Extracellular Matrix Proteins/genetics | 6 | 11.0 |
Receptor Protein-Tyrosine Kinases/*analysis/genetics | 5 | 41.0 |
Receptors, Growth Factor/*analysis/genetics | 5 | 100.0 |
Adenocarcinoma/blood supply/genetics/*metabolism | 2 | 100.0 |
Fibroblast Growth Factor 2/*biosynthesis/genetics | 3 | 42.0 |
Neovascularization, Pathologic/genetics/*metabolism | 4 | 100.0 |
C-Reactive Protein/metabolism | 4 | 1.0 |
Myocardial Revascularization/*methods | 2 | 50.0 |
src-Family Kinases/metabolism | 4 | 2.0 |
Enhancer Elements (Genetics) | 6 | 1.0 |
Erythropoietin/*biosynthesis/genetics | 2 | 9.0 |
Models, Genetic | 5 | 0.0 |
Nuclear Proteins/metabolism/*physiology | 2 | 6.0 |
RNA Interference | 5 | 1.0 |
RNA, Small Interfering/metabolism | 3 | 1.0 |
Blood Pressure | 13 | 2.0 |
*Infant, Premature | 2 | 3.0 |
Radiation Dosage | 2 | 2.0 |
Blood-Brain Barrier | 2 | 3.0 |
Leukocytes/metabolism | 2 | 1.0 |
*Magnetic Resonance Imaging | 3 | 1.0 |
Calcium Signaling/drug effects | 2 | 4.0 |
Leukemia, Myeloid, Chronic/*blood/*drug therapy | 2 | 66.0 |
Neuropilin-1/metabolism | 3 | 100.0 |
Piperazines/*therapeutic use | 5 | 10.0 |
Pyrimidines/*therapeutic use | 5 | 11.0 |
*Adenoviridae | 3 | 9.0 |
Mitogens | 2 | 2.0 |
Transduction, Genetic/*methods | 3 | 16.0 |
Apoptosis/*drug effects/physiology | 5 | 4.0 |
Kidney Glomerulus/*cytology/*physiology | 2 | 66.0 |
Protein Conformation | 16 | 0.0 |
Proteins/genetics/*physiology | 5 | 3.0 |
Cell Differentiation/genetics | 5 | 1.0 |
Embryo, Nonmammalian | 3 | 8.0 |
Gene Expression Regulation, Developmental/genetics | 2 | 2.0 |
Myocardium/cytology/*metabolism | 4 | 8.0 |
*Nuclear Proteins | 7 | 0.0 |
Signal Transduction/genetics | 3 | 1.0 |
Transcription Factors/genetics/*metabolism | 13 | 1.0 |
Zebrafish | 3 | 2.0 |
Drugs, Chinese Herbal/*pharmacology | 5 | 10.0 |
Monocytes/cytology/drug effects/metabolism | 3 | 11.0 |
Extracellular Matrix Proteins/biosynthesis | 4 | 50.0 |
Transforming Growth Factor beta/*biosynthesis | 2 | 8.0 |
Diabetes Mellitus/metabolism | 2 | 5.0 |
Arsenites/*pharmacology | 2 | 11.0 |
Glutathione/metabolism | 3 | 1.0 |
Gene Expression Regulation, Enzymologic/drug effects | 6 | 3.0 |
Biological Markers/urine | 4 | 6.0 |
Nitric Oxide/blood | 3 | 14.0 |
Breast Neoplasms/blood supply/metabolism/*pathology | 2 | 50.0 |
Cytokines/*physiology | 9 | 4.0 |
Interleukin-6/physiology | 4 | 6.0 |
Lymphokines/drug effects/genetics/*metabolism | 2 | 100.0 |
Adenocarcinoma/metabolism | 8 | 11.0 |
Carcinoma, Non-Small-Cell Lung/*metabolism | 3 | 11.0 |
Carcinoma, Squamous Cell/metabolism | 4 | 6.0 |
Bone Marrow/*blood supply/drug effects | 2 | 100.0 |
Hematologic Neoplasms/drug therapy/*pathology | 2 | 100.0 |
Microcirculation/drug effects/pathology | 2 | 66.0 |
Calcium/*physiology | 2 | 1.0 |
Isoenzymes/*physiology | 6 | 18.0 |
RNA, Neoplasm/genetics | 14 | 4.0 |
Syndrome | 2 | 0.0 |
Cell Cycle Proteins/analysis | 2 | 7.0 |
Proto-Oncogene Proteins/analysis | 10 | 5.0 |
Skin/*blood supply | 7 | 20.0 |
Cytokines/pharmacology | 14 | 3.0 |
Endometrium/*blood supply/cytology | 2 | 100.0 |
Gene Expression Regulation, Developmental/physiology | 4 | 5.0 |
Paracrine Communication/*physiology | 2 | 11.0 |
Steroids/pharmacology | 4 | 10.0 |
Carcinoma, Renal Cell/*drug therapy/pathology | 4 | 100.0 |
Constipation/chemically induced | 4 | 100.0 |
Cytokines/blood | 11 | 5.0 |
Kidney Neoplasms/*drug therapy/pathology | 2 | 50.0 |
Peripheral Nervous System Diseases/chemically induced | 2 | 11.0 |
Antirheumatic Agents/therapeutic use | 2 | 6.0 |
Extracellular Matrix Proteins/blood | 2 | 50.0 |
Endothelial Growth Factors/analysis/pharmacology | 2 | 100.0 |
Gelatinase B/*analysis | 3 | 37.0 |
Lymphokines/analysis/pharmacology | 2 | 100.0 |
Fibroblast Growth Factor 2/*genetics | 4 | 20.0 |
Interleukin-8/*genetics | 2 | 7.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/*physiology | 3 | 10.0 |
Breast Neoplasms/genetics/metabolism | 3 | 6.0 |
*Ligases | 12 | 6.0 |
Trans-Activators/*biosynthesis/genetics | 5 | 17.0 |
Ubiquitins/metabolism | 4 | 2.0 |
Recombinant Proteins/genetics/immunology/metabolism | 3 | 13.0 |
Blood Vessels/*growth & development | 2 | 66.0 |
*Heart Transplantation | 2 | 2.0 |
Blood Vessels/embryology | 2 | 50.0 |
DNA-Binding Proteins/genetics | 13 | 1.0 |
*Neovascularization, Physiologic/genetics | 3 | 60.0 |
Vertebrates | 2 | 3.0 |
Gingiva/*metabolism | 2 | 25.0 |
Gingivitis/*metabolism | 2 | 33.0 |
Periodontal Index | 2 | 4.0 |
Biological Markers/*analysis | 3 | 2.0 |
Loss of Heterozygosity | 3 | 0.0 |
*Neoplasm Metastasis | 8 | 9.0 |
Hemolytic-Uremic Syndrome/drug therapy/pathology | 2 | 100.0 |
*Renal Circulation | 2 | 25.0 |
Electrophoresis, Gel, Two-Dimensional | 3 | 0.0 |
Glycosylation | 10 | 1.0 |
*RNA Splicing | 6 | 2.0 |
Menstrual Cycle/*blood | 4 | 28.0 |
Ovary/*physiology | 2 | 5.0 |
Proto-Oncogene Proteins c-bcl-2/*metabolism | 7 | 2.0 |
Lymphokines/biosynthesis/genetics/*pharmacology | 2 | 100.0 |
*Cell Transplantation | 2 | 7.0 |
Genes, Reporter/genetics | 3 | 1.0 |
Neovascularization, Physiologic/drug effects/*genetics | 3 | 75.0 |
Ventricular Function, Left | 4 | 12.0 |
Endothelial Growth Factors/*biosynthesis/genetics/pharmacology | 5 | 100.0 |
Lymphokines/*biosynthesis/genetics/pharmacology | 5 | 62.0 |
Myocardial Revascularization/methods | 2 | 50.0 |
Hepatocyte Growth Factor/*blood | 12 | 11.0 |
Lupus Erythematosus, Systemic/*metabolism | 2 | 13.0 |
Transforming Growth Factor beta/*blood | 5 | 19.0 |
Endothelial Growth Factors/biosynthesis/blood | 2 | 100.0 |
Glycoproteins/*pharmacology | 2 | 2.0 |
Lymphokines/biosynthesis/blood | 2 | 100.0 |
Neoplasms, Experimental/*blood supply/drug therapy | 2 | 66.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 2 | 0.0 |
Epithelial Cells/*metabolism | 3 | 2.0 |
Kidney Glomerulus/*metabolism | 5 | 15.0 |
Codon, Initiator/*genetics | 2 | 13.0 |
Extracellular Matrix | 3 | 12.0 |
Intercellular Signaling Peptides and Proteins/genetics/*metabolism | 15 | 45.0 |
Pregnancy Trimester, Second | 6 | 2.0 |
Sequence Deletion | 13 | 0.0 |
Carcinoma, Squamous Cell/*chemistry/pathology | 3 | 13.0 |
Mouth Neoplasms/*chemistry/pathology | 2 | 22.0 |
Receptors, Cell Surface/genetics | 4 | 3.0 |
Endothelial Growth Factors/antagonists & inhibitors/*biosynthesis | 2 | 100.0 |
Lymphokines/antagonists & inhibitors/*biosynthesis | 2 | 50.0 |
Cell Adhesion/*drug effects | 2 | 3.0 |
Angioplasty, Balloon/adverse effects | 2 | 25.0 |
Ascorbic Acid/pharmacology | 2 | 3.0 |
Muscle, Smooth, Vascular/drug effects/*metabolism | 2 | 8.0 |
Reactive Oxygen Species/*physiology | 2 | 16.0 |
Thrombin/*pharmacology | 6 | 5.0 |
Transforming Growth Factor beta/biosynthesis | 5 | 10.0 |
Dinoprostone/*pharmacology | 5 | 9.0 |
Dose-Response Relationship, Radiation | 7 | 2.0 |
Endothelial Growth Factors/*biosynthesis/*genetics | 9 | 100.0 |
Lymphokines/*biosynthesis/*genetics | 8 | 100.0 |
Vitamin E/pharmacology | 2 | 6.0 |
Gene Frequency | 8 | 0.0 |
Genetic Predisposition to Disease | 8 | 0.0 |
*Polymorphism, Genetic | 10 | 0.0 |
DNA-Binding Proteins/*physiology | 8 | 1.0 |
Nuclear Proteins/*physiology | 6 | 4.0 |
Protein-Serine-Threonine Kinases/*physiology | 3 | 2.0 |
Sirolimus/pharmacology | 2 | 2.0 |
Enzyme Inhibitors/metabolism | 7 | 3.0 |
Vascular Endothelial Growth Factor A/antagonists & | 11 | 91.0 |
Vascular Endothelial Growth Factor A/*cerebrospinal fluid | 3 | 100.0 |
Platelet-Derived Growth Factor/analysis | 8 | 32.0 |
Receptors, Fibroblast Growth Factor/analysis | 5 | 31.0 |
*Embolization, Therapeutic | 3 | 13.0 |
Culture Media, Conditioned/pharmacology | 28 | 15.0 |
Embryo | 10 | 2.0 |
Endothelium, Vascular/*drug effects/*metabolism | 3 | 21.0 |
Fibrinogen/*metabolism | 2 | 2.0 |
Plasminogen Activator Inhibitor 1/*genetics | 2 | 5.0 |
Receptors, Cell Surface/*genetics | 3 | 1.0 |
Carcinoma, Hepatocellular/*pathology | 4 | 8.0 |
Liver Neoplasms/*pathology | 5 | 8.0 |
Blood Glucose | 2 | 2.0 |
*Diabetes Complications | 2 | 3.0 |
Erythrocyte Count | 2 | 2.0 |
Hemoglobin A, Glycosylated/metabolism | 3 | 2.0 |
Hemoglobins | 2 | 6.0 |
Cisplatin/administration & dosage | 9 | 4.0 |
Etoposide/administration & dosage | 3 | 2.0 |
Up-Regulation/drug effects/genetics | 4 | 22.0 |
*Orchiectomy | 3 | 16.0 |
Prostate-Specific Antigen/blood | 8 | 9.0 |
Vascular Endothelial Growth Factor Receptor-1/*blood | 9 | 100.0 |
Fatigue/chemically induced | 2 | 28.0 |
Thalidomide/adverse effects/*therapeutic use | 2 | 33.0 |
Chemokines, CXC/*metabolism | 3 | 5.0 |
Hematopoietic Stem Cells/*cytology | 4 | 1.0 |
Jurkat Cells | 4 | 0.0 |
Tetrazolium Salts/pharmacology | 2 | 3.0 |
Thiazoles/pharmacology | 4 | 3.0 |
Tissue Inhibitor of Metalloproteinase-1/metabolism | 5 | 17.0 |
Tissue Inhibitor of Metalloproteinase-2/metabolism | 3 | 13.0 |
*Autocrine Communication | 4 | 16.0 |
*Paracrine Communication | 6 | 37.0 |
Antibodies, Monoclonal/immunology | 8 | 0.0 |
Gene Library | 9 | 0.0 |
Immunotherapy | 9 | 2.0 |
Killer Cells, Natural/immunology | 2 | 0.0 |
Models, Immunological | 4 | 1.0 |
T-Lymphocytes/immunology | 5 | 0.0 |
Thymidine Phosphorylase/analysis | 7 | 87.0 |
*Leukocyte Count | 2 | 3.0 |
Lung Neoplasms/*blood | 4 | 18.0 |
Transplantation Conditioning | 2 | 3.0 |
Androgens/pharmacology | 3 | 6.0 |
Cell Differentiation/*drug effects | 3 | 1.0 |
Interferon-alpha/*pharmacology | 2 | 1.0 |
Prostatic Neoplasms/*pathology | 5 | 4.0 |
Receptors, Growth Factor/genetics/physiology | 4 | 36.0 |
Hepatectomy | 5 | 7.0 |
Antibodies/diagnostic use | 2 | 4.0 |
Carcinoma, Squamous Cell/blood supply/pathology | 2 | 100.0 |
Mouth Neoplasms/blood supply/*pathology | 3 | 60.0 |
Endothelial Growth Factors/biosynthesis/genetics/*physiology | 8 | 88.0 |
Lymphokines/biosynthesis/genetics/*physiology | 10 | 90.0 |
Neoplasms/blood supply/*pathology | 2 | 100.0 |
Macrophages/metabolism | 10 | 3.0 |
Enzyme Inhibitors/pharmacology/therapeutic use | 2 | 10.0 |
Multiple Myeloma/*drug therapy | 3 | 18.0 |
Granulosa Cells/*physiology | 2 | 22.0 |
Molsidomine/analogs & derivatives/pharmacology | 2 | 14.0 |
Nitric Oxide Donors/*pharmacology | 2 | 15.0 |
Penicillamine/analogs & derivatives/pharmacology | 2 | 14.0 |
*Transfection | 9 | 3.0 |
Cytomegalovirus/genetics | 5 | 5.0 |
Double-Blind Method | 14 | 0.0 |
Recombinant Fusion Proteins | 7 | 2.0 |
Vascular Endothelial Growth Factor, Endocrine-Gland-Derived | 3 | 75.0 |
Ovarian Follicle/pathology | 2 | 33.0 |
Amides/pharmacology | 3 | 5.0 |
Insulin-Like Growth Factor I/*pharmacology | 10 | 7.0 |
Mitogen-Activated Protein Kinase 1/drug effects/metabolism | 2 | 28.0 |
Mitogen-Activated Protein Kinases/drug effects/metabolism | 4 | 9.0 |
Somatostatin/agonists/*pharmacology | 2 | 100.0 |
Ascitic Fluid/*metabolism | 7 | 29.0 |
Laparoscopy | 7 | 20.0 |
Macrophages, Peritoneal/*metabolism | 2 | 9.0 |
Monocytes/metabolism | 9 | 2.0 |
Cells, Cultured/drug effects/metabolism | 4 | 9.0 |
Endothelium, Vascular/drug effects/*enzymology | 3 | 33.0 |
Signal Transduction/drug effects/physiology | 14 | 5.0 |
Exercise Tolerance/drug effects | 2 | 33.0 |
Platelet Aggregation Inhibitors/pharmacology/therapeutic use | 2 | 66.0 |
Matched-Pair Analysis | 3 | 3.0 |
Receptor, Angiotensin, Type 1 | 3 | 2.0 |
Receptors, Angiotensin/*antagonists & inhibitors | 2 | 2.0 |
Intercellular Signaling Peptides and Proteins/biosynthesis/*genetics | 3 | 42.0 |
Calcium Chloride/pharmacology | 2 | 9.0 |
Platelet Activating Factor/*biosynthesis | 2 | 22.0 |
Myelodysplastic Syndromes/*drug therapy | 2 | 14.0 |
*Cell Hypoxia | 34 | 47.0 |
Partial Pressure | 10 | 20.0 |
CA-125 Antigen/analysis | 4 | 20.0 |
Pleural Effusion/*chemistry | 3 | 42.0 |
Choroid/*blood supply/metabolism | 2 | 100.0 |
Nitric Oxide/*biosynthesis | 2 | 4.0 |
Proto-Oncogene Proteins/*chemistry/genetics/*metabolism | 2 | 10.0 |
Recombinant Proteins/chemistry/metabolism | 7 | 1.0 |
Spectrum Analysis, Mass | 4 | 0.0 |
Altitude | 5 | 20.0 |
Carrier Proteins/metabolism | 5 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 2 | 0.0 |
Cyclin D1/biosynthesis | 5 | 12.0 |
Protein p53/biosynthesis | 5 | 3.0 |
Cytosol/metabolism | 8 | 1.0 |
Endothelium, Vascular/*cytology/drug effects/*metabolism | 2 | 33.0 |
*Receptors, Cytokine | 3 | 2.0 |
Cytokines/*biosynthesis | 6 | 1.0 |
Synovial Membrane/metabolism | 2 | 7.0 |
Neovascularization, Pathologic/genetics/metabolism | 10 | 58.0 |
Up-Regulation/genetics | 2 | 2.0 |
*Zebrafish Proteins | 2 | 0.0 |
Hydrogen-Ion Concentration | 12 | 0.0 |
Antioxidants/metabolism | 2 | 2.0 |
Catalase/metabolism | 3 | 4.0 |
Oxidation-Reduction/drug effects | 4 | 5.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors/metabolism | 2 | 2.0 |
S-Nitrosoglutathione/pharmacology | 2 | 33.0 |
Superoxide Dismutase/metabolism | 3 | 3.0 |
Endothelial Growth Factors/*biosynthesis/immunology | 6 | 100.0 |
Lymphokines/*biosynthesis/immunology | 4 | 57.0 |
Endothelial Growth Factors/biosynthesis/*pharmacology | 3 | 100.0 |
Lymphokines/biosynthesis/*pharmacology | 3 | 60.0 |
Genetic Markers | 4 | 0.0 |
Tumor Markers, Biological/*genetics | 2 | 1.0 |
Endometrium/*pathology | 4 | 20.0 |
Hysterectomy | 6 | 7.0 |
Neoplasm Proteins/*blood | 12 | 21.0 |
Postmenopause | 7 | 3.0 |
*Adenoviridae/genetics | 2 | 50.0 |
Exercise Test | 5 | 1.0 |
Femoral Artery | 3 | 27.0 |
Infusions, Intra-Arterial | 4 | 6.0 |
Lymphokines/*administration & dosage/biosynthesis/genetics | 2 | 100.0 |
Peripheral Vascular Diseases/physiopathology/*therapy | 3 | 100.0 |
Administration, Topical | 6 | 5.0 |
Budesonide/*pharmacology | 2 | 33.0 |
Endothelial Growth Factors/genetics/*secretion | 3 | 100.0 |
Dendritic Cells/*immunology | 3 | 1.0 |
Heart Defects, Congenital/*blood | 2 | 100.0 |
Hepatocyte Growth Factor/blood | 9 | 40.0 |
Endothelial Growth Factors/*administration & dosage | 6 | 100.0 |
Equipment Design | 3 | 2.0 |
Lymphokines/*administration & dosage | 6 | 60.0 |
Recombinant Proteins/administration & dosage | 5 | 5.0 |
Thrombosis/pathology | 3 | 21.0 |
Carcinoma, Non-Small-Cell Lung/*blood supply | 2 | 50.0 |
Cytokines/analysis | 3 | 4.0 |
Lung Neoplasms/*blood supply | 2 | 33.0 |
Cell Culture Techniques/*methods | 4 | 4.0 |
Feedback | 2 | 1.0 |
Kidney | 6 | 1.0 |
Protein Processing, Post-Translational | 10 | 1.0 |
Substrate Specificity | 11 | 0.0 |
src Homology Domains | 3 | 0.0 |
Ovarian Neoplasms/*drug therapy/metabolism | 3 | 23.0 |
Proto-Oncogene Proteins c-fos/genetics | 2 | 3.0 |
Receptor, Epidermal Growth Factor/genetics | 2 | 1.0 |
Cell Communication/drug effects | 2 | 5.0 |
Chemotaxis, Leukocyte | 2 | 1.0 |
Blood Vessels/*pathology | 2 | 18.0 |
Nitric-Oxide Synthase/*analysis/genetics | 2 | 66.0 |
Biomedical Engineering | 3 | 18.0 |
Wound Healing/*physiology | 8 | 12.0 |
Epidermal Growth Factor/*metabolism | 2 | 0.0 |
*Coronary Artery Bypass | 4 | 5.0 |
Postoperative Complications/etiology | 2 | 5.0 |
Combined Modality Therapy/methods | 2 | 11.0 |
Preoperative Care/methods | 2 | 7.0 |
Radiotherapy, Adjuvant/methods | 2 | 50.0 |
Ovarian Neoplasms/*metabolism/mortality/pathology | 3 | 30.0 |
Blood Coagulation/drug effects | 2 | 1.0 |
Trans-Activators/metabolism | 6 | 0.0 |
Endothelium, Vascular/drug effects/pathology/*physiopathology | 2 | 50.0 |
Proteinuria | 2 | 5.0 |
Receptor Protein-Tyrosine Kinases/analysis/genetics | 2 | 28.0 |
Thymidine Phosphorylase/metabolism | 10 | 71.0 |
Organ Size | 10 | 5.0 |
Protein p53/genetics | 3 | 1.0 |
Protein Kinase C/antagonists & inhibitors/*physiology | 2 | 7.0 |
RNA Stability/drug effects | 2 | 14.0 |
Drug Therapy, Combination | 12 | 0.0 |
Melphalan/administration & dosage | 2 | 4.0 |
Prednisolone/administration & dosage | 2 | 2.0 |
Hemangiosarcoma/genetics/*metabolism/pathology | 2 | 100.0 |
Endothelial Growth Factors/*biosynthesis/blood/genetics | 4 | 100.0 |
Head and Neck Neoplasms/blood/*metabolism | 2 | 100.0 |
Lymphokines/*biosynthesis/blood/genetics | 4 | 100.0 |
MAP Kinase Signaling System/drug effects/*physiology | 3 | 7.0 |
Proto-Oncogene Protein c-met/metabolism | 5 | 6.0 |
Breast Neoplasms/metabolism/*pathology | 2 | 2.0 |
Esophageal Neoplasms/*metabolism/pathology | 2 | 8.0 |
Endothelial Cells/physiology | 4 | 44.0 |
Imidazoles/*pharmacology | 3 | 4.0 |
Pyrimidines/*pharmacology | 3 | 4.0 |
Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors | 5 | 100.0 |
Vascular Endothelial Growth Factor Receptor-2/antagonists & | 6 | 75.0 |
Angiogenic Proteins/*metabolism | 2 | 100.0 |
Carcinoma, Non-Small-Cell Lung/*metabolism/pathology/surgery | 2 | 50.0 |
Lung Neoplasms/*metabolism/pathology/surgery | 2 | 50.0 |
Protein p53/genetics/*metabolism | 4 | 2.0 |
Vascular Endothelial Growth Factor Receptor-1/*physiology | 4 | 100.0 |
Vascular Endothelial Growth Factor Receptor-2/physiology | 2 | 100.0 |
Animals, Genetically Modified | 2 | 0.0 |
Coturnix | 2 | 8.0 |
Heart/*embryology | 3 | 5.0 |
Recombinant Proteins/genetics/metabolism | 3 | 0.0 |
Fibroblast Growth Factor 2/metabolism/pharmacology | 3 | 42.0 |
Platelet Membrane Glycoproteins/antagonists & inhibitors | 2 | 25.0 |
Triazoles/pharmacology | 3 | 10.0 |
Cytokines/*pharmacology | 8 | 2.0 |
Stimulation, Chemical | 11 | 2.0 |
Vascular Endothelial Growth Factor A/analysis/*secretion | 2 | 100.0 |
Peptide Hydrolases/metabolism | 2 | 1.0 |
Active Transport, Cell Nucleus | 4 | 1.0 |
I-kappa B/*metabolism | 2 | 14.0 |
Inflammation | 13 | 3.0 |
Isoenzymes/metabolism | 11 | 2.0 |
Models, Chemical | 2 | 0.0 |
Poly(ADP-ribose) Polymerases/metabolism | 4 | 3.0 |
Prostaglandin-Endoperoxide Synthase/metabolism | 8 | 11.0 |
Temperature | 4 | 0.0 |
Interleukin-18/*blood | 3 | 23.0 |
Nitrates/blood | 2 | 7.0 |
Tamoxifen/*therapeutic use | 4 | 5.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis | 5 | 3.0 |
Vascular Endothelial Growth Factors/biosynthesis | 2 | 100.0 |
Adenocarcinoma/blood supply/metabolism/pathology | 3 | 75.0 |
Blood Specimen Collection/methods | 4 | 21.0 |
Neoplasm Circulating Cells | 5 | 17.0 |
Neoplasms/*blood | 5 | 11.0 |
Neovascularization, Pathologic/blood | 12 | 92.0 |
Endothelial Growth Factors/*biosynthesis/*chemistry | 2 | 100.0 |
Lung/*metabolism | 4 | 4.0 |
Lymphokines/*biosynthesis/*chemistry | 2 | 100.0 |
Autocrine Communication/*physiology | 6 | 21.0 |
Placenta/*blood supply | 3 | 18.0 |
Pregnancy Proteins/*metabolism | 9 | 16.0 |
Arthritis, Rheumatoid/*physiopathology | 3 | 23.0 |
Glioma | 5 | 6.0 |
Neoplasms/*physiopathology | 4 | 15.0 |
Antibody Specificity | 9 | 0.0 |
Endothelial Growth Factors/toxicity | 3 | 100.0 |
Heparan Sulfate Proteoglycan/*metabolism | 2 | 12.0 |
Retinal Vessels/drug effects/*metabolism/pathology | 3 | 100.0 |
Adenocarcinoma/*pathology | 5 | 6.0 |
Breast Neoplasms/*pathology | 13 | 6.0 |
Arteriosclerosis/metabolism | 3 | 5.0 |
Brain Edema/physiopathology | 2 | 100.0 |
Brain Neoplasms/*physiopathology | 2 | 11.0 |
Glioblastoma/*physiopathology | 2 | 50.0 |
Chemotaxis/*physiology | 4 | 11.0 |
Spleen/pathology | 3 | 4.0 |
Biopsy, Needle | 14 | 3.0 |
Brain Neoplasms/*blood supply/pathology | 4 | 80.0 |
Glioblastoma/*blood supply/pathology | 2 | 100.0 |
Thymidine Phosphorylase/*pharmacology | 2 | 100.0 |
Microdialysis | 4 | 14.0 |
Sesquiterpenes/*pharmacology | 7 | 20.0 |
Breast Neoplasms/drug therapy/*metabolism/pathology | 2 | 16.0 |
Keratinocytes/cytology/*drug effects/metabolism | 2 | 13.0 |
Skin, Artificial | 3 | 60.0 |
Down-Regulation/genetics | 2 | 3.0 |
Lipid A/pharmacology | 2 | 10.0 |
Lipopolysaccharides/*pharmacology | 8 | 1.0 |
Membrane Proteins/*genetics | 3 | 0.0 |
Neutrophils/*metabolism | 6 | 3.0 |
Protein Isoforms/*genetics | 5 | 20.0 |
Blood Component Removal | 3 | 6.0 |
Blood Platelets/secretion | 2 | 33.0 |
Blood Preservation | 2 | 2.0 |
Antineoplastic Agents, Hormonal/therapeutic use | 3 | 6.0 |
Fibroblast Growth Factor 2/genetics/*metabolism | 2 | 14.0 |
Oxygen Consumption | 9 | 3.0 |
Carcinoma, Squamous Cell/blood supply/*metabolism/pathology | 5 | 100.0 |
Head and Neck Neoplasms/blood supply/*metabolism/pathology | 3 | 100.0 |
Carcinoma/*metabolism | 8 | 9.0 |
Precancerous Conditions/*metabolism | 5 | 27.0 |
Prostate/*metabolism | 5 | 6.0 |
Prostatic Intraepithelial Neoplasia/*metabolism | 2 | 40.0 |
Prostatic Neoplasms/*metabolism | 9 | 7.0 |
Biopsy/methods | 2 | 4.0 |
*Castration | 2 | 20.0 |
Prostatic Neoplasms/*metabolism/pathology | 3 | 3.0 |
Diabetes Complications | 5 | 3.0 |
Diabetes Mellitus/*metabolism | 2 | 5.0 |
Endothelial Growth Factors/analysis/metabolism | 3 | 75.0 |
Fibroblast Growth Factors/metabolism | 7 | 13.0 |
Growth Substances/*metabolism | 16 | 10.0 |
RNA/analysis | 5 | 2.0 |
Digestive System Neoplasms/*metabolism/pathology | 2 | 66.0 |
Leiomyosarcoma/*metabolism/pathology | 2 | 50.0 |
Transforming Growth Factor alpha/biosynthesis | 3 | 21.0 |
Endothelium, Vascular/enzymology | 4 | 9.0 |
Protein Kinase C/metabolism | 15 | 3.0 |
Cells, Cultured/drug effects | 8 | 8.0 |
Hematopoiesis/drug effects | 2 | 2.0 |
Immune Tolerance/drug effects | 2 | 7.0 |
Immunologic Surveillance | 2 | 7.0 |
Fetal Blood/*cytology | 2 | 1.0 |
Fibronectins/genetics | 2 | 6.0 |
Mitogens/*pharmacology | 4 | 3.0 |
Neoplasms/*blood supply/*drug therapy | 4 | 66.0 |
DNA-Binding Proteins/*metabolism/physiology | 2 | 5.0 |
*Membrane Transport Proteins | 2 | 0.0 |
Phosphoproteins/*physiology | 2 | 2.0 |
Platelet-Derived Growth Factor/pharmacology | 9 | 4.0 |
beta-Galactosidase/metabolism | 3 | 1.0 |
Diabetes Mellitus, Type 2/metabolism | 2 | 7.0 |
Endothelial Growth Factors/*genetics/secretion | 3 | 100.0 |
Lymphokines/*genetics/secretion | 3 | 60.0 |
Staining and Labeling | 17 | 2.0 |
Thrombospondin 1/genetics/*metabolism | 2 | 33.0 |
Albuminuria | 4 | 8.0 |
Diabetes Mellitus, Type 1/blood/*physiopathology | 2 | 5.0 |
Fibrinogen/analysis | 3 | 1.0 |
Hemoglobin A, Glycosylated/analysis | 5 | 1.0 |
Lisinopril/*therapeutic use | 3 | 33.0 |
Smoking | 4 | 1.0 |
Coronary Disease/etiology | 2 | 5.0 |
Diabetes Mellitus/genetics | 2 | 5.0 |
Endoplasmic Reticulum/metabolism | 2 | 0.0 |
RNA, Antisense/pharmacology | 2 | 11.0 |
Transforming Growth Factor beta/physiology | 7 | 7.0 |
Flavonoids/pharmacology | 24 | 7.0 |
MAP Kinase Kinase 1 | 3 | 1.0 |
Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors | 5 | 10.0 |
Multiple Myeloma/metabolism/*pathology | 2 | 10.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors | 4 | 4.0 |
Proto-Oncogene Proteins c-raf/metabolism | 3 | 3.0 |
Cell Aggregation | 2 | 1.0 |
Hepatectomy/methods | 2 | 13.0 |
*Liver Circulation | 2 | 28.0 |
Liver Regeneration/*physiology | 2 | 8.0 |
Membrane Glycoproteins/*metabolism | 7 | 1.0 |
Endothelial Growth Factors/analysis/biosynthesis | 3 | 100.0 |
Factor VIII/analysis | 11 | 10.0 |
Lymphokines/analysis/biosynthesis | 3 | 100.0 |
Prostate-Specific Antigen/biosynthesis | 2 | 15.0 |
Antibodies, Monoclonal/immunology/*pharmacology | 4 | 8.0 |
Actins/biosynthesis | 2 | 4.0 |
Albumins/biosynthesis | 2 | 16.0 |
Endothelial Growth Factors/*genetics/*physiology | 4 | 100.0 |
Lymphokines/*genetics/*physiology | 4 | 100.0 |
Endothelium, Vascular/*chemistry | 3 | 15.0 |
Tumor Virus Infections/metabolism/pathology/virology | 2 | 100.0 |
Proto-Oncogene Proteins/*blood | 4 | 57.0 |
Calcimycin/pharmacology | 3 | 1.0 |
Egtazic Acid/analogs & derivatives/pharmacology | 2 | 7.0 |
Chorionic Gonadotropin/administration & dosage | 4 | 26.0 |
Infertility/etiology | 2 | 25.0 |
Vascular Cell Adhesion Molecule-1/*analysis | 4 | 33.0 |
*Proanthocyanidins | 4 | 40.0 |
Seeds/chemistry | 3 | 27.0 |
Antibodies | 7 | 1.0 |
Culture Media, Serum-Free/pharmacology | 6 | 5.0 |
Cysteine Proteinase Inhibitors/pharmacology | 3 | 1.0 |
Oligopeptides/pharmacology | 6 | 3.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 11 | 3.0 |
Endothelium, Vascular/cytology/*enzymology | 6 | 28.0 |
Interleukin-10/pharmacology | 3 | 4.0 |
Bone Neoplasms/secondary | 4 | 9.0 |
Cell Adhesion Molecules/*metabolism | 3 | 1.0 |
Interleukin-8/pharmacology | 3 | 6.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 2 | 0.0 |
Interferon Alfa-2b/*therapeutic use | 2 | 5.0 |
Interleukin-8/*blood | 4 | 10.0 |
Neovascularization, Pathologic/*immunology | 7 | 63.0 |
Plasma/chemistry | 4 | 12.0 |
Neovascularization, Physiologic/*drug effects/*physiology | 2 | 66.0 |
Binding, Competitive | 20 | 1.0 |
Colonic Neoplasms/pathology | 4 | 7.0 |
Neovascularization, Pathologic/genetics | 15 | 45.0 |
RNA Splicing | 13 | 2.0 |
Reference Standards | 3 | 1.0 |
*Reverse Transcriptase Polymerase Chain Reaction | 7 | 12.0 |
Critical Illness | 2 | 7.0 |
Protein Isoforms/*therapeutic use | 2 | 100.0 |
Butadienes/pharmacology | 2 | 3.0 |
Chimeric Proteins/metabolism | 4 | 2.0 |
HIV-1/*physiology | 2 | 0.0 |
Nitriles/pharmacology | 5 | 4.0 |
Neovascularization, Pathologic/*etiology/pathology | 4 | 66.0 |
Endothelin-1/biosynthesis/genetics | 2 | 100.0 |
DNA, Complementary/*analysis | 2 | 9.0 |
Breast Neoplasms/*diagnosis/metabolism/pathology | 2 | 66.0 |
Computer Systems | 4 | 7.0 |
Lymphatic Metastasis/genetics | 3 | 11.0 |
Chorion/blood supply/physiology | 2 | 66.0 |
Ethanol/*pharmacology | 3 | 2.0 |
Muscle, Smooth, Vascular/cytology/drug effects/*physiology | 3 | 33.0 |
Nuclear Proteins/genetics | 8 | 2.0 |
Electric Impedance | 3 | 5.0 |
Arthritis, Rheumatoid/*metabolism/pathology | 4 | 10.0 |
Osteoarthritis/metabolism | 5 | 14.0 |
*Biocompatible Materials | 4 | 11.0 |
Heparin | 4 | 5.0 |
Endothelium, Vascular/cytology/physiology | 6 | 30.0 |
Heparan Sulfate Proteoglycan/metabolism | 4 | 14.0 |
Radioligand Assay | 7 | 1.0 |
Receptor Protein-Tyrosine Kinases/*chemistry/*metabolism | 2 | 25.0 |
Extracellular Matrix Proteins/*metabolism | 4 | 6.0 |
Protein-Serine-Threonine Kinases/genetics/metabolism | 3 | 2.0 |
Muscle, Smooth, Vascular/*physiology | 2 | 11.0 |
Plasmids/*genetics | 2 | 9.0 |
Atrial Natriuretic Factor/*metabolism | 2 | 15.0 |
Myocardium/*metabolism/pathology | 2 | 7.0 |
Oligonucleotide Array Sequence Analysis/*methods | 6 | 5.0 |
Growth Substances | 2 | 12.0 |
Placenta | 6 | 14.0 |
Transforming Growth Factor beta/analysis/*secretion | 2 | 100.0 |
*Gene Expression Regulation, Neoplastic/drug effects | 6 | 10.0 |
Nerve Tissue Proteins/*biosynthesis/genetics | 4 | 9.0 |
Granulocytes/chemistry | 2 | 16.0 |
Interleukin-6/analysis | 5 | 6.0 |
Platelet Transfusion/adverse effects | 2 | 25.0 |
Drug Carriers | 3 | 2.0 |
Fibrin/*chemistry | 2 | 40.0 |
Isoenzymes/*biosynthesis/genetics | 2 | 8.0 |
NF-kappa B/physiology | 5 | 5.0 |
Prostaglandin-Endoperoxide Synthase/*biosynthesis/genetics | 2 | 14.0 |
*Nerve Tissue Proteins | 2 | 0.0 |
Endothelial Growth Factors/*antagonists & inhibitors/*pharmacology | 2 | 100.0 |
Lymphokines/*antagonists & inhibitors/*pharmacology | 2 | 100.0 |
Cell Death | 3 | 0.0 |
*Down-Regulation | 5 | 1.0 |
Endothelial Growth Factors/*analysis/physiology | 8 | 100.0 |
Lymphokines/*analysis/physiology | 8 | 88.0 |
Menstrual Cycle/physiology | 14 | 35.0 |
Amino Acid Substitution | 10 | 0.0 |
DNA Replication/drug effects | 5 | 2.0 |
Anticarcinogenic Agents/*pharmacology | 3 | 3.0 |
Ovarian Hyperstimulation Syndrome/*blood | 2 | 100.0 |
Ovarian Cysts/*metabolism | 2 | 50.0 |
Pigment Epithelium of Eye/*drug effects/metabolism | 4 | 50.0 |
Carcinoma, Ductal, Breast/blood supply/metabolism/pathology | 2 | 100.0 |
Melanoma/blood supply/*metabolism/pathology | 2 | 100.0 |
Dyes | 2 | 1.0 |
*Renal Dialysis | 3 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/*analysis | 3 | 3.0 |
Biological Assay | 10 | 3.0 |
Bone Marrow Examination | 3 | 8.0 |
Liver Neoplasms/*secondary | 4 | 20.0 |
Plasminogen Activator Inhibitor 1/analysis | 2 | 6.0 |
Plasminogen Activator Inhibitor 2/analysis | 2 | 66.0 |
Blood Flow Velocity | 6 | 6.0 |
Genes, p53/physiology | 2 | 7.0 |
Protein p53/*physiology | 2 | 1.0 |
Actins/*physiology | 2 | 5.0 |
*Heat-Shock Proteins | 2 | 3.0 |
Neoplasm Proteins/physiology | 2 | 3.0 |
Protein-Serine-Threonine Kinases/physiology | 2 | 2.0 |
Glutathione/*metabolism | 4 | 6.0 |
L-Lactate Dehydrogenase/metabolism | 4 | 2.0 |
DNA-Binding Proteins/*biosynthesis | 5 | 4.0 |
Nuclear Proteins/*biosynthesis | 7 | 16.0 |
DNA, Antisense/genetics | 4 | 8.0 |
Endoplasmic Reticulum/*metabolism | 3 | 2.0 |
Endothelial Growth Factors/biosynthesis/metabolism | 2 | 100.0 |
Lymphokines/biosynthesis/metabolism | 2 | 100.0 |
Neovascularization, Pathologic/immunology/*metabolism | 3 | 100.0 |
Adenocarcinoma/genetics/*metabolism | 2 | 11.0 |
Anticholesteremic Agents/therapeutic use | 2 | 6.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/*metabolism | 3 | 4.0 |
Antibiotics, Antineoplastic/pharmacology | 6 | 7.0 |
Lysophospholipids/*pharmacology | 2 | 5.0 |
Proto-Oncogene Proteins c-jun/metabolism | 2 | 1.0 |
Receptors, Cell Surface/biosynthesis | 4 | 11.0 |
*Receptors, G-Protein-Coupled | 5 | 1.0 |
Receptors, Lysophosphatidic Acid | 4 | 9.0 |
5' Untranslated Regions | 4 | 2.0 |
Open Reading Frames | 2 | 0.0 |
U937 Cells | 9 | 2.0 |
Proto-Oncogene Proteins | 2 | 5.0 |
Cell Division/*physiology | 5 | 2.0 |
Proto-Oncogene Proteins/metabolism/*physiology | 3 | 6.0 |
Inhibitory Concentration 50 | 7 | 2.0 |
Neoplasms, Experimental/drug therapy | 3 | 12.0 |
DNA-Binding Proteins/*biosynthesis/genetics | 2 | 2.0 |
Nuclear Proteins/*biosynthesis/genetics | 2 | 8.0 |
Homeostasis/*physiology | 2 | 4.0 |
Oxygen/*physiology | 7 | 33.0 |
Lymphokines/*genetics/*metabolism | 11 | 78.0 |
Oxygen/toxicity | 3 | 50.0 |
Cell Adhesion Molecules/analysis | 6 | 3.0 |
Cytokines/biosynthesis/genetics | 2 | 3.0 |
DNA/analysis | 4 | 0.0 |
Pancreatic Neoplasms/*pathology | 3 | 8.0 |
Myocardium/cytology | 2 | 6.0 |
Corneal Neovascularization | 2 | 66.0 |
Lymphokines/administration & dosage/*pharmacology | 7 | 77.0 |
Mice, Obese | 2 | 4.0 |
Endotoxins/*pharmacology | 2 | 2.0 |
Endothelial Growth Factors/*isolation & purification | 2 | 100.0 |
Indicators and Reagents | 6 | 2.0 |
Lymphokines/*isolation & purification | 2 | 22.0 |
Adenoma/metabolism | 4 | 10.0 |
Carcinoma, Papillary/metabolism | 3 | 27.0 |
Protein Isoforms/*metabolism | 3 | 12.0 |
Thyroid Neoplasms/*metabolism | 4 | 10.0 |
Crystallization | 3 | 1.0 |
Escherichia coli/genetics | 4 | 0.0 |
Models, Molecular | 27 | 0.0 |
Protein Denaturation | 3 | 1.0 |
Recombinant Proteins/chemistry/isolation & purification/metabolism | 2 | 2.0 |
Spleen/cytology | 2 | 1.0 |
Fibroblasts/*physiology | 5 | 8.0 |
Neovascularization, Physiologic/*genetics | 22 | 64.0 |
Skin/cytology | 4 | 2.0 |
Isoenzymes/physiology | 2 | 4.0 |
Neoplasms/blood supply | 13 | 72.0 |
Neovascularization, Pathologic/drug therapy/*physiopathology | 6 | 85.0 |
Prostaglandin-Endoperoxide Synthase/physiology | 2 | 22.0 |
DNA/drug effects/metabolism | 3 | 7.0 |
DNA, Antisense/*pharmacology | 3 | 23.0 |
Angiostatins | 12 | 75.0 |
Blotting, Northern/methods | 2 | 3.0 |
Blotting, Western/methods | 13 | 7.0 |
Fetal Growth Retardation/*metabolism | 4 | 20.0 |
*Gestational Age | 3 | 5.0 |
Trophoblasts/chemistry | 6 | 30.0 |
Colorectal Neoplasms/blood/drug therapy | 2 | 66.0 |
DNA-Binding Protein, Cyclic AMP-Responsive/*metabolism | 2 | 2.0 |
Extracellular Matrix Proteins/*biosynthesis | 2 | 22.0 |
Endothelial Growth Factors/*blood/*genetics | 3 | 100.0 |
Insulin/therapeutic use | 2 | 1.0 |
Lymphokines/*blood/*genetics | 3 | 100.0 |
Sex Characteristics | 3 | 0.0 |
*Thiazolidinediones | 2 | 2.0 |
Glucocorticoids/therapeutic use | 3 | 4.0 |
Prednisolone/therapeutic use | 5 | 5.0 |
Trophoblasts/*metabolism | 4 | 8.0 |
Epidermal Growth Factor/metabolism | 4 | 1.0 |
Keratinocytes/metabolism | 3 | 2.0 |
Mitogen-Activated Protein Kinase 1/antagonists & inhibitors | 4 | 22.0 |
Prostatic Neoplasms/metabolism | 3 | 5.0 |
Sesquiterpenes/*therapeutic use | 2 | 50.0 |
Carcinoma/metabolism | 2 | 3.0 |
Epidermal Growth Factor/*physiology | 3 | 2.0 |
Prostatic Hyperplasia/metabolism | 2 | 6.0 |
Receptors, Mitogen/metabolism | 7 | 35.0 |
Blood Platelets | 2 | 8.0 |
Carcinoma/*pathology | 5 | 8.0 |
Wound Healing/drug effects | 2 | 6.0 |
Receptor Protein-Tyrosine Kinases/drug effects/metabolism | 3 | 50.0 |
Receptors, Growth Factor/drug effects/metabolism | 3 | 60.0 |
Recombinant Proteins/chemistry/genetics/pharmacology | 2 | 28.0 |
Angiogenesis Inducing Agents/*blood | 12 | 92.0 |
Antigens, CD31/blood | 4 | 44.0 |
Longitudinal Studies | 7 | 0.0 |
Vascular Cell Adhesion Molecule-1/*blood | 7 | 26.0 |
Fluorodeoxyglucose F18/metabolism | 2 | 100.0 |
Monosaccharide Transport Proteins/genetics/metabolism | 2 | 18.0 |
Tomography, Emission-Computed | 6 | 5.0 |
Neovascularization, Pathologic/*enzymology/pathology | 4 | 50.0 |
RNA/genetics | 2 | 1.0 |
Prostatic Neoplasms/*blood supply/metabolism/pathology | 4 | 80.0 |
RNA, Messenger/*genetics/metabolism | 4 | 5.0 |
Endothelial Growth Factors/*immunology/metabolism | 3 | 100.0 |
Lymphokines/*immunology/metabolism | 3 | 100.0 |
Confidence Intervals | 6 | 1.0 |
Radiotherapy, Adjuvant/adverse effects | 2 | 40.0 |
Attention Deficit Disorder with Hyperactivity/*ethnology | 2 | 18.0 |
Culture | 2 | 13.0 |
England | 2 | 1.0 |
Patient Compliance | 2 | 1.0 |
Quality of Life | 4 | 2.0 |
Tomography, Spiral Computed/*methods | 2 | 66.0 |
Great Britain | 2 | 0.0 |
*Health Policy | 2 | 5.0 |
Receptors, Vascular Endothelial Growth Factor/*biosynthesis | 6 | 100.0 |
Arthroplasty, Replacement, Hip/adverse effects/*instrumentation/methods | 2 | 22.0 |
Equipment Failure Analysis/methods | 2 | 18.0 |
Osteolysis/etiology/prevention & control | 2 | 22.0 |
Prosthesis Design | 2 | 4.0 |
International Cooperation | 2 | 2.0 |
World Health | 2 | 3.0 |
Cytokines/immunology | 2 | 1.0 |
Immune System/*physiology | 3 | 4.0 |
Inflammation/*physiopathology | 2 | 3.0 |
Pain | 3 | 10.0 |
Glucocorticoids/*therapeutic use | 2 | 5.0 |
*Immunosuppression | 3 | 3.0 |
Uveitis, Posterior/*drug therapy | 2 | 33.0 |
Myocardium/metabolism | 6 | 2.0 |
Steroids/therapeutic use | 2 | 5.0 |
HIV/*genetics | 2 | 3.0 |
Systole | 3 | 3.0 |
Adaptation, Physiological/*physiology | 3 | 14.0 |
Diabetes Mellitus, Type 1/complications/psychology | 2 | 40.0 |
Fibromyalgia/*physiopathology | 2 | 40.0 |
Medical History Taking | 2 | 5.0 |
Somatoform Disorders/*physiopathology | 2 | 40.0 |
Stress Disorders, Post-Traumatic/complications/*physiopathology | 2 | 40.0 |
Vascular Endothelial Growth Factor A/antagonists & inhibitors/metabolism | 3 | 100.0 |
Serpins/*metabolism | 5 | 31.0 |
Adenocarcinoma/*metabolism/mortality/pathology | 3 | 20.0 |
Camptothecin/*analogs & derivatives/therapeutic use | 4 | 57.0 |
Drug Delivery Systems | 5 | 5.0 |
Enzyme Induction/drug effects | 3 | 0.0 |
NF-kappa B/antagonists & inhibitors/*metabolism | 3 | 5.0 |
Oxidative Stress/physiology | 4 | 5.0 |
Superoxide Dismutase/*biosynthesis | 2 | 22.0 |
Blood Vessels/metabolism | 4 | 14.0 |
Neuroglia/metabolism | 2 | 2.0 |
Vascular Endothelial Growth Factor Receptor-3/*metabolism | 3 | 60.0 |
Interleukin-8/genetics/*metabolism | 4 | 19.0 |
Tumor Necrosis Factor-alpha/genetics/metabolism | 2 | 3.0 |
Image Processing, Computer-Assisted/methods | 2 | 10.0 |
Injections, Intravenous | 6 | 0.0 |
Retinopathy of Prematurity/*metabolism | 3 | 75.0 |
Serpins/metabolism | 2 | 12.0 |
Neoplasm Staging/*methods | 3 | 8.0 |
*Tomography, X-Ray Computed | 2 | 2.0 |
Neovascularization, Pathologic/metabolism/physiopathology | 2 | 66.0 |
Vascular Endothelial Growth Factor A/metabolism/pharmacology | 3 | 100.0 |
Chorionic Gonadotropin, beta Subunit, Human/blood | 3 | 18.0 |
Pregnancy/*blood | 10 | 6.0 |
Endothelium, Vascular/cytology/*drug effects/*physiology | 5 | 71.0 |
Exons/genetics | 4 | 0.0 |
Fibroblast Growth Factor 2/antagonists & inhibitors/pharmacology | 3 | 75.0 |
Fibroblasts/cytology | 7 | 3.0 |
Growth Substances/*physiology | 7 | 5.0 |
Renal Circulation/physiology | 3 | 23.0 |
Graft Survival | 3 | 0.0 |
Ischemia/pathology/*therapy | 2 | 66.0 |
Neovascularization, Pathologic/therapy | 3 | 60.0 |
*Skin Transplantation | 4 | 21.0 |
Endothelium, Vascular/cytology/*drug effects/physiology | 6 | 30.0 |
Lipoproteins, LDL/*pharmacology | 7 | 12.0 |
Magnetic Resonance Spectroscopy | 5 | 0.0 |
Protein Structure, Secondary | 10 | 0.0 |
Cerebrovascular Circulation/*physiology | 5 | 20.0 |
Brain Neoplasms/genetics/*metabolism/pathology | 3 | 25.0 |
Hemangioblastoma/genetics/*metabolism/pathology | 2 | 100.0 |
Nuclear Proteins/immunology | 2 | 6.0 |
Pedigree | 4 | 0.0 |
Antibodies/therapeutic use | 4 | 23.0 |
Interleukin-6/immunology/pharmacology | 2 | 40.0 |
Estradiol/analogs & derivatives/*pharmacology | 3 | 18.0 |
Adrenalectomy | 2 | 4.0 |
Tissue Inhibitor of Metalloproteinase-2/*blood | 2 | 66.0 |
Kidney/metabolism | 4 | 1.0 |
Proto-Oncogene Proteins/biosynthesis/genetics | 3 | 3.0 |
Cervix Neoplasms/*blood supply/metabolism/pathology | 3 | 100.0 |
Cytoplasm/chemistry | 3 | 1.0 |
Epithelium/chemistry | 4 | 3.0 |
Brain Neoplasms/*metabolism | 6 | 8.0 |
Glioblastoma/genetics/*metabolism/pathology | 2 | 28.0 |
Benzimidazoles/pharmacology | 3 | 7.0 |
Peptides/chemistry | 2 | 0.0 |
Antimetabolites, Antineoplastic/pharmacology | 2 | 2.0 |
Estrogens/metabolism | 2 | 2.0 |
Mifepristone/pharmacology | 5 | 6.0 |
Progesterone/metabolism | 3 | 3.0 |
Progestins/*metabolism | 2 | 40.0 |
Receptors, Progesterone/metabolism | 7 | 3.0 |
Arteriosclerosis/*metabolism | 3 | 4.0 |
Macrophages/*metabolism | 8 | 3.0 |
Oligonucleotides/*pharmacology | 3 | 27.0 |
Astrocytoma/blood supply/genetics/*metabolism/pathology | 2 | 100.0 |
Brain Neoplasms/blood supply/genetics/*metabolism/pathology | 2 | 66.0 |
Glioblastoma/blood supply/genetics/*metabolism/pathology | 2 | 100.0 |
Collagen Type XVIII | 5 | 45.0 |
Sarcoma/*blood | 2 | 50.0 |
Antimetabolites, Antineoplastic/*therapeutic use | 3 | 7.0 |
Depression, Chemical | 6 | 3.0 |
Carcinoma, Squamous Cell/*blood supply/metabolism | 2 | 66.0 |
Mouth Neoplasms/*blood supply/metabolism | 2 | 100.0 |
Androgens/physiology | 2 | 4.0 |
Anoxia/physiopathology | 2 | 13.0 |
Coronary Circulation/*drug effects | 2 | 14.0 |
Quail | 3 | 7.0 |
Citrate (si)-Synthase/metabolism | 2 | 3.0 |
von Willebrand Factor/*metabolism | 4 | 1.0 |
Creatinine/urine | 3 | 2.0 |
Fibroblast Growth Factor 2/*biosynthesis/blood | 2 | 100.0 |
Alprostadil/*pharmacology | 2 | 18.0 |
Fibrosis | 4 | 2.0 |
Vasodilator Agents/*pharmacology | 3 | 6.0 |
Caspases/analysis | 2 | 10.0 |
Gelatinase B/analysis | 2 | 11.0 |
Endothelial Growth Factors/*blood/immunology | 3 | 100.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 4 | 2.0 |
Lymphokines/*blood/immunology | 3 | 75.0 |
Octreotide/*pharmacology | 2 | 9.0 |
Carcinogenicity Tests | 4 | 5.0 |
Blood Vessels/physiology | 4 | 44.0 |
Menstruation/*physiology | 2 | 28.0 |
*Cell Division | 3 | 1.0 |
Macrophage Colony-Stimulating Factor/metabolism | 2 | 20.0 |
Osteoarthritis/metabolism/*pathology | 2 | 66.0 |
Radionuclide Imaging/methods | 2 | 28.0 |
Eye Proteins/analysis | 2 | 25.0 |
Vitreous Body/*chemistry | 10 | 66.0 |
Endothelial Growth Factors/analysis/*physiology | 7 | 100.0 |
Lymphokines/analysis/*physiology | 7 | 87.0 |
*Radiographic Image Enhancement | 2 | 66.0 |
Cell Transformation, Viral/*physiology | 2 | 11.0 |
Pertussis Toxin | 3 | 1.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/metabolism | 5 | 7.0 |
Proto-Oncogene Proteins/antagonists & inhibitors/*metabolism | 2 | 7.0 |
Virulence Factors, Bordetella/pharmacology | 4 | 2.0 |
Clinical Trials, Phase III | 7 | 16.0 |
Tumor Markers, Biological/*urine | 3 | 11.0 |
Carrier Proteins/blood | 2 | 1.0 |
Peptide Fragments/blood | 2 | 1.0 |
Ribonuclease, Pancreatic/blood | 5 | 100.0 |
Cell Hypoxia/drug effects | 3 | 50.0 |
Cyclic GMP/metabolism | 7 | 8.0 |
Erythropoietin/*pharmacology | 3 | 2.0 |
Blood Proteins/metabolism | 4 | 1.0 |
Oocytes/physiology | 2 | 1.0 |
Endothelial Growth Factors/*toxicity | 2 | 100.0 |
Lymphokines/*toxicity | 2 | 100.0 |
Glycoproteins/analysis | 2 | 3.0 |
Lymphokines/genetics/physiology | 4 | 80.0 |
World Health Organization | 3 | 3.0 |
Neoplasms/*blood supply/pathology | 3 | 60.0 |
Angiogenesis Inducing Agents/biosynthesis/*genetics | 2 | 66.0 |
RNA, Messenger/genetics/*metabolism | 5 | 4.0 |
Matrix Metalloproteinases/*biosynthesis/metabolism | 2 | 66.0 |
Colon/metabolism | 4 | 3.0 |
Oncogene Proteins/*physiology | 2 | 8.0 |
Antibodies, Monoclonal/metabolism | 5 | 1.0 |
Follicular Fluid/drug effects/metabolism | 2 | 100.0 |
Ovulation Induction/*methods | 4 | 36.0 |
Cytokines/secretion | 2 | 2.0 |
Transplantation, Autologous | 2 | 0.0 |
Mesothelioma/blood supply/*metabolism | 2 | 100.0 |
Pleural Effusion, Malignant/metabolism | 2 | 50.0 |
Pleural Neoplasms/blood supply/*metabolism | 2 | 100.0 |
Iodine Radioisotopes | 7 | 1.0 |
*Alternative Splicing | 22 | 3.0 |
Electrophoresis, Agar Gel | 8 | 1.0 |
Endothelial Growth Factors/*blood/genetics | 3 | 100.0 |
Inflammation/metabolism | 3 | 3.0 |
Lymphokines/*blood/genetics | 3 | 100.0 |
Neoplasms/blood supply/metabolism | 2 | 100.0 |
DNA Primers/genetics | 16 | 1.0 |
Transforming Growth Factor beta/genetics | 5 | 5.0 |
Lung Neoplasms/*metabolism/*mortality/pathology | 2 | 100.0 |
Laser-Doppler Flowmetry | 6 | 15.0 |
*Nucleoside-Diphosphate Kinase | 4 | 6.0 |
Endothelial Growth Factors/analysis/blood | 3 | 100.0 |
Lymph Nodes/*metabolism | 2 | 11.0 |
Lymphokines/analysis/blood | 2 | 100.0 |
Astrocytes/*metabolism | 2 | 3.0 |
Renal Circulation/*physiology | 2 | 40.0 |
Endothelial Growth Factors/*biosynthesis/secretion | 5 | 100.0 |
Lymphokines/*biosynthesis/secretion | 5 | 83.0 |
Magnetic Resonance Angiography | 2 | 12.0 |
RNA, Catalytic/*pharmacology | 3 | 42.0 |
Capillaries/cytology/physiology | 2 | 66.0 |
Peptides/pharmacology | 5 | 2.0 |
Extracellular Matrix Proteins/analysis | 5 | 27.0 |
Maleimides/pharmacology | 8 | 8.0 |
Protein Isoforms/analysis/biosynthesis | 2 | 40.0 |
Biotechnology | 3 | 10.0 |
Coronary Disease/*therapy | 2 | 28.0 |
Gene Therapy/adverse effects/*methods | 2 | 28.0 |
Peripheral Vascular Diseases/*therapy | 4 | 100.0 |
Endothelial Cells/cytology/*drug effects | 4 | 100.0 |
Fibrin | 2 | 20.0 |
Gels | 6 | 6.0 |
Brain/*metabolism | 9 | 2.0 |
Vascular Endothelial Growth Factors/*immunology | 2 | 100.0 |
Phosphoproteins/metabolism | 11 | 1.0 |
Proteasome Endopeptidase Complex/metabolism | 2 | 18.0 |
Ribosomal Protein S6 Kinases/metabolism | 2 | 2.0 |
Stilbenes/*pharmacology | 2 | 3.0 |
Transcription Factors/*antagonists & inhibitors | 4 | 25.0 |
Vascular Endothelial Growth Factor A/*biosynthesis/metabolism | 8 | 88.0 |
Vascular Endothelial Growth Factor C/metabolism | 3 | 50.0 |
Vascular Endothelial Growth Factor D/metabolism | 3 | 75.0 |
Intercellular Adhesion Molecule-1/*biosynthesis | 3 | 6.0 |
Interleukin-6/biosynthesis/metabolism | 2 | 28.0 |
von Willebrand Factor/biosynthesis | 4 | 17.0 |
Cyclin D1/metabolism | 3 | 2.0 |
Mitogen-Activated Protein Kinase 1/antagonists & inhibitors/metabolism | 4 | 16.0 |
Tumor Suppressor Proteins/metabolism | 6 | 5.0 |
Transcription Factors/biosynthesis/genetics | 2 | 2.0 |
Vascular Endothelial Growth Factor A/biosynthesis/genetics | 6 | 85.0 |
Atmospheric Pressure | 2 | 15.0 |
Cell Count/methods | 3 | 5.0 |
Hyperoxia | 2 | 66.0 |
Oxygen/*pharmacology | 5 | 26.0 |
*Estrogen Replacement Therapy | 4 | 3.0 |
Greece | 2 | 2.0 |
Neovascularization, Pathologic/metabolism/prevention & control | 3 | 100.0 |
POEMS Syndrome/*complications | 2 | 100.0 |
Lymphangiogenesis/*physiology | 5 | 100.0 |
Endothelial Growth Factors/*pharmacology/physiology | 4 | 100.0 |
Lymphokines/*pharmacology/physiology | 4 | 57.0 |
MAP Kinase Signaling System/*physiology | 5 | 5.0 |
Mitogen-Activated Protein Kinases/*physiology | 4 | 5.0 |
Epidermal Growth Factor/physiology | 3 | 3.0 |
Neoplasm Proteins/genetics/*physiology | 2 | 4.0 |
Platelet-Derived Growth Factor/physiology | 5 | 12.0 |
Receptors, Growth Factor/drug effects/genetics/physiology | 2 | 100.0 |
Endothelial Growth Factors/antagonists & inhibitors/*physiology | 7 | 100.0 |
Lymphokines/antagonists & inhibitors/*physiology | 7 | 87.0 |
Membrane Glycoproteins/physiology | 3 | 1.0 |
Protein Isoforms/physiology | 3 | 7.0 |
Proteins/physiology | 7 | 4.0 |
Receptors, Cell Surface/physiology | 4 | 3.0 |
Adenocarcinoma/metabolism/pathology | 2 | 3.0 |
Stomach Neoplasms/*metabolism/pathology | 8 | 14.0 |
Alkyl and Aryl Transferases/*antagonists & inhibitors | 3 | 8.0 |
Immunosuppressive Agents/therapeutic use | 2 | 0.0 |
Carcinoma, Ductal, Breast/blood supply/*metabolism/pathology | 3 | 60.0 |
Carrier Proteins/*physiology | 5 | 2.0 |
Collagen/physiology | 2 | 12.0 |
Cornea/blood supply/drug effects | 3 | 50.0 |
Hepatocyte Growth Factor/*pharmacology | 5 | 3.0 |
Carcinoembryonic Antigen/blood | 5 | 8.0 |
Carcinoma, Squamous Cell/*genetics | 3 | 1.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors/*metabolism | 4 | 5.0 |
Monocytes/*metabolism | 7 | 1.0 |
Transcription Factor, Sp1/*physiology | 2 | 2.0 |
Adenocarcinoma/*metabolism/pathology | 6 | 5.0 |
Endometrial Neoplasms/*metabolism/pathology | 3 | 9.0 |
Insulin/*pharmacology | 5 | 2.0 |
Placenta/*physiology | 4 | 14.0 |
Neoplasms/*blood supply | 11 | 57.0 |
Pericytes/metabolism | 2 | 66.0 |
Neutrophils/metabolism | 2 | 1.0 |
Neovascularization, Pathologic/*enzymology | 7 | 70.0 |
Protein-Tyrosine Kinase/genetics/metabolism | 2 | 2.0 |
Intracranial Arteriovenous Malformations/*metabolism/pathology | 2 | 100.0 |
Receptors, Cell Surface/metabolism | 8 | 1.0 |
Stem Cells/drug effects | 2 | 9.0 |
Endothelium, Vascular/drug effects/physiopathology | 3 | 37.0 |
Myocardial Ischemia/*physiopathology | 2 | 25.0 |
Carcinoma, Non-Small-Cell Lung/blood supply/*metabolism | 2 | 100.0 |
Lung/metabolism | 5 | 2.0 |
Lung Neoplasms/blood supply/*metabolism | 2 | 100.0 |
DNA, Complementary/*genetics | 3 | 1.0 |
Muscle, Smooth, Vascular/cytology | 6 | 20.0 |
Human Growth Hormone/*secretion | 2 | 5.0 |
Thrombospondin 1/genetics | 2 | 16.0 |
Collagen/*genetics | 3 | 0.0 |
Fluorescent Dyes/diagnostic use | 3 | 8.0 |
Injections, Intralesional | 3 | 6.0 |
Neovascularization, Pathologic/genetics/*prevention & control | 2 | 100.0 |
Peptide Fragments/*genetics | 3 | 6.0 |
Vascular Cell Adhesion Molecule-1/analysis | 7 | 17.0 |
Endothelium, Vascular/chemistry/*cytology | 2 | 33.0 |
Microcirculation/drug effects | 10 | 37.0 |
Carcinoma, Non-Small-Cell Lung/*blood supply/pathology | 2 | 100.0 |
Lung Neoplasms/*blood supply/pathology | 2 | 66.0 |
Endothelial Growth Factors/genetics/*metabolism/secretion | 2 | 100.0 |
Lymphokines/genetics/*metabolism/secretion | 2 | 100.0 |
Carcinoma, Squamous Cell/*blood supply/pathology | 5 | 83.0 |
Fibroblast Growth Factor 2/*analysis | 10 | 52.0 |
Methylprednisolone/therapeutic use | 3 | 6.0 |
Bucladesine/pharmacology | 3 | 1.0 |
Visual Acuity | 3 | 1.0 |
Colorectal Neoplasms/*metabolism/pathology | 5 | 10.0 |
Plasminogen Activator Inhibitor 1/metabolism | 3 | 6.0 |
Tissue Plasminogen Activator/metabolism | 2 | 5.0 |
CA-15-3 Antigen/blood | 2 | 15.0 |
Antineoplastic Agents, Phytogenic/*therapeutic use | 3 | 9.0 |
Paclitaxel/*therapeutic use | 4 | 26.0 |
*Botulinum Toxins | 2 | 4.0 |
Culture Media, Conditioned/analysis/pharmacology | 2 | 40.0 |
Interleukin-6/*biosynthesis/genetics | 2 | 5.0 |
Membrane Fusion | 2 | 1.0 |
Neovascularization, Pathologic/*enzymology/genetics | 2 | 100.0 |
Endothelial Growth Factors/genetics/physiology | 3 | 100.0 |
Neovascularization, Pathologic/pathology/*physiopathology | 4 | 100.0 |
Phthalazines/*pharmacology | 3 | 42.0 |
Breast Neoplasms/blood supply/*metabolism/*pathology | 2 | 66.0 |
Transforming Growth Factor beta/blood | 7 | 26.0 |
Mice, Inbred DBA | 6 | 1.0 |
*Adenoviruses, Human | 2 | 25.0 |
Heart/*drug effects | 2 | 5.0 |
Isoquinolines/pharmacology | 2 | 1.0 |
Nitric-Oxide Synthase/antagonists & inhibitors | 12 | 25.0 |
Phosphodiesterase Inhibitors/*pharmacology | 2 | 4.0 |
Purinones/pharmacology | 2 | 18.0 |
beta-Galactosidase/genetics | 5 | 4.0 |
omega-N-Methylarginine/pharmacology | 6 | 13.0 |
Lymphokines/genetics/metabolism/*therapeutic use | 2 | 100.0 |
Recombinant Proteins/therapeutic use | 8 | 2.0 |
Colon/blood supply | 2 | 66.0 |
Melanoma/blood supply/*metabolism | 2 | 50.0 |
Neoplasm Proteins/*analysis/blood | 4 | 57.0 |
Lung Neoplasms/pathology/secondary | 2 | 15.0 |
Endothelial Growth Factors/genetics/metabolism/*physiology | 3 | 100.0 |
DNA/chemistry | 5 | 1.0 |
Gamma Rays | 2 | 0.0 |
Recombinant Proteins/chemistry | 7 | 2.0 |
DNA Methylation | 4 | 0.0 |
Stromal Cells/secretion | 2 | 28.0 |
Vascular Endothelial Growth Factor A/secretion | 4 | 57.0 |
Hepatocyte Growth Factor/metabolism | 7 | 13.0 |
Neoplasm Recurrence, Local/pathology | 3 | 5.0 |
*Evolution, Molecular | 2 | 0.0 |
Haplotypes/genetics | 2 | 0.0 |
Hepatic Artery | 4 | 7.0 |
Liver/metabolism/pathology | 3 | 6.0 |
Ubiquitin-Protein Ligases/metabolism | 2 | 4.0 |
Consensus Sequence | 6 | 0.0 |
Isoenzymes/antagonists & inhibitors/*metabolism | 2 | 5.0 |
*JNK Mitogen-Activated Protein Kinases | 6 | 6.0 |
Prostaglandin D2/analogs & derivatives/*pharmacology | 2 | 25.0 |
Trans-Activation (Genetics)/drug effects | 7 | 3.0 |
Vascular Endothelial Growth Factor A/antagonists & inhibitors/*metabolism | 3 | 100.0 |
Liver/metabolism | 5 | 0.0 |
Neoplasm Invasiveness/physiopathology | 2 | 11.0 |
Carcinoma, Squamous Cell/blood supply/*metabolism | 5 | 83.0 |
Esophageal Neoplasms/blood supply/*metabolism | 2 | 100.0 |
Cell Transformation, Neoplastic/genetics | 3 | 1.0 |
Tumor Suppressor Proteins/*genetics | 3 | 2.0 |
Ubiquitin-Protein Ligases/*genetics | 2 | 5.0 |
Awards and Prizes | 2 | 15.0 |
Maternal Age | 3 | 3.0 |
*Pregnancy Outcome | 2 | 3.0 |
Pregnancy, High-Risk | 3 | 7.0 |
Choriocarcinoma | 2 | 5.0 |
Vascular Endothelial Growth Factor A/genetics | 24 | 80.0 |
Vascular Endothelial Growth Factor Receptor-1/*genetics/metabolism | 2 | 100.0 |
Endothelial Growth Factors/*antagonists & inhibitors/physiology | 5 | 100.0 |
Neovascularization, Pathologic/genetics/metabolism/*pathology | 2 | 100.0 |
Receptor Protein-Tyrosine Kinases/analysis/*genetics | 2 | 28.0 |
Fibrin/*metabolism | 3 | 7.0 |
Protein Kinases/metabolism | 6 | 1.0 |
Chickens | 3 | 0.0 |
Molecular Mimicry | 2 | 2.0 |
Epoprostenol/*biosynthesis | 2 | 8.0 |
Breast Neoplasms/*blood supply/metabolism | 2 | 50.0 |
Decidua/*metabolism | 2 | 5.0 |
Pre-Eclampsia/*metabolism | 5 | 23.0 |
Muscle, Smooth, Vascular/cytology/drug effects/*metabolism | 3 | 11.0 |
Nitric Oxide Donors/pharmacology | 6 | 11.0 |
Nitroso Compounds/pharmacology | 2 | 11.0 |
Antigens, CD45/analysis | 2 | 0.0 |
Cadherins/analysis | 5 | 15.0 |
Epoprostenol/metabolism | 5 | 29.0 |
Trans-Activators/genetics | 3 | 1.0 |
Growth Substances/*therapeutic use | 2 | 15.0 |
Pericardium | 2 | 33.0 |
Peripheral Vascular Diseases/therapy | 2 | 100.0 |
Culture Media | 15 | 2.0 |
Forskolin/pharmacology | 6 | 1.0 |
Lung Neoplasms/*physiopathology | 2 | 20.0 |
Mitogens/pharmacology | 5 | 1.0 |
Ischemia/metabolism | 3 | 33.0 |
Neoplasm Recurrence, Local/metabolism/pathology | 2 | 14.0 |
Carcinoma, Renal Cell/*genetics/pathology | 2 | 5.0 |
Gelatinase B/genetics | 2 | 13.0 |
Neoplasm Metastasis/*genetics/pathology | 2 | 20.0 |
Neovascularization, Pathologic/*genetics/pathology | 3 | 60.0 |
Protein Kinase C/antagonists & inhibitors/metabolism | 5 | 5.0 |
Umbilical Veins/cytology/enzymology | 3 | 75.0 |
Endothelial Growth Factors/*immunology/physiology | 2 | 100.0 |
Follicle Stimulating Hormone/blood | 4 | 0.0 |
Luteinizing Hormone/blood | 3 | 0.0 |
Lymphokines/*immunology/physiology | 2 | 100.0 |
Ovarian Follicle/*physiology | 3 | 12.0 |
Thyroglobulin/blood | 2 | 3.0 |
DNA/biosynthesis/drug effects | 4 | 15.0 |
Muscle, Smooth, Vascular/cytology/*drug effects/metabolism | 3 | 16.0 |
Lung Transplantation/*physiology | 2 | 33.0 |
Fluorouracil/administration & dosage/adverse effects | 3 | 20.0 |
Leucovorin/administration & dosage/adverse effects | 2 | 20.0 |
Cell Death/drug effects | 3 | 1.0 |
Myocardium/pathology | 3 | 3.0 |
*Cell Communication | 4 | 4.0 |
Interleukin-6/*physiology | 2 | 2.0 |
Angiogenesis Inhibitors/metabolism | 2 | 40.0 |
Isoenzymes/biosynthesis | 4 | 8.0 |
Trans-Activators/*biosynthesis | 6 | 11.0 |
*Chemotherapy, Adjuvant | 2 | 28.0 |
Cystectomy | 2 | 25.0 |
Doxorubicin/administration & dosage | 4 | 2.0 |
Methotrexate/administration & dosage | 3 | 3.0 |
Microcirculation/metabolism | 4 | 33.0 |
Antineoplastic Agents/adverse effects/*therapeutic use | 3 | 9.0 |
Endothelial Growth Factors/blood/urine | 2 | 100.0 |
Fibroblast Growth Factor 2/blood/urine | 2 | 100.0 |
Kidney Neoplasms/blood/*drug therapy | 2 | 100.0 |
Lymphokines/blood/urine | 2 | 100.0 |
Cervix Uteri/metabolism | 2 | 11.0 |
Premenopause | 5 | 5.0 |
Prostaglandin-Endoperoxide Synthase/biosynthesis | 3 | 15.0 |
Kidney Neoplasms/*blood | 2 | 40.0 |
Endothelial Growth Factors/antagonists & inhibitors/genetics | 2 | 100.0 |
Lymphokines/antagonists & inhibitors/genetics | 2 | 100.0 |
Tumor Cells, Cultured/*drug effects | 2 | 4.0 |
Breast Neoplasms/*chemistry/pathology | 2 | 3.0 |
Cytosol/chemistry | 4 | 7.0 |
Receptors, Estrogen/*analysis | 4 | 1.0 |
Receptors, Progesterone/*analysis | 3 | 1.0 |
Thrombospondin 1/analysis | 3 | 100.0 |
Leukocytes, Mononuclear/drug effects/*metabolism | 2 | 5.0 |
Genes, ras/*physiology | 3 | 11.0 |
3' Untranslated Regions/*genetics | 2 | 5.0 |
Endothelial Growth Factors/blood/*genetics | 4 | 100.0 |
Lymphokines/blood/*genetics | 4 | 100.0 |
*Point Mutation | 3 | 0.0 |
Polymorphism, Single-Stranded Conformational | 6 | 0.0 |
Variation (Genetics) | 15 | 0.0 |
Megakaryocytes/cytology | 2 | 8.0 |
Energy Metabolism | 3 | 1.0 |
Growth Substances/*biosynthesis/metabolism | 2 | 50.0 |
*Physical Endurance | 2 | 4.0 |
Capillary Permeability/*immunology | 2 | 100.0 |
Chemokines/physiology | 2 | 7.0 |
HIV-1/*immunology | 2 | 0.0 |
Fibroblast Growth Factors/genetics | 3 | 7.0 |
Nitroprusside/pharmacology | 5 | 6.0 |
Penicillamine/*analogs & derivatives/pharmacology | 3 | 37.0 |
Receptor Protein-Tyrosine Kinases/immunology/*physiology | 2 | 66.0 |
Receptors, Growth Factor/immunology/*physiology | 2 | 66.0 |
Pre-Eclampsia/physiopathology | 2 | 40.0 |
Pregnancy/*physiology | 3 | 6.0 |
Fetus/*physiology | 2 | 5.0 |
*Cell Adhesion | 4 | 2.0 |
Monocyte Chemoattractant Protein-1/pharmacology | 2 | 9.0 |
Fibroblast Growth Factor 2/*biosynthesis | 12 | 54.0 |
Menstrual Cycle/*physiology | 3 | 5.0 |
Receptor, Epidermal Growth Factor/*biosynthesis | 3 | 2.0 |
Glycoproteins/metabolism | 3 | 1.0 |
Insulin-Like Growth Factor I/metabolism | 3 | 1.0 |
Hyperoxia/complications | 2 | 100.0 |
Nitroarginine/pharmacology | 3 | 23.0 |
Diffusion | 4 | 4.0 |
Neovascularization, Physiologic/genetics | 4 | 36.0 |
Colorectal Neoplasms/*blood/pathology | 2 | 25.0 |
Fibrinolysis | 3 | 1.0 |
Lymphokines/metabolism/*physiology | 8 | 88.0 |
Protein Isoforms/metabolism | 8 | 4.0 |
Cell Adhesion Molecules | 2 | 3.0 |
Cell Transformation, Neoplastic/pathology | 4 | 9.0 |
Myocardial Infarction/*metabolism/pathology | 2 | 28.0 |
Laterality | 2 | 3.0 |
Mice, Inbred Strains | 7 | 0.0 |
Nerve Regeneration/drug effects/physiology | 2 | 40.0 |
Receptors, Growth Factor/*genetics/physiology | 3 | 100.0 |
Neoplasm Proteins/genetics/*metabolism | 9 | 4.0 |
Embryo/*metabolism | 2 | 3.0 |
Embryonic and Fetal Development/physiology | 5 | 5.0 |
Allantois/blood supply/drug effects | 5 | 83.0 |
Growth Inhibitors/*pharmacology | 3 | 1.0 |
Endothelium, Vascular/chemistry | 9 | 15.0 |
Follicular Fluid/chemistry | 2 | 20.0 |
Radioimmunoassay/methods | 2 | 1.0 |
Glucose/*pharmacology | 8 | 10.0 |
Bladder Neoplasms/*genetics/metabolism/pathology | 2 | 14.0 |
Carcinoma in Situ/genetics/metabolism/pathology | 2 | 25.0 |
Carcinoma, Transitional Cell/*genetics/metabolism/pathology | 2 | 33.0 |
Colorimetry | 2 | 3.0 |
Growth Substances/biosynthesis/genetics | 4 | 25.0 |
Interleukin-8/biosynthesis/genetics | 2 | 8.0 |
RNA, Neoplasm/biosynthesis/genetics | 6 | 10.0 |
L-Lactate Dehydrogenase/analysis | 3 | 7.0 |
Pleural Effusion, Malignant/chemistry | 2 | 66.0 |
Transforming Growth Factor beta/*analysis | 2 | 13.0 |
Endothelium, Vascular/drug effects/physiology | 3 | 15.0 |
Recovery of Function | 3 | 12.0 |
Thymidine Phosphorylase/*physiology | 3 | 100.0 |
Lymphokines/*antagonists & inhibitors/physiology | 4 | 100.0 |
Nerve Tissue Proteins/chemistry/*genetics | 2 | 4.0 |
Adenocarcinoma, Mucinous/diagnosis/metabolism/pathology | 2 | 100.0 |
Phenylalanine/*analogs & derivatives/pharmacology | 4 | 22.0 |
Platelet Activation/*drug effects | 2 | 3.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors | 5 | 5.0 |
Ion Transport/drug effects | 2 | 5.0 |
Protein Processing, Post-Translational/drug effects | 2 | 1.0 |
Retina/*chemistry | 3 | 25.0 |
Retinal Detachment/*metabolism | 3 | 75.0 |
Endometrium/*blood supply/chemistry | 2 | 100.0 |
Receptor Protein-Tyrosine Kinases/metabolism/physiology | 2 | 100.0 |
Steroids/*pharmacology | 4 | 20.0 |
Matrix Metalloproteinases/metabolism | 7 | 14.0 |
Oligonucleotides, Antisense/genetics | 2 | 5.0 |
Pleura/*pathology | 2 | 33.0 |
Breast Neoplasms/*blood supply/pathology | 4 | 36.0 |
Neovascularization, Pathologic/etiology | 12 | 54.0 |
RNA/genetics/metabolism | 2 | 1.0 |
Growth Substances/physiology | 11 | 10.0 |
Hormones/physiology | 3 | 10.0 |
Ovary/*blood supply | 2 | 40.0 |
Ovulation | 3 | 5.0 |
Extracellular Matrix/*metabolism | 6 | 6.0 |
*5' Untranslated Regions | 4 | 15.0 |
Esophageal Neoplasms/blood supply/*metabolism/pathology | 3 | 100.0 |
*Lymphangiogenesis | 3 | 60.0 |
Anoxia/*genetics | 4 | 57.0 |
Cell Polarity | 3 | 2.0 |
Insulin-Like Growth Factor Binding Protein 3/*metabolism | 2 | 22.0 |
Mitogen-Activated Protein Kinase Kinases/metabolism | 3 | 1.0 |
Pigment Epithelium of Eye/*metabolism | 3 | 9.0 |
Kidney Neoplasms/*metabolism/pathology | 3 | 9.0 |
Membrane Glycoproteins/analysis/*genetics | 2 | 13.0 |
DNA Fragmentation | 7 | 2.0 |
Carcinoma, Non-Small-Cell Lung/*genetics/pathology | 2 | 7.0 |
Lung Neoplasms/*genetics/pathology | 2 | 2.0 |
Skin Transplantation | 2 | 7.0 |
Thymidine/pharmacokinetics | 2 | 12.0 |
Fluorouracil/administration & dosage | 9 | 7.0 |
Leucovorin/administration & dosage | 3 | 9.0 |
Arthritis, Rheumatoid/*drug therapy/metabolism | 2 | 28.0 |
Placenta/blood supply/*metabolism | 3 | 60.0 |
Receptors, Aryl Hydrocarbon/genetics/physiology | 2 | 66.0 |
Trophoblasts/metabolism | 2 | 5.0 |
Crystallography, X-Ray | 8 | 1.0 |
Endothelial Growth Factors/chemistry/metabolism | 2 | 100.0 |
Platelet-Derived Growth Factor/*analysis | 3 | 37.0 |
Life Tables | 10 | 5.0 |
Gastric Mucosa/*chemistry | 2 | 15.0 |
Ascitic Fluid/metabolism | 6 | 31.0 |
Endothelium, Vascular/pathology/physiopathology | 2 | 50.0 |
Ovarian Neoplasms/*blood supply/metabolism | 2 | 100.0 |
Receptor, Endothelin A | 5 | 18.0 |
Receptor, Endothelin B | 2 | 3.0 |
Receptors, Endothelin/metabolism | 2 | 50.0 |
Receptors, Fibroblast Growth Factor/*metabolism | 2 | 3.0 |
Breast/*chemistry | 2 | 8.0 |
Chromatography, Gel | 3 | 0.0 |
Diabetes Mellitus, Type 1/metabolism | 2 | 16.0 |
Milk, Human/*chemistry | 2 | 4.0 |
Pregnancy in Diabetics/metabolism | 2 | 40.0 |
Anti-Bacterial Agents/*pharmacology | 2 | 1.0 |
Endothelial Growth Factors/analysis/*pharmacology | 2 | 100.0 |
RNA/isolation & purification | 2 | 3.0 |
RNA, Messenger/analysis/drug effects | 2 | 25.0 |
Roxithromycin/*pharmacology | 2 | 28.0 |
Respiratory Syncytial Virus Infections/*metabolism | 2 | 50.0 |
*Respiratory Syncytial Viruses | 2 | 40.0 |
Pancreatic Neoplasms/*metabolism/pathology | 3 | 6.0 |
Blood Glucose/*metabolism | 4 | 1.0 |
Diabetes Mellitus, Type 1/*blood/drug therapy | 2 | 5.0 |
Diabetic Retinopathy/blood | 3 | 15.0 |
Tumor Markers, Biological/metabolism | 19 | 4.0 |
Antigens, CD34/blood | 3 | 5.0 |
Protein Isoforms/analysis/genetics | 2 | 15.0 |
Adenosine/metabolism/pharmacology | 2 | 100.0 |
RNA, Messenger/*biosynthesis | 13 | 5.0 |
Sheep | 10 | 1.0 |
Viral Proteins/genetics/*metabolism | 2 | 3.0 |
Pelvis | 2 | 7.0 |
Progestins/*pharmacology | 2 | 8.0 |
Lung Neoplasms/secondary | 4 | 4.0 |
*Protein-Tyrosine Kinase | 2 | 0.0 |
Breast Neoplasms/*blood/pathology | 3 | 27.0 |
Chemiluminescent Measurements | 4 | 2.0 |
ROC Curve | 8 | 4.0 |
Growth Substances/*analysis | 6 | 19.0 |
Transforming Growth Factor alpha/analysis | 5 | 15.0 |
Uterine Neoplasms/*pathology | 2 | 8.0 |
Breast Neoplasms/genetics | 3 | 1.0 |
Carcinoma, Small Cell/*blood/pathology | 2 | 100.0 |
Fibrin Fibrinogen Degradation Products/metabolism | 2 | 2.0 |
Lung Neoplasms/*blood/pathology | 3 | 50.0 |
Embryonic and Fetal Development/*drug effects | 2 | 15.0 |
Morphogenesis/drug effects | 4 | 17.0 |
Antibodies/*therapeutic use | 6 | 31.0 |
Endothelial Growth Factors/*antagonists & inhibitors/immunology | 6 | 100.0 |
Lymphokines/*antagonists & inhibitors/immunology | 6 | 100.0 |
Carboplatin/therapeutic use | 2 | 22.0 |
Endometrium/cytology/*metabolism | 5 | 16.0 |
Cell Division/genetics | 9 | 2.0 |
DNA/genetics | 9 | 0.0 |
DNA, Recombinant/genetics | 2 | 3.0 |
Feasibility Studies | 2 | 0.0 |
Receptors, Chemokine/*physiology | 2 | 4.0 |
Viral Proteins/*physiology | 2 | 6.0 |
Melanoma/metabolism/*pathology | 2 | 11.0 |
Anoxia/complications | 3 | 50.0 |
Arteries | 3 | 5.0 |
Insulin-Like Growth Factor I/analysis | 2 | 1.0 |
Gene Expression/*genetics | 2 | 1.0 |
Membrane Proteins/*metabolism | 3 | 0.0 |
Phosphoproteins/*metabolism | 3 | 0.0 |
Collateral Circulation/physiology | 5 | 83.0 |
Endothelial Growth Factors/genetics/*therapeutic use | 2 | 100.0 |
Lymphokines/genetics/*therapeutic use | 2 | 100.0 |
Endothelial Growth Factors/biosynthesis/*blood | 3 | 100.0 |
Lymphokines/biosynthesis/*blood | 3 | 75.0 |
Photography | 2 | 15.0 |
Brain Ischemia/*metabolism | 3 | 27.0 |
Antigens, CD18/metabolism | 2 | 4.0 |
Macrophage-1 Antigen/metabolism | 2 | 2.0 |
Endothelin-1/*biosynthesis | 2 | 40.0 |
*Ultraviolet Rays | 4 | 1.0 |
Area Under Curve | 2 | 0.0 |
Cross-Over Studies | 3 | 0.0 |
Medroxyprogesterone 17-Acetate/*pharmacology | 4 | 40.0 |
Sesquiterpenes/pharmacology | 4 | 25.0 |
Diabetes Mellitus, Type 1/*complications | 3 | 11.0 |
Diabetic Retinopathy/therapy | 2 | 100.0 |
Insulin-Like Growth Factor I/physiology | 3 | 9.0 |
Angiography | 7 | 17.0 |
Mutagenesis | 8 | 0.0 |
Proteoglycans/metabolism | 5 | 6.0 |
Endothelial Growth Factors/antagonists & inhibitors/pharmacology | 3 | 100.0 |
Heparin/metabolism | 5 | 4.0 |
Lymphokines/antagonists & inhibitors/pharmacology | 2 | 50.0 |
Zinc/metabolism | 2 | 2.0 |
Colonic Neoplasms/*drug therapy/metabolism | 2 | 40.0 |
Cyclic AMP/metabolism/pharmacology | 2 | 28.0 |
Receptors, Prostaglandin E/genetics/metabolism | 2 | 50.0 |
Endothelial Growth Factors/genetics/pharmacology/*physiology | 2 | 100.0 |
Receptor Protein-Tyrosine Kinases/genetics/physiology | 3 | 30.0 |
Stomach Neoplasms/*blood supply/mortality/*pathology/surgery | 2 | 100.0 |
Protein Isoforms/*blood | 8 | 72.0 |
Androgen Antagonists/*therapeutic use | 2 | 5.0 |
Carcinoma, Non-Small-Cell Lung/*metabolism/pathology | 2 | 8.0 |
Lung Neoplasms/*metabolism/pathology | 3 | 4.0 |
Blood Platelets/cytology/*physiology | 2 | 18.0 |
Plasma | 3 | 4.0 |
Liver Neoplasms | 4 | 1.0 |
Estradiol/*analogs & derivatives/*pharmacology | 2 | 10.0 |
Naphthoquinones/*pharmacology | 2 | 9.0 |
Prostatic Neoplasms/*drug therapy/metabolism/pathology | 2 | 20.0 |
Injections, Intraperitoneal | 2 | 1.0 |
Prostatic Neoplasms/blood supply/*drug therapy/pathology | 2 | 66.0 |
Chorionic Gonadotropin/pharmacology | 10 | 7.0 |
Endothelial Growth Factors/analysis/*biosynthesis/genetics | 5 | 100.0 |
Gonadotropins, Equine/pharmacology | 2 | 9.0 |
Granulosa Cells/chemistry | 2 | 10.0 |
Horses | 3 | 2.0 |
Lymphokines/analysis/*biosynthesis/genetics | 5 | 62.0 |
Ovarian Follicle/drug effects/*metabolism | 3 | 75.0 |
Theca Cells/chemistry | 2 | 28.0 |
Precancerous Conditions/*blood supply/metabolism/pathology | 2 | 66.0 |
Cell Membrane Permeability/*drug effects | 3 | 20.0 |
Triazoles/*pharmacology | 5 | 38.0 |
Breast Neoplasms/*drug therapy/pathology | 2 | 5.0 |
Genitalia, Female/*blood supply | 2 | 100.0 |
*Angiogenesis Inhibitors | 3 | 75.0 |
*Genes, p53 | 12 | 2.0 |
Vascular Endothelial Growth Factor A/pharmacology/*physiology | 5 | 100.0 |
Ovary/physiology | 2 | 9.0 |
CA-125 Antigen/blood | 5 | 17.0 |
Macrophages/immunology/*metabolism | 2 | 6.0 |
Macrophages/metabolism/pathology | 2 | 7.0 |
Muscle, Smooth, Vascular/metabolism/pathology | 3 | 16.0 |
Inflammation Mediators/*physiology | 2 | 8.0 |
RNA, Messenger/biosynthesis/genetics/metabolism | 2 | 12.0 |
Breast Neoplasms/*genetics/metabolism/*pathology | 2 | 16.0 |
Protein Kinase C/physiology | 4 | 2.0 |
Calcium Channels/metabolism | 2 | 6.0 |
Antibodies/immunology/pharmacology | 4 | 12.0 |
Autocrine Communication/*drug effects | 3 | 42.0 |
Fibroblasts/drug effects/metabolism | 3 | 2.0 |
Interleukin-6/genetics | 2 | 2.0 |
Neoplasm Invasiveness/genetics | 3 | 6.0 |
Stromelysin 1/genetics | 3 | 16.0 |
Fibroblast Growth Factor 2/*analysis/blood | 3 | 100.0 |
Interferon-alpha/therapeutic use | 2 | 5.0 |
Arsenicals/*pharmacology | 2 | 7.0 |
Oxides/*pharmacology | 2 | 8.0 |
Cell Line, Transformed/drug effects/metabolism | 2 | 40.0 |
Genes, ras | 7 | 2.0 |
Lactones/pharmacology | 2 | 5.0 |
Nucleic Acid Conformation | 3 | 0.0 |
Neoplasm Proteins/biosynthesis/genetics/*physiology | 5 | 10.0 |
Retinal Vessels/metabolism | 4 | 66.0 |
*Immunohistochemistry | 3 | 3.0 |
Spheroids, Cellular | 2 | 16.0 |
Intestinal Mucosa/*pathology | 2 | 8.0 |
Antibodies, Monoclonal/*pharmacology/therapeutic use | 3 | 16.0 |
Endothelium, Vascular/drug effects/metabolism/pathology | 3 | 60.0 |
Nuclear Proteins | 2 | 4.0 |
Muscle, Skeletal/metabolism | 6 | 3.0 |
Antigens, CD/immunology | 2 | 0.0 |
Lung/cytology/drug effects/metabolism | 2 | 25.0 |
Lung Neoplasms/blood supply/*metabolism/pathology | 4 | 66.0 |
Dinoprostone/biosynthesis/pharmacology | 2 | 40.0 |
Cadherins/biosynthesis | 2 | 7.0 |
Cell Adhesion Molecules/biosynthesis | 2 | 2.0 |
Fibroblast Growth Factor 1/pharmacology | 2 | 8.0 |
*Plant Lectins | 4 | 3.0 |
Chromatography, Ion Exchange | 3 | 0.0 |
Pregnancy Proteins/*biosynthesis/isolation & purification/*pharmacology | 2 | 100.0 |
Growth Substances/*genetics | 5 | 4.0 |
Endothelium, Vascular | 14 | 31.0 |
Blood Platelets/drug effects/*physiology | 2 | 4.0 |
Neutrophils/*physiology | 3 | 2.0 |
Exercise/*physiology | 13 | 3.0 |
Knee Joint | 2 | 10.0 |
Muscle, Skeletal/blood supply/*physiology | 2 | 50.0 |
Rest | 3 | 6.0 |
Bone Neoplasms/blood supply/*metabolism/pathology | 2 | 100.0 |
DNA Probes | 9 | 0.0 |
DNA-Binding Proteins/genetics/*physiology | 3 | 1.0 |
Gene Expression Regulation, Leukemic | 2 | 2.0 |
Gene Silencing | 3 | 0.0 |
Nuclear Proteins/genetics/*physiology | 4 | 8.0 |
Lung Neoplasms/pathology | 2 | 3.0 |
Liver/chemistry | 2 | 2.0 |
Carcinoma, Hepatocellular/blood supply/*metabolism/*secondary | 2 | 100.0 |
Neovascularization, Pathologic/*therapy | 6 | 85.0 |
Carcinoma, Squamous Cell/*genetics/pathology | 2 | 3.0 |
Fibroblast Growth Factor 1/analysis | 2 | 66.0 |
Cyst Fluid/*metabolism | 3 | 100.0 |
Neovascularization, Pathologic/blood/pathology/physiopathology | 2 | 100.0 |
Germinoma/*blood supply/metabolism | 2 | 100.0 |
Testicular Neoplasms/*blood supply/metabolism | 2 | 100.0 |
Neutrophils/*immunology | 2 | 1.0 |
*Neutrophils | 2 | 13.0 |
Glomerulonephritis/*physiopathology | 2 | 40.0 |
Endothelial Growth Factors/*antagonists & inhibitors/genetics | 4 | 100.0 |
Lymphokines/*antagonists & inhibitors/genetics | 4 | 100.0 |
*Blood-Retinal Barrier | 2 | 66.0 |
Inflammation Mediators/pharmacology | 3 | 13.0 |
Muscle, Smooth, Vascular/cytology/drug effects | 3 | 60.0 |
Tuberculosis, Pleural/*metabolism | 2 | 100.0 |
Fibrinolytic Agents/therapeutic use | 2 | 11.0 |
Epithelial Cells/chemistry | 3 | 8.0 |
Proto-Oncogene Proteins/*analysis/genetics | 2 | 6.0 |
Anoxia/blood | 2 | 22.0 |
Choroid/blood supply | 4 | 50.0 |
Lymphokines/toxicity | 2 | 100.0 |
Fluorescein Angiography | 15 | 13.0 |
Pigment Epithelium of Eye/metabolism | 6 | 20.0 |
Rats, Inbred BN | 2 | 4.0 |
*Laser Coagulation | 2 | 22.0 |
von Willebrand Factor/*analysis | 3 | 1.0 |
Nerve Tissue Proteins/*metabolism | 5 | 1.0 |
Embryo/*physiology | 2 | 10.0 |
Oocyte Donation | 3 | 50.0 |
*Gene Expression Regulation/drug effects | 5 | 2.0 |
Kidney/pathology | 3 | 2.0 |
Carcinoma, Hepatocellular | 4 | 1.0 |
Immune Sera | 3 | 1.0 |
Interleukin-2/therapeutic use | 2 | 5.0 |
Palliative Care | 3 | 7.0 |
Adenosine Diphosphate/pharmacology | 3 | 2.0 |
Calcium/pharmacology | 3 | 1.0 |
POEMS Syndrome/*blood/drug therapy | 2 | 100.0 |
Platelet Aggregation/physiology | 2 | 5.0 |
Neuroblastoma/*drug therapy | 2 | 50.0 |
Fetus | 2 | 0.0 |
Basement Membrane/metabolism | 2 | 3.0 |
Collagen/biosynthesis | 2 | 4.0 |
Mesoderm/cytology | 2 | 5.0 |
Stem Cells | 2 | 1.0 |
Allantois/drug effects | 3 | 100.0 |
Blood Vessels/chemistry | 2 | 33.0 |
Chemotactic Factors/*pharmacology | 2 | 5.0 |
Chorion/drug effects | 3 | 100.0 |
Microcirculation/chemistry | 2 | 33.0 |
Interleukin-8/physiology | 2 | 15.0 |
Membrane Glycoproteins/*biosynthesis | 2 | 2.0 |
Mitogen-Activated Protein Kinases/genetics/*metabolism | 2 | 4.0 |
Prostate/cytology/*metabolism | 3 | 27.0 |
Protein-Tyrosine Kinase/genetics/*metabolism | 2 | 1.0 |
Proto-Oncogene Protein c-kit/*metabolism | 2 | 4.0 |
Pigment Epithelium of Eye/cytology/*metabolism | 2 | 14.0 |
Keratinocytes/cytology/metabolism | 2 | 7.0 |
Trans-Activators/*physiology | 2 | 0.0 |
Materials Testing | 2 | 2.0 |
Solvents | 2 | 3.0 |
Endothelial Growth Factors/genetics/immunology/*metabolism | 3 | 100.0 |
Lymphokines/genetics/immunology/*metabolism | 3 | 75.0 |
Receptor Protein-Tyrosine Kinases/genetics/immunology/*metabolism | 2 | 50.0 |
Receptors, Growth Factor/genetics/immunology/*metabolism | 2 | 100.0 |
*Neoplasm Circulating Cells | 2 | 5.0 |
Stomach Neoplasms/blood supply/*pathology | 3 | 100.0 |
Endothelial Growth Factors/*analysis/metabolism | 3 | 100.0 |
Lymphokines/*analysis/metabolism | 2 | 100.0 |
Receptor Protein-Tyrosine Kinases/*analysis/metabolism | 2 | 100.0 |
Receptors, Growth Factor/*analysis/metabolism | 2 | 66.0 |
Proto-Oncogene Proteins/antagonists & inhibitors | 2 | 11.0 |
Eosine Yellowish-(YS)/diagnostic use | 2 | 22.0 |
Hematoxylin/diagnostic use | 2 | 28.0 |
Periodic Acid-Schiff Reaction | 2 | 7.0 |
Interleukin-1/biosynthesis | 3 | 1.0 |
Brain Neoplasms/*metabolism/pathology | 7 | 15.0 |
Glioma/*metabolism/pathology | 3 | 11.0 |
Endothelial Growth Factors/analysis/*immunology | 2 | 100.0 |
Lymphokines/analysis/*immunology | 2 | 100.0 |
Plasminogen/metabolism | 2 | 5.0 |
RNA, Messenger/analysis/biosynthesis | 9 | 3.0 |
Vascular Endothelial Growth Factor A/*analysis/metabolism | 2 | 100.0 |
I-kappa B/metabolism | 4 | 5.0 |
JNK Mitogen-Activated Protein Kinases/metabolism | 2 | 12.0 |
Gelatinase A/*biosynthesis | 2 | 22.0 |
Gelatinase B/*biosynthesis | 3 | 21.0 |
Matrix Metalloproteinases/biosynthesis | 2 | 33.0 |
Endometrial Neoplasms/blood supply/*pathology | 2 | 100.0 |
Colorectal Neoplasms/*metabolism | 2 | 4.0 |
Cyclooxygenase Inhibitors/*pharmacology | 4 | 11.0 |
Neoplasm Proteins/blood | 2 | 12.0 |
Vascular Endothelial Growth Factors/*blood | 12 | 100.0 |
Vascular Endothelial Growth Factor A/physiology | 7 | 87.0 |
Burns/surgery | 2 | 100.0 |
*Skin, Artificial | 7 | 70.0 |
Tissue Culture Techniques | 2 | 28.0 |
Vascular Endothelial Growth Factors/*metabolism | 10 | 100.0 |
Antitubercular Agents/therapeutic use | 2 | 6.0 |
*Blood-Brain Barrier | 2 | 8.0 |
Heat-Shock Proteins 90/*metabolism | 2 | 8.0 |
Vinculin/metabolism | 2 | 8.0 |
Vascular Endothelial Growth Factor A/*secretion | 4 | 100.0 |
Tissue Engineering/methods | 2 | 16.0 |
Transplantation, Homologous | 9 | 1.0 |
Amputation | 3 | 21.0 |
PC12 Cells | 4 | 1.0 |
Peripheral Vascular Diseases/*metabolism | 2 | 100.0 |
Pulmonary Artery/*metabolism | 2 | 40.0 |
Ovary/blood supply | 4 | 57.0 |
Liver Cirrhosis/pathology | 2 | 13.0 |
Biphenyl Compounds/pharmacology | 2 | 7.0 |
Ischemia/*metabolism | 2 | 33.0 |
Ovarian Hyperstimulation Syndrome/*diagnosis/etiology | 2 | 100.0 |
Anti-Bacterial Agents/*therapeutic use | 2 | 4.0 |
Fibroblast Growth Factor 2/drug effects | 2 | 100.0 |
Gene Expression Regulation, Neoplastic/*genetics | 5 | 2.0 |
Antigens, CD31/*biosynthesis | 3 | 60.0 |
Carcinoma, Non-Small-Cell Lung/blood supply/*metabolism/mortality | 3 | 100.0 |
Lung Neoplasms/blood supply/*metabolism/mortality | 3 | 100.0 |
Microcirculation/*metabolism | 2 | 40.0 |
Prostaglandin-Endoperoxide Synthase/*physiology | 5 | 45.0 |
Endothelial Growth Factors/antagonists & inhibitors/genetics/*metabolism | 2 | 100.0 |
Lymphokines/antagonists & inhibitors/genetics/*metabolism | 2 | 100.0 |
Receptor Protein-Tyrosine Kinases/antagonists & inhibitors/*metabolism | 3 | 30.0 |
Receptors, Growth Factor/antagonists & inhibitors/*metabolism | 3 | 100.0 |
DNA/*administration & dosage | 2 | 22.0 |
Carcinoma, Renal Cell/blood supply/*metabolism | 2 | 100.0 |
Kidney Neoplasms/blood supply/*metabolism | 2 | 66.0 |
Receptors, Tumor Necrosis Factor/blood | 2 | 2.0 |
Perfusion | 6 | 2.0 |
Stress, Mechanical | 14 | 4.0 |
Oligonucleotide Probes/chemistry | 2 | 6.0 |
Trophoblasts/cytology/drug effects/*metabolism | 2 | 28.0 |
Pregnancy Proteins/genetics/*physiology | 2 | 66.0 |
Proto-Oncogene Proteins/genetics/*physiology | 3 | 3.0 |
Ischemia/*drug therapy | 2 | 100.0 |
Glomerular Filtration Rate | 3 | 2.0 |
Peptides/*metabolism | 3 | 1.0 |
Bone Marrow/blood supply | 7 | 70.0 |
Lymphoma, Non-Hodgkin/metabolism/pathology | 2 | 50.0 |
Stromal Cells/pathology | 4 | 7.0 |
Factor X/pharmacology | 2 | 40.0 |
Fibroblasts/*metabolism | 7 | 4.0 |
Allantois/blood supply | 4 | 28.0 |
Chorion/blood supply | 4 | 28.0 |
Receptors, Fibroblast Growth Factor/genetics | 3 | 4.0 |
Transcription Factors/*pharmacology | 2 | 8.0 |
Brain Neoplasms/*pathology | 2 | 2.0 |
Fibronectins/analysis | 2 | 3.0 |
Muscle, Smooth, Vascular/pathology | 2 | 10.0 |
Thyroid Neoplasms/*metabolism/*pathology | 2 | 40.0 |
Arteriosclerosis/metabolism/pathology | 2 | 15.0 |
Coronary Vessels/metabolism | 3 | 14.0 |
Diabetes Mellitus, Experimental/metabolism | 2 | 18.0 |
Diabetic Retinopathy/metabolism | 6 | 75.0 |
Transcription Factors/antagonists & inhibitors | 2 | 18.0 |
Down-Regulation/*drug effects | 2 | 3.0 |
Interleukin-8/*secretion | 2 | 8.0 |
Melphalan/pharmacology | 2 | 12.0 |
P-Selectin/metabolism | 3 | 6.0 |
Ascites/metabolism/*prevention & control | 2 | 100.0 |
Receptors, Mitogen/antagonists & inhibitors | 2 | 100.0 |
Genes, Tumor Suppressor/genetics | 2 | 1.0 |
Protein Isoforms/antagonists & inhibitors/*physiology | 3 | 100.0 |
Receptors, Growth Factor/antagonists & inhibitors/physiology | 2 | 100.0 |
Parathyroid Hormone-Related Protein | 2 | 2.0 |
Proteins/pharmacology | 3 | 4.0 |
Carcinoma, Squamous Cell/*pathology | 3 | 3.0 |
L Cells (Cell Line) | 2 | 0.0 |
Lymphocyte Activation | 3 | 0.0 |
Pyrrolidines/pharmacology | 2 | 4.0 |
T-Lymphocyte Subsets/immunology | 2 | 0.0 |
Thiocarbamates/pharmacology | 3 | 5.0 |
Angiogenesis Inhibitors/*pharmacology/*therapeutic use | 2 | 100.0 |
Research Design | 5 | 5.0 |
Recombinant Proteins/chemistry/metabolism/pharmacology | 3 | 16.0 |
Oligodeoxyribonucleotides, Antisense/*pharmacology | 3 | 14.0 |
Vascular Endothelial Growth Factor A/*biosynthesis/pharmacology | 4 | 100.0 |
Bladder Neoplasms/*blood supply/*metabolism/pathology | 2 | 100.0 |
Carcinoma, Transitional Cell/*blood supply/*metabolism/pathology | 2 | 100.0 |
Diabetic Nephropathies/*etiology | 2 | 40.0 |
Kidney/*physiopathology | 2 | 3.0 |
Receptors, Vascular Endothelial Growth Factor/biosynthesis | 6 | 85.0 |
Follicular Phase | 3 | 6.0 |
*Transcription, Genetic/drug effects | 3 | 2.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/*metabolism | 2 | 7.0 |
Itraconazole/*metabolism/*pharmacology | 2 | 66.0 |
Microsomes, Liver/drug effects/enzymology | 2 | 2.0 |
Endothelium, Vascular/cytology/drug effects/*growth & development | 2 | 100.0 |
Receptor, TIE-2/genetics/*metabolism | 2 | 66.0 |
Antigens, CD44/*analysis | 3 | 2.0 |
Antigens, CD44/*metabolism | 3 | 1.0 |
Brain/metabolism | 9 | 1.0 |
Bone Marrow Cells/cytology/drug effects | 3 | 23.0 |
Leukocytes/cytology/drug effects | 2 | 40.0 |
Platelet-Derived Growth Factor/antagonists & inhibitors/pharmacology | 2 | 50.0 |
Adenoviruses, Human/genetics | 2 | 4.0 |
Intercellular Adhesion Molecule-1/analysis | 4 | 3.0 |
Endothelial Growth Factors/blood/metabolism | 3 | 100.0 |
Interleukin-6/blood/metabolism | 3 | 23.0 |
Lymphokines/blood/metabolism | 3 | 75.0 |
Specific Pathogen-Free Organisms | 4 | 4.0 |
Muscle, Smooth, Vascular/*metabolism | 3 | 6.0 |
Body Fluids/*metabolism | 2 | 9.0 |
Carcinoma, Squamous Cell/blood supply/mortality/pathology/surgery | 2 | 100.0 |
Neoplasm Recurrence, Local/diagnosis | 2 | 6.0 |
Receptor, IGF Type 1/genetics/*physiology | 2 | 25.0 |
Erythropoietin/blood | 3 | 5.0 |
Phenanthridines/pharmacology | 2 | 10.0 |
Phorbol 12,13-Dibutyrate/pharmacology | 3 | 5.0 |
Antibodies, Monoclonal/analysis | 4 | 4.0 |
Dexamethasone/therapeutic use | 2 | 11.0 |
Nitric Oxide/biosynthesis | 8 | 10.0 |
Second Messenger Systems | 6 | 6.0 |
Endometriosis/*complications | 2 | 33.0 |
Endothelium, Vascular/drug effects/pathology/physiopathology | 2 | 100.0 |
Tissue Extracts/pharmacology | 3 | 13.0 |
Ovarian Neoplasms/blood supply/*metabolism/pathology | 2 | 100.0 |
Genetic Vectors/*genetics | 2 | 2.0 |
Body Fluids/metabolism | 3 | 10.0 |
Retinal Detachment/metabolism | 2 | 100.0 |
Retinal Perforations/metabolism | 2 | 50.0 |
Tretinoin/pharmacology | 3 | 0.0 |
Baculoviridae | 3 | 5.0 |
Spodoptera | 7 | 2.0 |
Antibodies/metabolism | 3 | 3.0 |
Endothelial Growth Factors/*antagonists & inhibitors/genetics/physiology | 2 | 100.0 |
Lymphokines/*antagonists & inhibitors/genetics/physiology | 2 | 100.0 |
Growth Substances/blood | 2 | 15.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 8 | 2.0 |
*Mitogen-Activated Protein Kinases | 8 | 2.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/*metabolism | 2 | 3.0 |
Cell Hypoxia/genetics | 5 | 29.0 |
*Genes, bcl-2 | 2 | 3.0 |
Endothelial Growth Factors/genetics/pharmacology | 3 | 100.0 |
Lymphokines/genetics/pharmacology | 3 | 100.0 |
Skin/*blood supply/pathology | 2 | 28.0 |
Thymidine Phosphorylase/*analysis/genetics | 4 | 100.0 |
Colonic Neoplasms/*metabolism | 6 | 7.0 |
Genes, myc | 6 | 2.0 |
Epithelium/physiology | 2 | 2.0 |
12-Hydroxy-5,8,10,14-eicosatetraenoic Acid/pharmacology | 2 | 50.0 |
Bone Morphogenetic Proteins/*pharmacology | 2 | 3.0 |
Hematopoietic Stem Cells/*cytology/immunology | 2 | 2.0 |
*Receptors, Cell Surface | 3 | 0.0 |
Coronary Artery Bypass | 5 | 8.0 |
Melanoma/*drug therapy | 5 | 26.0 |
Ovarian Neoplasms/*drug therapy | 2 | 10.0 |
Heart Defects, Congenital/complications | 2 | 66.0 |
Fibroblasts | 3 | 0.0 |
Conserved Sequence | 4 | 0.0 |
KB Cells | 2 | 2.0 |
Xenopus | 3 | 0.0 |
Glioma/*blood supply | 2 | 66.0 |
Isomerism | 8 | 3.0 |
Colonic Neoplasms/*pathology | 5 | 6.0 |
Liver Neoplasms/blood supply/*metabolism/*secondary | 3 | 100.0 |
Vascular Endothelial Growth Factors/metabolism | 4 | 57.0 |
Glial Fibrillary Acidic Protein/analysis | 3 | 1.0 |
Neuropilin-1/*analysis | 2 | 100.0 |
Receptors, Vascular Endothelial Growth Factor/*analysis | 7 | 87.0 |
Neuroglia/*metabolism | 3 | 6.0 |
Retina/*cytology | 2 | 18.0 |
Vascular Endothelial Growth Factor A/*metabolism/pharmacology | 2 | 50.0 |
Tonsil/metabolism | 2 | 11.0 |
Vascular Endothelial Growth Factor A/*antagonists & inhibitors/metabolism | 5 | 100.0 |
Adenocarcinoma/blood supply/*metabolism/pathology | 5 | 71.0 |
Colorectal Neoplasms/blood supply/*metabolism/pathology | 3 | 100.0 |
Cell Adhesion Molecules/metabolism | 6 | 2.0 |
Endometriosis/*etiology/pathology | 2 | 100.0 |
Amniotic Fluid/*chemistry | 2 | 4.0 |
Nasal Polyps/*metabolism/pathology | 2 | 16.0 |
Protein Isoforms/biosynthesis | 4 | 22.0 |
Neoplasms/*metabolism/pathology | 3 | 9.0 |
Plasminogen Activator Inhibitor 1/genetics | 2 | 6.0 |
Receptors, Mitogen/*metabolism | 4 | 25.0 |
Neoplasms/*blood/pathology | 2 | 25.0 |
Aorta/cytology/drug effects/metabolism | 3 | 60.0 |
Keratinocytes/drug effects/*metabolism | 2 | 7.0 |
Neovascularization, Pathologic/etiology/metabolism | 2 | 50.0 |
Endothelium, Vascular/*cytology/physiology | 2 | 10.0 |
Fibroblast Growth Factor 2/analysis/*biosynthesis | 3 | 100.0 |
Luteal Phase/blood | 2 | 33.0 |
*Proto-Oncogene Proteins c-bcl-2 | 5 | 1.0 |
Endometrium/metabolism/pathology | 2 | 28.0 |
Angiogenesis Inducing Agents/pharmacology | 4 | 100.0 |
Stromal Cells/drug effects/metabolism | 3 | 17.0 |
Membrane Proteins/genetics/*metabolism | 2 | 0.0 |
Liver Neoplasms/pathology/*secondary | 2 | 28.0 |
Recombinant Proteins/biosynthesis | 8 | 1.0 |
Endothelial Growth Factors/therapeutic use | 2 | 100.0 |
Lymphokines/therapeutic use | 2 | 100.0 |
Culture Media/chemistry | 5 | 13.0 |
Peritoneal Cavity/pathology | 2 | 28.0 |
Endothelial Growth Factors/genetics/*metabolism/physiology | 3 | 100.0 |
Lymphokines/genetics/*metabolism/physiology | 3 | 75.0 |
Brain Neoplasms/*genetics/metabolism/pathology | 3 | 13.0 |
Arteries/metabolism | 2 | 12.0 |
Gene Expression Regulation, Viral | 4 | 1.0 |
Trans-Activators/genetics/*physiology | 2 | 2.0 |
Receptors, Androgen/*physiology | 2 | 6.0 |
Receptors, Estrogen/*physiology | 3 | 9.0 |
Endothelial Growth Factors/administration & dosage/*therapeutic use | 2 | 100.0 |
Ischemia/therapy | 6 | 85.0 |
Lymphokines/administration & dosage/*therapeutic use | 3 | 100.0 |
Diabetic Nephropathies/metabolism | 3 | 37.0 |
Kidney Diseases/*metabolism | 2 | 8.0 |
Kidney Neoplasms/*metabolism | 2 | 7.0 |
Femoral Artery/surgery | 2 | 33.0 |
Cyclooxygenase Inhibitors/*therapeutic use | 2 | 20.0 |
Gonadal Steroid Hormones/*physiology | 2 | 11.0 |
Prostatic Neoplasms/blood supply | 2 | 100.0 |
Zinc Fingers/*genetics | 2 | 1.0 |
Colonic Neoplasms/blood supply/*drug therapy | 2 | 100.0 |
Endothelium, Vascular/cytology/*drug effects/enzymology/metabolism | 2 | 50.0 |
Peptide Mapping | 3 | 0.0 |
Collateral Circulation/genetics | 2 | 100.0 |
Myocardium | 2 | 25.0 |
Gene Amplification | 2 | 0.0 |
Angiogenesis Inducing Agents/analysis/*metabolism | 2 | 100.0 |
Lymphokines/analysis/metabolism | 2 | 50.0 |
Prolactin/*blood | 2 | 0.0 |
Transcription Factors | 4 | 4.0 |
Vascular Endothelial Growth Factor C/*biosynthesis | 3 | 100.0 |
Chromosome Mapping | 11 | 0.0 |
Hospitalization | 2 | 1.0 |
Angiopoietin-1/analysis | 2 | 100.0 |
Hypertension/*drug therapy/pathology/physiopathology | 2 | 66.0 |
Vascular Endothelial Growth Factor Receptor-2/*antagonists & | 5 | 55.0 |
Antigens, Neoplasm/metabolism | 3 | 4.0 |
Cell Division/*genetics | 2 | 3.0 |
Vascular Endothelial Growth Factor Receptor-1/*genetics | 4 | 80.0 |
Cadherins/*metabolism | 3 | 4.0 |
Retinal Neovascularization/*physiopathology | 2 | 100.0 |
Capillaries/metabolism | 3 | 13.0 |
Thromboplastin/*biosynthesis/genetics | 2 | 4.0 |
Tumor Markers, Biological/*biosynthesis/genetics | 2 | 6.0 |
Neoplasm Circulating Cells/*pathology | 2 | 20.0 |
Adenocarcinoma/*blood supply/pathology | 2 | 25.0 |
Colonic Neoplasms/*blood supply/pathology | 3 | 75.0 |
Gelatinase A/*metabolism | 4 | 12.0 |
Transforming Growth Factor alpha/pharmacology | 3 | 3.0 |
Liver/blood supply | 4 | 26.0 |
Physical Endurance/physiology | 2 | 6.0 |
Embryonic and Fetal Development/*physiology | 2 | 4.0 |
Fetal Growth Retardation/physiopathology | 2 | 40.0 |
Trophoblasts/*physiology | 2 | 11.0 |
Endothelium, Vascular/cytology/*drug effects/*metabolism | 3 | 23.0 |
Skin/blood supply/drug effects | 3 | 100.0 |
Steroids/physiology | 2 | 22.0 |
*Postmenopause | 3 | 4.0 |
Angiotensin II/pharmacology | 5 | 6.0 |
Mesocricetus | 2 | 1.0 |
Receptors, Angiotensin/antagonists & inhibitors | 3 | 6.0 |
Carcinoma, Non-Small-Cell Lung/*blood supply/mortality/*pathology | 2 | 100.0 |
Lung Neoplasms/*blood supply/mortality/*pathology | 2 | 100.0 |
Breast Neoplasms/blood supply/*pathology | 3 | 60.0 |
Gonadotropins/*adverse effects | 2 | 100.0 |
Ovulation Induction/*adverse effects | 2 | 66.0 |
*Gene Expression Regulation, Viral | 2 | 0.0 |
Genes, Viral | 3 | 1.0 |
Introns | 4 | 0.0 |
RNA Processing, Post-Transcriptional | 5 | 4.0 |
Trans-Activators/*genetics | 2 | 0.0 |
Viral Proteins/*genetics | 2 | 2.0 |
Oligonucleotides/pharmacology | 4 | 11.0 |
Membrane Proteins/metabolism | 6 | 1.0 |
Naphthalenes/pharmacology | 3 | 3.0 |
Retinoids/*pharmacology | 3 | 5.0 |
Melanoma/*metabolism/pathology | 4 | 10.0 |
Endometriosis/*metabolism/pathology | 2 | 12.0 |
Neoplasm Proteins/*genetics | 5 | 0.0 |
Ovarian Hyperstimulation Syndrome/*physiopathology | 3 | 100.0 |
Bone Marrow Cells/*cytology/drug effects | 2 | 33.0 |
Fibronectins/*pharmacology | 3 | 17.0 |
Stromal Cells/cytology | 4 | 8.0 |
Protein-Tyrosine-Phosphatase/*metabolism | 2 | 1.0 |
Bone Marrow Cells/*cytology | 2 | 4.0 |
Endothelium, Vascular/cytology/pathology | 2 | 66.0 |
Leukemia, Myelocytic, Acute/*pathology | 2 | 5.0 |
Luciferases/biosynthesis/genetics | 3 | 5.0 |
*Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Tumor Stem Cells/metabolism | 2 | 12.0 |
Skin/metabolism | 4 | 2.0 |
Gadolinium DTPA | 2 | 16.0 |
Synovial Fluid/*metabolism | 2 | 8.0 |
Peritoneum/blood supply/*metabolism | 2 | 100.0 |
Calcium Channel Blockers/*pharmacology | 3 | 8.0 |
Microcirculation/metabolism/pathology | 5 | 71.0 |
Carcinoma, Renal Cell/*blood/mortality | 2 | 100.0 |
Kidney Neoplasms/*blood/mortality | 2 | 100.0 |
Enzyme Inhibitors/*chemical synthesis/chemistry/*pharmacology | 2 | 28.0 |
Indoles/*chemical synthesis/chemistry/*pharmacology | 2 | 100.0 |
Cell Count/drug effects | 3 | 4.0 |
Contraceptive Agents, Female/*pharmacology | 2 | 33.0 |
Endometrium/*cytology | 2 | 10.0 |
Receptors, Estrogen/*metabolism | 3 | 1.0 |
Exertion/*physiology | 3 | 4.0 |
Muscle, Skeletal/metabolism/*physiology | 2 | 15.0 |
Endothelial Growth Factors/chemistry/metabolism/*physiology | 3 | 100.0 |
Astrocytoma/*metabolism | 2 | 8.0 |
Brain/blood supply | 6 | 16.0 |
Glioblastoma/*metabolism | 3 | 9.0 |
Proto-Oncogene Proteins/biosynthesis/*metabolism | 2 | 9.0 |
Receptor Protein-Tyrosine Kinases/biosynthesis/*metabolism | 3 | 42.0 |
Neurons/metabolism | 3 | 0.0 |
Pyrroles/pharmacology | 5 | 10.0 |
Protein Kinase Inhibitors | 5 | 3.0 |
Endothelial Growth Factors/*genetics/pharmacology | 2 | 100.0 |
Extracellular Matrix/enzymology | 2 | 28.0 |
Lymphokines/*genetics/pharmacology | 2 | 50.0 |
MAP Kinase Signaling System/drug effects/physiology | 2 | 6.0 |
Procollagen/metabolism | 2 | 14.0 |
Protein Kinase C/pharmacology | 2 | 25.0 |
Pregnancy Proteins/*blood | 5 | 7.0 |
Pregnancy, Ectopic/*blood/diagnosis | 2 | 100.0 |
Endothelium, Vascular/*immunology | 2 | 2.0 |
Tumor Necrosis Factor-alpha/physiology | 2 | 1.0 |
Angiogenesis Inducing Agents/analysis/metabolism | 2 | 100.0 |
Breast Neoplasms/pathology | 2 | 1.0 |
*Ribonuclease, Pancreatic | 3 | 17.0 |
Dihydrotestosterone/analogs & derivatives/pharmacology | 2 | 50.0 |
Granulosa Cells/drug effects/*metabolism | 2 | 8.0 |
Progesterone Congeners/pharmacology | 2 | 11.0 |
Promegestone/pharmacology | 2 | 12.0 |
Endothelial Growth Factors/*biosynthesis/pharmacology | 2 | 100.0 |
Retinal Vessels/drug effects/*physiology | 2 | 100.0 |
Lipids/blood | 3 | 0.0 |
Lipoproteins, HDL Cholesterol/blood | 2 | 0.0 |
Asthma/*drug therapy | 2 | 10.0 |
Heart/physiology | 2 | 5.0 |
Colonic Neoplasms/blood/*drug therapy | 2 | 40.0 |
Neutropenia/chemically induced | 2 | 5.0 |
Quinazolines/administration & dosage/adverse effects/blood | 2 | 40.0 |
Rectal Neoplasms/blood/*drug therapy | 2 | 40.0 |
Ethanol/pharmacology | 2 | 3.0 |
Thapsigargin/pharmacology | 2 | 1.0 |
Stomach/metabolism | 2 | 5.0 |
Neoplasms/pathology | 2 | 7.0 |
Pyrroles/*therapeutic use | 9 | 24.0 |
Balloon Dilatation/adverse effects | 2 | 22.0 |
Endothelial Cells/*cytology/drug effects/metabolism | 2 | 100.0 |
RNA, Small Interfering/pharmacology | 5 | 6.0 |
Wound Healing/genetics/*physiology | 3 | 75.0 |
Neurofilament Proteins/metabolism | 2 | 3.0 |
Endothelium, Vascular/*physiopathology | 6 | 6.0 |
Neovascularization, Pathologic/blood/*physiopathology | 2 | 100.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Receptors, Aryl Hydrocarbon/metabolism | 3 | 7.0 |
Vascular Endothelial Growth Factors/genetics/*metabolism | 2 | 100.0 |
DNA | 3 | 0.0 |
Neovascularization, Physiologic/genetics/*physiology | 2 | 20.0 |
Pregnancy Proteins/genetics | 3 | 100.0 |
*Gene Expression Regulation, Developmental | 13 | 2.0 |
Oligonucleotides, Antisense | 4 | 4.0 |
Pericytes/*metabolism | 2 | 100.0 |
Pregnancy Proteins/genetics/*metabolism | 6 | 66.0 |
Breast Neoplasms/chemistry/microbiology/*radiotherapy | 2 | 100.0 |
Neoplasm Recurrence, Local/*chemistry | 2 | 66.0 |
Leukemia, Myeloid/*blood/mortality | 3 | 100.0 |
Prostatic Diseases/*blood | 2 | 66.0 |
Endothelium, Vascular/embryology/*metabolism | 3 | 60.0 |
Fetal Heart/metabolism | 2 | 33.0 |
Fetal Proteins/*metabolism | 3 | 21.0 |
Heart/growth & development | 2 | 25.0 |
Lymph Nodes/growth & development/metabolism | 2 | 100.0 |
Muscle Proteins/*metabolism | 2 | 4.0 |
Interleukin-12/*metabolism | 2 | 15.0 |
Epitopes/chemistry | 2 | 2.0 |
Point Mutation | 4 | 0.0 |
Plasminogen Inactivators/*metabolism | 2 | 11.0 |
*Fibroblast Growth Factors | 2 | 2.0 |
Skin/*metabolism | 3 | 2.0 |
Heparin/*metabolism | 3 | 3.0 |
Immunoglobulins/chemistry/metabolism | 2 | 50.0 |
Receptor Protein-Tyrosine Kinases/*chemistry/metabolism | 2 | 28.0 |
Receptors, Growth Factor/*chemistry/metabolism | 2 | 100.0 |
Nuclear Magnetic Resonance, Biomolecular | 4 | 2.0 |
Nephrectomy | 5 | 5.0 |
Melanoma/*metabolism | 5 | 7.0 |
Immunization | 2 | 0.0 |
T-Lymphocytes, Cytotoxic/immunology | 2 | 0.0 |
Angiogenesis Inhibitors/administration & dosage/*therapeutic use | 3 | 100.0 |
Mesoderm/metabolism | 2 | 2.0 |
Extracellular Space/metabolism | 2 | 3.0 |
Plasminogen Activator Inhibitor 1/blood | 2 | 1.0 |
Protein Isoforms/*pharmacology | 2 | 66.0 |
Corpus Luteum/metabolism | 2 | 22.0 |
Ovary/*metabolism | 3 | 5.0 |
Adenosine-5'-(N-ethylcarboxamide)/pharmacology | 2 | 25.0 |
Receptors, Purinergic P1/*metabolism | 2 | 50.0 |
Retinal Vessels/cytology/*metabolism | 3 | 100.0 |
Pre-Eclampsia/*blood/etiology | 3 | 37.0 |
Bronchopulmonary Dysplasia/prevention & control | 2 | 100.0 |
Infant, Premature/*metabolism | 2 | 10.0 |
Cardiac Surgical Procedures | 2 | 10.0 |
Plasmids/administration & dosage | 4 | 57.0 |
Heparin/*metabolism/pharmacology | 2 | 15.0 |
Hemoglobins/*analysis | 2 | 3.0 |
Glioblastoma/metabolism | 3 | 13.0 |
Cell Division/genetics/physiology | 2 | 4.0 |
Endothelium, Vascular/cytology/*embryology | 3 | 75.0 |
Skin Neoplasms/blood supply/*metabolism/pathology | 2 | 100.0 |
Thrombospondin 1/*analysis | 2 | 66.0 |
*Stents | 3 | 4.0 |
Vascular Endothelial Growth Factors/analysis/*genetics | 2 | 100.0 |
Endothelial Cells/pathology | 2 | 50.0 |
Cells, Cultured/cytology/drug effects | 2 | 18.0 |
Infusion Pumps | 2 | 7.0 |
Vascular Endothelial Growth Factor A/*blood/metabolism | 2 | 100.0 |
Antigens, Neoplasm/analysis | 2 | 0.0 |
Apoptosis/genetics | 4 | 1.0 |
Exudates and Transudates/metabolism | 2 | 20.0 |
Macrophages, Alveolar/metabolism | 2 | 7.0 |
Endothelial Growth Factors/biosynthesis/*physiology | 14 | 100.0 |
Lymphokines/biosynthesis/*physiology | 13 | 86.0 |
Neoplasm Metastasis/*physiopathology | 4 | 13.0 |
Endothelial Growth Factors/immunology/*physiology | 3 | 100.0 |
Lymphokines/immunology/*physiology | 3 | 100.0 |
Myometrium/*blood supply | 2 | 40.0 |
Pleural Effusion/*chemistry/etiology | 2 | 66.0 |
Carcinoma/genetics/metabolism/*pathology | 2 | 20.0 |
Creatinine/blood | 3 | 0.0 |
*Follicular Phase | 2 | 16.0 |
Granulosa Cells/*metabolism | 9 | 22.0 |
Bone Neoplasms/*blood/*secondary | 2 | 66.0 |
Prostatic Neoplasms/*blood/pathology | 2 | 20.0 |
*Lung Neoplasms | 2 | 8.0 |
Restriction Mapping | 7 | 0.0 |
Oxygen | 2 | 15.0 |
Mitotic Index | 7 | 4.0 |
Protein p53/analysis/genetics | 2 | 8.0 |
Biological Transport/drug effects | 2 | 0.0 |
Macromolecular Substances | 10 | 0.0 |
Coronary Vessels/*chemistry | 2 | 40.0 |
Platelet Aggregation/*physiology | 2 | 8.0 |
Platelet-Derived Growth Factor/*physiology | 5 | 21.0 |
Genes, p53/genetics | 3 | 1.0 |
Hydrocortisone/pharmacology | 3 | 3.0 |
Cytokines/*analysis | 5 | 5.0 |
Thyroid Neoplasms/*metabolism/pathology | 2 | 4.0 |
Lymphatic System/*physiology | 2 | 66.0 |
Protein p53/analysis/*biosynthesis | 2 | 9.0 |
Hyaluronic Acid/metabolism | 2 | 2.0 |
Skin Neoplasms/*metabolism | 2 | 5.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/physiology | 2 | 5.0 |
Chemotactic Factors/physiology | 2 | 20.0 |
Head and Neck Neoplasms/*genetics/pathology | 3 | 10.0 |
Precancerous Conditions | 2 | 11.0 |
Eye Proteins/*metabolism | 4 | 18.0 |
Drainage | 3 | 15.0 |
Fertilization in Vitro/*adverse effects | 2 | 50.0 |
Interleukin-1/analysis | 2 | 2.0 |
Interleukin-8/analysis | 4 | 9.0 |
Paracentesis | 2 | 25.0 |
Cell Division/immunology | 2 | 0.0 |
Cell Movement/immunology | 3 | 3.0 |
Gastrectomy | 2 | 3.0 |
Alternative Splicing/*genetics | 2 | 1.0 |
Neuropilin-1/*genetics/metabolism | 2 | 50.0 |
Semaphorins/metabolism | 2 | 100.0 |
Genetic Engineering | 4 | 4.0 |
Sputum/*metabolism | 2 | 66.0 |
Neoplasms/*therapy | 2 | 1.0 |
*Gastrectomy | 2 | 8.0 |
*Postoperative Complications | 2 | 3.0 |
Joints/blood supply | 2 | 100.0 |
Vascular Endothelial Growth Factor A/analysis/blood | 2 | 100.0 |
Pre-Eclampsia/metabolism | 2 | 33.0 |
Life Style | 2 | 1.0 |
Lymphokines/genetics/*secretion | 2 | 100.0 |
*Coronary Circulation | 2 | 11.0 |
DNA, Complementary/biosynthesis | 2 | 3.0 |
Coronary Disease/surgery | 2 | 14.0 |
Leg/blood supply | 3 | 9.0 |
Neovascularization, Pathologic/*metabolism/physiopathology | 2 | 50.0 |
Collagenases/*metabolism | 5 | 17.0 |
Gelatinase B | 6 | 7.0 |
Tumor Markers, Biological/biosynthesis | 2 | 5.0 |
Tumor Stem Cell Assay | 4 | 2.0 |
Intercellular Adhesion Molecule-1/*biosynthesis/genetics | 2 | 10.0 |
Interleukin-1/physiology | 2 | 2.0 |
Cross Reactions | 3 | 0.0 |
Dendritic Cells/physiology | 2 | 6.0 |
Endothelial Growth Factors/analysis/*secretion | 2 | 100.0 |
Lymphokines/analysis/*secretion | 2 | 100.0 |
Stomach Neoplasms/*blood/pathology | 4 | 30.0 |
Carbazoles/pharmacology | 2 | 4.0 |
Bone Marrow Transplantation | 3 | 1.0 |
Stem Cells/*cytology/drug effects | 2 | 14.0 |
Calibration | 3 | 2.0 |
Myocardial Ischemia/*metabolism | 2 | 22.0 |
X-Rays | 2 | 1.0 |
Epithelial Cells/*physiology | 2 | 6.0 |
Endothelial Growth Factors/metabolism/secretion | 2 | 100.0 |
Fibroblast Growth Factor 2/metabolism/secretion | 2 | 100.0 |
Interleukin-8/metabolism/secretion | 2 | 50.0 |
Lymphokines/metabolism/secretion | 2 | 100.0 |
Leukocytes, Mononuclear/*metabolism | 3 | 2.0 |
Cervix Neoplasms/*blood supply/metabolism/mortality | 2 | 100.0 |
Aqueous Humor/metabolism | 5 | 45.0 |
Colonic Neoplasms/metabolism | 4 | 7.0 |
Endothelial Growth Factors/*analysis/immunology | 6 | 100.0 |
Lymphokines/*analysis/immunology | 6 | 75.0 |
Neoplasms/*metabolism | 4 | 4.0 |
Ovarian Neoplasms/metabolism | 3 | 8.0 |
Stomach Neoplasms/metabolism | 3 | 20.0 |
Cyclin D1/analysis | 2 | 5.0 |
Breast Neoplasms/genetics/*metabolism | 4 | 6.0 |
Neoplasms, Hormone-Dependent/genetics/*metabolism | 2 | 28.0 |
Gelatinases/metabolism | 3 | 9.0 |
Metalloendopeptidases/metabolism | 4 | 6.0 |
Autoradiography | 4 | 0.0 |
Brain/*physiopathology | 2 | 4.0 |
Bronchial Neoplasms/genetics/*metabolism/pathology | 2 | 66.0 |
Precancerous Conditions/genetics/*metabolism/pathology | 2 | 50.0 |
Endothelium, Vascular/pathology/*physiology | 2 | 40.0 |
Gene Targeting | 2 | 0.0 |
Neovascularization, Pathologic/genetics/physiopathology | 2 | 50.0 |
Biosensing Techniques | 3 | 5.0 |
Decidua/cytology/metabolism | 2 | 40.0 |
Densitometry | 3 | 2.0 |
Carcinoma, Squamous Cell/blood supply/mortality/*pathology/surgery | 2 | 100.0 |
Esophageal Neoplasms/blood supply/mortality/*pathology/surgery | 2 | 100.0 |
Esophagectomy | 3 | 21.0 |
Esophagus/blood supply/pathology | 2 | 100.0 |
Colon/pathology | 2 | 4.0 |
Platelet-Derived Growth Factor/genetics | 5 | 15.0 |
Catalytic Domain | 3 | 1.0 |
Growth Substances/chemistry | 2 | 40.0 |
Peptide Fragments/chemistry | 2 | 1.0 |
*Protein Conformation | 3 | 1.0 |
Protein Folding | 7 | 1.0 |
Echocardiography | 5 | 2.0 |
Adenocarcinoma/genetics/metabolism/*pathology | 2 | 10.0 |
Postoperative Period | 10 | 3.0 |
Gastric Mucosa/metabolism | 2 | 4.0 |
Cardiovascular Diseases/*genetics/*therapy | 2 | 100.0 |
Antineoplastic Agents/administration & dosage/*therapeutic use | 3 | 17.0 |
Camptothecin/administration & dosage/*analogs & derivatives | 3 | 23.0 |
Organoplatinum Compounds/administration & dosage | 2 | 18.0 |
Pyrimidines/therapeutic use | 2 | 9.0 |
Vascular Endothelial Growth Factor A/*urine | 2 | 100.0 |
Vascular Endothelial Growth Factor Receptor-1/metabolism | 9 | 100.0 |
Cell Line, Tumor/drug effects/metabolism | 2 | 16.0 |
Endothelial Cells/drug effects/metabolism | 2 | 33.0 |
Peptides/genetics/metabolism | 2 | 4.0 |
Transcription Factors/*biosynthesis/genetics | 6 | 6.0 |
Extracellular Matrix Proteins/*biosynthesis/genetics | 2 | 40.0 |
Vascular Endothelial Growth Factor Receptor-2/biosynthesis/genetics | 4 | 66.0 |
Liver Cirrhosis/complications/metabolism | 2 | 66.0 |
Cervix Neoplasms/*blood supply/*metabolism/pathology | 2 | 100.0 |
Chelating Agents/pharmacology | 3 | 3.0 |
Erythropoietin/*genetics | 3 | 8.0 |
Ionomycin/pharmacology | 3 | 1.0 |
*Embryonic and Fetal Development | 5 | 4.0 |
Ultrasonography, Prenatal | 3 | 4.0 |
Stomach Neoplasms/*blood supply/pathology | 2 | 40.0 |
Neovascularization, Pathologic/pathology/prevention & control | 2 | 100.0 |
Neoplasms, Experimental/*metabolism/pathology | 2 | 40.0 |
*Ultrasonics | 2 | 12.0 |
*Environment | 2 | 4.0 |
Ovary/*blood supply/ultrasonography | 2 | 100.0 |
Ultrasonography, Doppler, Pulsed | 3 | 60.0 |
Thromboplastin/*biosynthesis | 5 | 6.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 5 | 1.0 |
Hepatocyte Growth Factor/pharmacology | 3 | 4.0 |
Aging/*physiology | 2 | 0.0 |
Nasopharyngeal Neoplasms/*metabolism/pathology | 4 | 57.0 |
Head and Neck Neoplasms/blood supply/*metabolism | 3 | 100.0 |
Endothelial Growth Factors/*analysis/biosynthesis | 5 | 100.0 |
Epithelium/chemistry/pathology | 2 | 5.0 |
Lymphokines/*analysis/biosynthesis | 5 | 100.0 |
Up-Regulation/*drug effects | 4 | 5.0 |
Endothelium, Vascular/*cytology/*physiology | 3 | 30.0 |
Brain Neoplasms/blood supply/*metabolism | 2 | 100.0 |
Glioma/blood supply/*metabolism | 3 | 100.0 |
Amniotic Fluid/*metabolism | 3 | 7.0 |
GTPase-Activating Proteins | 2 | 1.0 |
Endothelial Growth Factors/antagonists & inhibitors/*genetics | 2 | 66.0 |
Lymphokines/antagonists & inhibitors/*genetics | 2 | 100.0 |
Cell Membrane | 2 | 3.0 |
Suramin/pharmacology | 4 | 11.0 |
Intestinal Mucosa/metabolism | 4 | 3.0 |
Bronchopulmonary Dysplasia/metabolism | 2 | 100.0 |
Suction | 2 | 11.0 |
Smoking/*adverse effects | 3 | 1.0 |
Thrombospondins/analysis | 2 | 40.0 |
Glioma/metabolism/pathology | 2 | 28.0 |
Brain/*blood supply | 4 | 12.0 |
Prostatic Neoplasms/*blood | 2 | 7.0 |
Epithelium/metabolism/pathology | 2 | 3.0 |
Receptors, Mitogen/genetics | 5 | 71.0 |
Tissue Plasminogen Activator/genetics | 2 | 20.0 |
Inflammation Mediators/*metabolism | 2 | 3.0 |
Integrin beta3/metabolism | 2 | 18.0 |
CD40 Ligand/metabolism | 2 | 8.0 |
Retinoblastoma Protein/metabolism | 2 | 0.0 |
Ribosomal Protein S6 Kinases/*metabolism | 2 | 8.0 |
Cerebrovascular Circulation | 5 | 9.0 |
Vascular Endothelial Growth Factor A/administration & | 3 | 100.0 |
Glomerular Mesangium/cytology/*physiology | 2 | 22.0 |
Receptor, Angiotensin, Type 2 | 2 | 2.0 |
Receptors, Mitogen/biosynthesis | 4 | 100.0 |
Brain Neoplasms/blood supply/*chemistry | 2 | 100.0 |
Cytokines/analysis/*biosynthesis | 2 | 14.0 |
Proteoglycans/*metabolism | 2 | 3.0 |
Cerebellar Neoplasms/genetics | 2 | 16.0 |
Hemangioblastoma/genetics | 2 | 22.0 |
Endothelial Growth Factors/*blood/metabolism | 3 | 100.0 |
Lymphokines/*blood/metabolism | 3 | 100.0 |
Plasma Cells/*metabolism | 2 | 16.0 |
Endothelial Growth Factors/*metabolism/secretion | 2 | 100.0 |
Lymphokines/*metabolism/secretion | 2 | 66.0 |
Helicobacter pylori | 2 | 5.0 |
*Regeneration | 2 | 7.0 |
Transforming Growth Factor alpha/physiology | 2 | 7.0 |
Recombinant Proteins/immunology | 3 | 0.0 |
Growth Substances/*biosynthesis/genetics | 3 | 11.0 |
Immunoglobulins, Intravenous/therapeutic use | 2 | 5.0 |
Receptor Protein-Tyrosine Kinases/chemistry/*metabolism | 4 | 26.0 |
Trophoblasts/cytology/metabolism | 2 | 25.0 |
Eye/blood supply | 4 | 100.0 |
Recombinant Proteins/administration & dosage/pharmacology | 5 | 8.0 |
Serum Albumin, Bovine/metabolism | 2 | 9.0 |
Mitogen-Activated Protein Kinase 1 | 2 | 1.0 |
Breast Neoplasms/*blood supply | 3 | 50.0 |
Fibroblast Growth Factor 1 | 2 | 7.0 |
Ovulation/physiology | 2 | 12.0 |
Endometrium/drug effects/*metabolism | 2 | 16.0 |
Levonorgestrel/*pharmacology | 2 | 40.0 |
GTP-Binding Proteins/physiology | 2 | 3.0 |
Liver Neoplasms/pathology/secondary | 2 | 20.0 |
Endothelium, Vascular/cytology/*drug effects/*enzymology | 2 | 33.0 |
Vascular Endothelial Growth Factor A/*biosynthesis/*genetics | 4 | 100.0 |
Vascular Endothelial Growth Factor A/*administration & | 3 | 100.0 |
Breast Neoplasms/*metabolism/*pathology | 2 | 5.0 |
Integrin alpha6beta4/*metabolism | 2 | 40.0 |
Brain-Derived Neurotrophic Factor/metabolism | 2 | 7.0 |
Gelatin | 2 | 13.0 |
Neuroprotective Agents/metabolism | 2 | 13.0 |
Neovascularization, Physiologic/*drug effects/genetics | 3 | 75.0 |
Skin Neoplasms/*metabolism/pathology | 5 | 7.0 |
Cell Adhesion Molecules/physiology | 2 | 2.0 |
Proteinuria/etiology | 2 | 6.0 |
Infertility, Female/etiology | 2 | 20.0 |
Astrocytoma/*genetics/metabolism/pathology | 2 | 16.0 |
Gene Fusion | 2 | 2.0 |
Glial Fibrillary Acidic Protein/*genetics | 2 | 9.0 |
Ischemia/*metabolism/pathology | 2 | 100.0 |
Retinal Neovascularization/etiology/*metabolism/pathology | 2 | 100.0 |
Wound Healing/drug effects/*physiology | 3 | 20.0 |
Endothelium, Vascular/metabolism/physiology | 2 | 66.0 |
Recombinant Proteins/metabolism/pharmacology | 6 | 5.0 |
Neutrophils/chemistry | 2 | 14.0 |
*Vitrectomy | 2 | 33.0 |
Heart Rate/physiology | 2 | 2.0 |
Protein Kinase C/*physiology | 4 | 4.0 |
Neovascularization, Pathologic/*metabolism/prevention & control | 2 | 100.0 |
Angiotensin II/*physiology | 3 | 8.0 |
Myocardium/*pathology | 2 | 5.0 |
Cell Movement/*drug effects/physiology | 3 | 16.0 |
*Chemoembolization, Therapeutic | 5 | 20.0 |
Lymphokines/genetics/metabolism/*physiology | 2 | 100.0 |
Neoplasms/*chemistry | 2 | 14.0 |
Receptors, Growth Factor/chemistry/*metabolism | 3 | 100.0 |
Protein p53/*biosynthesis/genetics | 3 | 8.0 |
Thrombospondin 1/*biosynthesis | 2 | 50.0 |
Embryo, Nonmammalian/physiology | 2 | 6.0 |
Integrins/physiology | 3 | 4.0 |
Carcinoma, Hepatocellular/*metabolism | 4 | 3.0 |
Liver Neoplasms/*metabolism | 4 | 4.0 |
Granulocyte Colony-Stimulating Factor/biosynthesis | 3 | 27.0 |
Androgens/metabolism | 2 | 3.0 |
RNA, Messenger/*analysis/genetics | 2 | 4.0 |
*Variation (Genetics) | 2 | 0.0 |
DNA/*metabolism | 2 | 0.0 |
Heat | 3 | 0.0 |
Choroid/*blood supply | 2 | 50.0 |
Fundus Oculi | 3 | 3.0 |
Neovascularization, Pathologic/etiology/*metabolism/pathology | 2 | 100.0 |
RNA, Neoplasm/*biosynthesis | 3 | 27.0 |
Orf virus/*genetics | 2 | 100.0 |
Egtazic Acid/pharmacology | 3 | 2.0 |
Oligodeoxyribonucleotides, Antisense/pharmacology | 5 | 10.0 |
RNA-Binding Proteins/*metabolism | 2 | 2.0 |
Anticoagulants/therapeutic use | 2 | 2.0 |
Myocardial Infarction/*blood/drug therapy | 2 | 20.0 |
Endothelial Growth Factors/*analysis/genetics/physiology | 2 | 66.0 |
Lymphokines/*analysis/genetics/physiology | 3 | 60.0 |
Ovarian Neoplasms/*metabolism/mortality | 2 | 66.0 |
Ovary/metabolism | 3 | 3.0 |
Carcinoma, Non-Small-Cell Lung/blood supply/*metabolism/pathology | 3 | 60.0 |
Plasminogen/*genetics | 2 | 11.0 |
Myocytes, Smooth Muscle/metabolism | 3 | 30.0 |
Serum Albumin, Bovine/pharmacokinetics | 2 | 50.0 |
Ovarian Neoplasms/*blood | 2 | 15.0 |
Fibroblast Growth Factor 1/genetics | 2 | 40.0 |
Insulin-Like Growth Factor II/genetics | 2 | 2.0 |
Mouth Mucosa/cytology | 2 | 20.0 |
Vascular Endothelial Growth Factor Receptor-1/*analysis | 4 | 100.0 |
Vascular Endothelial Growth Factor Receptor-3/*analysis | 2 | 100.0 |
Extremities | 2 | 7.0 |
Blood Platelets/*physiology | 3 | 1.0 |
Endostatins/*blood | 4 | 80.0 |
Wounds and Injuries/*metabolism/surgery | 2 | 100.0 |
Vascular Endothelial Growth Factor A/*blood/*cerebrospinal fluid | 2 | 100.0 |
Surgical Procedures, Minimally Invasive | 2 | 22.0 |
Tomography, Emission-Computed, Single-Photon | 3 | 5.0 |
Myocardial Ischemia/physiopathology/*therapy | 3 | 100.0 |
Mammary Tumor Virus, Mouse/genetics | 2 | 5.0 |
Bone Marrow Cells/cytology | 4 | 5.0 |
Leukemia, Myeloid/drug therapy/pathology | 2 | 50.0 |
Chromogranins/metabolism | 2 | 6.0 |
Neurosecretory Systems/*pathology | 2 | 16.0 |
Anoxia/genetics/*metabolism | 2 | 40.0 |
Lymphokines/chemistry/metabolism/*physiology | 2 | 100.0 |
Sodium/metabolism | 2 | 1.0 |
Decidua/metabolism | 2 | 7.0 |
Edetic Acid | 2 | 4.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
*Antibodies, Monoclonal | 2 | 0.0 |
Breast/metabolism | 2 | 2.0 |
Carcinoma, Lobular/blood supply/*metabolism/pathology | 2 | 100.0 |
Astrocytes/pathology | 3 | 8.0 |
Neurons/pathology | 2 | 1.0 |
*Bile Ducts, Intrahepatic | 2 | 6.0 |
Tumor Cells, Cultured/pathology | 2 | 3.0 |
Chromatography, Affinity | 8 | 1.0 |
Astrocytoma/*genetics/pathology | 2 | 8.0 |
Genes, ras/*genetics | 3 | 3.0 |
Receptors, Platelet-Derived Growth Factor/metabolism | 3 | 6.0 |
Gene Expression/*physiology | 3 | 3.0 |
Liver Neoplasms/*prevention & control/*secondary | 2 | 100.0 |
Breast Neoplasms/blood supply/*metabolism | 4 | 100.0 |
Endothelial Growth Factors/*analysis/*genetics | 2 | 100.0 |
Lymphokines/*analysis/*genetics | 2 | 100.0 |
Lung Neoplasms/*blood supply/mortality/*pathology/surgery | 2 | 100.0 |
Prostatic Neoplasms/*metabolism/*pathology | 2 | 11.0 |
Neovascularization, Pathologic/genetics/*physiopathology | 2 | 100.0 |
Thyroid Gland/*blood supply | 2 | 100.0 |
Proteins/genetics/physiology | 2 | 3.0 |
Receptor, Epidermal Growth Factor/*analysis | 2 | 0.0 |
Antimutagenic Agents/pharmacology | 2 | 33.0 |
Erythropoietin/biosynthesis/genetics | 2 | 50.0 |
Gene Expression Regulation, Neoplastic/*drug effects/physiology | 2 | 66.0 |
Keratinocytes/cytology/*metabolism | 2 | 5.0 |
*Multigene Family | 2 | 0.0 |
Motor Neurons/metabolism/pathology | 2 | 22.0 |
Point Mutation/genetics | 2 | 0.0 |
Nitric-Oxide Synthase/genetics | 3 | 8.0 |
Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors | 5 | 83.0 |
Neoplasms/metabolism | 4 | 4.0 |
Receptors, Platelet-Derived Growth Factor/genetics | 2 | 13.0 |
Gene Expression Regulation/drug effects/*genetics | 2 | 14.0 |
Vascular Endothelial Growth Factor A/analysis/*antagonists & | 2 | 100.0 |
Angiotensin II/metabolism | 4 | 9.0 |
Rats, Inbred SHR | 2 | 2.0 |
Androgens/*pharmacology | 3 | 5.0 |
Dihydrotestosterone/pharmacology | 3 | 3.0 |
Brain Chemistry | 3 | 1.0 |
Protein Binding/genetics | 2 | 0.0 |
Brain Neoplasms/genetics/metabolism/pathology | 2 | 33.0 |
Fetus/*metabolism | 3 | 3.0 |
Retina/*chemistry/pathology | 2 | 100.0 |
Hepatocyte Growth Factor/*analysis | 2 | 8.0 |
Retinal Diseases/*metabolism | 2 | 40.0 |
Ovulation Induction/methods | 2 | 25.0 |
Blood Volume | 2 | 4.0 |
Carcinoma, Squamous Cell/*blood supply/*metabolism | 4 | 100.0 |
Esophageal Neoplasms/*blood supply/*metabolism | 2 | 100.0 |
Endothelial Growth Factors/*genetics/*pharmacology | 2 | 100.0 |
Lymphokines/*genetics/*pharmacology | 2 | 100.0 |
Colorectal Neoplasms/metabolism/*pathology | 3 | 14.0 |
Gelatinase A | 4 | 5.0 |
Urinary Plasminogen Activator/*metabolism | 5 | 13.0 |
DNA, Neoplasm/metabolism | 3 | 2.0 |
Losartan/pharmacology | 2 | 6.0 |
Receptor, Platelet-Derived Growth Factor beta | 2 | 11.0 |
Kidney/*blood supply | 2 | 20.0 |
Growth Substances/genetics/metabolism | 2 | 15.0 |
Retina/metabolism/pathology | 3 | 18.0 |
Microcirculation/drug effects/physiology | 2 | 66.0 |
Diabetes Mellitus, Type 2/complications/*metabolism | 2 | 20.0 |
Hypertension/complications/metabolism | 2 | 66.0 |
Cyst Fluid/metabolism | 2 | 50.0 |
Vascular Endothelial Growth Factor A/blood/*metabolism | 7 | 100.0 |
Epidermis/*metabolism | 2 | 8.0 |
Keloid/*metabolism | 2 | 50.0 |
Base Sequence/genetics | 2 | 0.0 |
Neoplasm Invasiveness/*pathology | 2 | 7.0 |
Neoplasm Metastasis/pathology | 2 | 9.0 |
Vascular Endothelial Growth Factor A/biosynthesis/*physiology | 4 | 100.0 |
Angiogenesis Inhibitors/metabolism/*pharmacology | 2 | 100.0 |
Multiple Myeloma/blood/*drug therapy/pathology | 3 | 75.0 |
Thalidomide/*pharmacology | 4 | 23.0 |
Microtubule-Associated Proteins/metabolism | 2 | 1.0 |
Kidney Diseases/physiopathology | 2 | 28.0 |
Epinephrine/pharmacology | 2 | 2.0 |
Megakaryocytes/metabolism | 2 | 5.0 |
RNA-Directed DNA Polymerase | 7 | 5.0 |
Neovascularization, Pathologic/*drug therapy/metabolism | 2 | 50.0 |
Choroid/metabolism | 2 | 33.0 |
Fetus/metabolism | 2 | 1.0 |
Chromosome Deletion | 2 | 0.0 |
Chromosomes, Human, Pair 3/genetics | 3 | 2.0 |
Placenta/growth & development | 2 | 50.0 |
Endothelial Growth Factors/analysis/biosynthesis/*physiology | 2 | 100.0 |
Lymphokines/analysis/biosynthesis/*physiology | 2 | 100.0 |
Muscle, Smooth, Vascular | 2 | 50.0 |
Transfection/genetics | 4 | 2.0 |
*Platelet Activation | 2 | 1.0 |
Nitric-Oxide Synthase/*analysis | 3 | 20.0 |
Central Nervous System Neoplasms/*genetics/pathology | 2 | 20.0 |
Carcinoma/*blood | 2 | 16.0 |
Neoplasm Metastasis/*genetics | 2 | 3.0 |
Adenocarcinoma/genetics/*metabolism/pathology | 2 | 7.0 |
Head and Neck Neoplasms/metabolism | 2 | 28.0 |
Melanoma/metabolism | 4 | 14.0 |
Sarcoma/metabolism | 2 | 16.0 |
Helix-Loop-Helix Motifs | 5 | 2.0 |
Endometrium/blood supply/drug effects/*metabolism | 2 | 100.0 |
Carcinoma, Hepatocellular/*blood/*secondary | 2 | 100.0 |
Liver Function Tests | 3 | 1.0 |
Cell Adhesion Molecules/drug effects/*metabolism | 2 | 50.0 |
Platelet Activating Factor/*pharmacology | 2 | 8.0 |
Vascular Endothelial Growth Factor Receptor-2/genetics/*metabolism | 6 | 85.0 |
Serpins/*analysis | 3 | 100.0 |
Antibodies, Monoclonal/*administration & dosage | 3 | 10.0 |
Receptor, TIE-2/genetics | 3 | 50.0 |
Vascular Endothelial Growth Factor Receptor-2/genetics | 6 | 54.0 |
Blood Vessels/metabolism/*physiology | 3 | 75.0 |
Vascular Endothelial Growth Factor A/metabolism/*physiology | 4 | 100.0 |
Pulmonary Artery/cytology | 3 | 30.0 |
Carcinoma, Squamous Cell/*blood supply/genetics/pathology | 2 | 100.0 |
Receptors, Vascular Endothelial Growth Factor/analysis | 2 | 66.0 |
Mitosis/drug effects | 2 | 1.0 |
Receptor, IGF Type 1/antagonists & inhibitors | 2 | 100.0 |
ras Proteins/*genetics | 2 | 15.0 |
Progesterone/physiology | 2 | 20.0 |
Endothelial Growth Factors/*chemistry/genetics/metabolism | 3 | 100.0 |
Lymphokines/*chemistry/genetics/metabolism | 4 | 66.0 |
Protein p53/analysis/biosynthesis | 2 | 40.0 |
Lectins/analysis | 2 | 13.0 |
Fetal Blood | 2 | 1.0 |
NF-kappa B/antagonists & inhibitors/*physiology | 2 | 11.0 |
Pregnancy Trimester, First/blood | 2 | 25.0 |
Carcinoma, Non-Small-Cell Lung/*blood | 3 | 42.0 |
Carcinoma, Non-Small-Cell Lung/*metabolism/pathology/secondary | 2 | 50.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 4 | 1.0 |
Adenocarcinoma/genetics/metabolism/pathology | 2 | 6.0 |
RNA, Messenger/*genetics/*metabolism | 3 | 6.0 |
Cell Hypoxia/genetics/physiology | 2 | 33.0 |
Gene Expression/genetics | 2 | 0.0 |
Monocytes | 2 | 2.0 |
Nausea/chemically induced | 2 | 6.0 |
Apoptosis/*genetics | 2 | 0.0 |
Enzyme Precursors/metabolism | 2 | 1.0 |
Portraits | 2 | 7.0 |
Trans-Activators/chemistry/genetics/*metabolism | 2 | 2.0 |
Catalysis | 2 | 0.0 |
Cell Membrane/*enzymology | 2 | 7.0 |
Membrane Microdomains/enzymology | 2 | 28.0 |
Tyrosine/chemistry | 3 | 2.0 |
Sulfonamides/administration & dosage | 2 | 50.0 |
Thalidomide/administration & dosage | 3 | 75.0 |
Vinblastine/administration & dosage/*analogs & derivatives | 2 | 33.0 |
Biological Transport, Active | 4 | 2.0 |
Cell Membrane/metabolism/ultrastructure | 3 | 5.0 |
Exfoliation Syndrome/metabolism/pathology | 3 | 18.0 |
Extracellular Matrix/metabolism/ultrastructure | 3 | 15.0 |
Ferritin/*metabolism | 3 | 11.0 |
Trabecular Meshwork/*metabolism/ultrastructure | 3 | 17.0 |
Trans-Activation (Genetics)/*physiology | 2 | 1.0 |
Recombinant Proteins/biosynthesis/drug effects/pharmacology | 2 | 100.0 |
Eosinophil Granule Proteins | 2 | 0.0 |
Sputum/chemistry | 3 | 21.0 |
Tumor Necrosis Factor-alpha/genetics/*metabolism | 2 | 3.0 |
Antigens, CD14/analysis | 2 | 1.0 |
Endothelial Cells/cytology | 5 | 62.0 |
Gelatinase A/genetics/*metabolism | 2 | 25.0 |
Pregnancy Proteins/genetics/*metabolism/pharmacology | 2 | 100.0 |
Colonic Neoplasms | 3 | 2.0 |
Intestinal Mucosa/metabolism/pathology | 2 | 6.0 |
Growth Inhibitors/*metabolism | 2 | 3.0 |
E-Selectin/*blood | 2 | 7.0 |
Endothelial Growth Factors/immunology/*pharmacology | 3 | 100.0 |
Lymphokines/immunology/*pharmacology | 3 | 75.0 |
Dendritic Cells/*cytology/drug effects/immunology | 2 | 20.0 |
Neovascularization, Pathologic/mortality/*pathology | 2 | 66.0 |
Hemodynamic Processes/*drug effects | 2 | 1.0 |
Stomach Neoplasms/genetics/*metabolism/*pathology | 2 | 40.0 |
Aortography | 2 | 11.0 |
Glycoproteins/*analysis | 3 | 4.0 |
Antibodies, Blocking/immunology | 2 | 11.0 |
Epithelium/pathology | 3 | 2.0 |
Peritoneal Neoplasms/*secondary | 2 | 25.0 |
Mesoderm | 2 | 6.0 |
Plasminogen Activators/analysis | 2 | 25.0 |
Fluorescent Dyes | 2 | 0.0 |
Prostatic Neoplasms/*blood supply/*pathology | 2 | 100.0 |
Fibroblasts/chemistry | 2 | 4.0 |
Calcium/physiology | 2 | 0.0 |
Pregnancy Complications/metabolism/*physiopathology | 2 | 100.0 |
Lymphatic Metastasis/*pathology | 6 | 17.0 |
Vascular Endothelial Growth Factor Receptor-2/*physiology | 3 | 100.0 |
Viral Proteins/pharmacology | 2 | 14.0 |
Sesquiterpenes/isolation & purification/*pharmacology | 2 | 100.0 |
Vascular Endothelial Growth Factor A/biosynthesis/*genetics | 7 | 100.0 |
Neurons/*metabolism | 2 | 0.0 |
Diabetic Retinopathy/*prevention & control | 2 | 100.0 |
Liver Cirrhosis/blood | 2 | 4.0 |
Deoxycytidine/*analogs & derivatives/therapeutic use | 3 | 27.0 |
Protease Inhibitors/metabolism | 2 | 6.0 |
Endothelial Growth Factors/biosynthesis/genetics/*metabolism | 2 | 100.0 |
Thrombopoietin/*metabolism/pharmacology | 2 | 33.0 |
Adenoma/blood supply/metabolism | 3 | 100.0 |
Thrombin/metabolism | 3 | 2.0 |
Progesterone/*pharmacology | 4 | 5.0 |
Proto-Oncogene Proteins/*chemistry/genetics/metabolism | 2 | 25.0 |
Receptor Protein-Tyrosine Kinases/*chemistry/genetics/metabolism | 2 | 100.0 |
Proto-Oncogene Proteins c-myc/analysis | 2 | 11.0 |
Iris/blood supply | 2 | 100.0 |
Endothelial Growth Factors/*analysis/immunology/physiology | 2 | 100.0 |
Lymphokines/*analysis/immunology/physiology | 2 | 100.0 |
*Brain Chemistry | 2 | 1.0 |
Colorectal Neoplasms/*blood | 3 | 60.0 |
Blood Coagulation/*physiology | 2 | 1.0 |
Interleukin-1/blood | 2 | 1.0 |
*Genes, src | 3 | 7.0 |
Cell Adhesion/drug effects/physiology | 3 | 5.0 |
Nitric Oxide/biosynthesis/*physiology | 2 | 25.0 |
Dexamethasone/administration & dosage | 2 | 6.0 |
Mouth Neoplasms/*blood supply/pathology | 2 | 66.0 |
*Exons | 3 | 0.0 |
Endothelial Cells/cytology/*physiology | 3 | 60.0 |
Chemoembolization, Therapeutic | 2 | 22.0 |
Neoplasm Circulating Cells/*metabolism/pathology | 2 | 50.0 |
Vascular Endothelial Growth Factor Receptor-1/genetics/metabolism | 3 | 100.0 |
Vascular Endothelial Growth Factor Receptor-2/genetics/metabolism | 8 | 80.0 |
Corpus Luteum/*physiology | 3 | 30.0 |
Lipoproteins, LDL/pharmacology | 3 | 7.0 |
Arachidonic Acid/metabolism | 4 | 4.0 |
Cell Membrane Permeability/physiology | 2 | 10.0 |
Receptors, Mitogen/*genetics | 3 | 50.0 |
Mouth Neoplasms/*metabolism | 2 | 8.0 |
Collateral Circulation/drug effects | 3 | 100.0 |
Diabetes Mellitus, Type 1/complications | 2 | 11.0 |
Diabetes Mellitus, Type 2/complications | 2 | 9.0 |
Diabetic Retinopathy/complications/*metabolism | 2 | 66.0 |
Chromosome Disorders | 2 | 0.0 |
Cyclic AMP/*metabolism | 2 | 0.0 |
Arteriosclerosis/physiopathology | 2 | 9.0 |
*Models, Cardiovascular | 2 | 6.0 |
Chemotaxis/*drug effects | 2 | 4.0 |
Blood Vessels/anatomy & histology | 3 | 100.0 |
Vascular Endothelial Growth Factor A/genetics/*pharmacology | 2 | 100.0 |
Isoenzymes/*antagonists & inhibitors | 3 | 9.0 |
Prostatic Hyperplasia/*metabolism/pathology | 2 | 6.0 |
Angiopoietin-2/genetics/*metabolism | 2 | 66.0 |
Vascular Endothelial Growth Factor Receptor-2/*blood | 3 | 100.0 |
Endostatins/pharmacology | 2 | 100.0 |
Adenoviruses, Human/*genetics | 2 | 1.0 |
Tumor Suppressor Proteins/*genetics/metabolism | 2 | 5.0 |
Angiopoietin-2/biosynthesis | 2 | 100.0 |
Neuropilin-1/biosynthesis | 2 | 100.0 |
Vascular Endothelial Growth Factor A/genetics/*physiology | 4 | 80.0 |
*Mitogen-Activated Protein Kinase Kinases | 3 | 3.0 |
Dose-Response Relationship, Immunologic | 3 | 0.0 |
Metals/pharmacology | 2 | 22.0 |
Lymphoma/*metabolism | 2 | 8.0 |
Genes, Tumor Suppressor/*physiology | 2 | 1.0 |
Cell Communication/*physiology | 2 | 3.0 |
Models, Structural | 3 | 1.0 |
Oligodeoxyribonucleotides | 7 | 0.0 |
Carcinoma/*metabolism/mortality/pathology | 2 | 33.0 |
Antigens, Neoplasm/*analysis | 2 | 0.0 |
Gastric Mucosa/chemistry | 2 | 11.0 |
Colorectal Neoplasms/*blood supply/*metabolism/pathology | 2 | 66.0 |
Adenocarcinoma, Follicular/metabolism | 2 | 40.0 |
RNA, Messenger/analysis/metabolism | 3 | 2.0 |
Luciferases/biosynthesis | 2 | 2.0 |
Platelet-Derived Growth Factor/chemistry | 3 | 100.0 |
Water/chemistry | 2 | 5.0 |
8-Bromo Cyclic Adenosine Monophosphate/pharmacology | 2 | 2.0 |
Brain/metabolism/pathology | 2 | 1.0 |
Freezing | 2 | 2.0 |
Adrenal Cortex/blood supply | 3 | 75.0 |
Clone Cells | 2 | 0.0 |
Receptors, Estrogen/biosynthesis | 2 | 4.0 |
Calcitriol/*pharmacology | 2 | 1.0 |
Cysteine | 2 | 1.0 |
Carrier Proteins/pharmacology | 4 | 6.0 |
Tumor Suppressor Proteins/genetics | 2 | 2.0 |
Ubiquitin-Protein Ligases/genetics | 2 | 10.0 |
Data Interpretation, Statistical | 3 | 1.0 |
Endothelial Growth Factors/chemistry/genetics/*physiology | 2 | 100.0 |
Lymphokines/chemistry/genetics/*physiology | 2 | 50.0 |
Transcription Factor, Sp1/*metabolism | 6 | 1.0 |
Base Composition | 2 | 0.0 |
*src-Family Kinases | 2 | 4.0 |
Arteries/physiology | 2 | 25.0 |
Pregnancy, Animal/*physiology | 2 | 22.0 |
Blood-Retinal Barrier/*physiology | 2 | 28.0 |
Glycosylation End Products, Advanced/*pharmacology | 2 | 20.0 |
Adenocarcinoma/*physiopathology | 2 | 50.0 |
Endopeptidases/metabolism | 2 | 1.0 |
Fibroblasts/cytology/drug effects/metabolism | 3 | 5.0 |
Genistein | 3 | 4.0 |
Isoflavones/pharmacology | 3 | 4.0 |
Antisense Elements (Genetics) | 6 | 10.0 |
Ovarian Neoplasms/*pathology | 2 | 3.0 |
RNA Probes | 6 | 4.0 |
Cytoskeletal Proteins/*metabolism | 2 | 1.0 |
Antineoplastic Agents/*administration & dosage | 2 | 3.0 |
Tissue Inhibitor of Metalloproteinase-1/analysis | 3 | 33.0 |
Vascular Endothelial Growth Factors/analysis | 2 | 100.0 |
Hemodynamic Processes/drug effects | 2 | 1.0 |
Eye/*blood supply | 3 | 100.0 |
*Transduction, Genetic | 2 | 2.0 |
Levonorgestrel/pharmacology | 2 | 33.0 |
*Chromosome Mapping | 3 | 0.0 |
Lymphokines/chemistry/*genetics/metabolism | 2 | 100.0 |
Endothelium, Vascular/*cytology/*drug effects | 2 | 22.0 |
Membranes | 2 | 18.0 |
Fibroblast Growth Factor 2/*analysis/biosynthesis | 2 | 66.0 |
Receptor Protein-Tyrosine Kinases/drug effects/*physiology | 2 | 50.0 |
Oncogene Protein pp60(v-src)/*physiology | 2 | 40.0 |
Serum Albumin/*metabolism | 2 | 4.0 |
Retina/ultrastructure | 2 | 100.0 |
Software | 2 | 0.0 |
Brain/blood supply/embryology | 2 | 50.0 |
Retina | 2 | 28.0 |
Sarcoma, Kaposi/*metabolism/pathology | 2 | 40.0 |
Endothelial Cells/pathology/physiology | 2 | 66.0 |
Receptor, TIE-2/analysis | 2 | 66.0 |
Gene Expression Regulation, Enzymologic/*physiology | 2 | 2.0 |
Vascular Endothelial Growth Factor A/*biosynthesis/genetics/secretion | 2 | 100.0 |
Endothelium, Vascular/drug effects/secretion | 2 | 33.0 |
Vascular Endothelial Growth Factor A/*blood/secretion | 2 | 100.0 |
Adenocarcinoma/*genetics/pathology | 2 | 2.0 |
Vascular Endothelial Growth Factor A/blood/*genetics | 2 | 100.0 |
Vascular Endothelial Growth Factor A/*antagonists & inhibitors/genetics | 2 | 100.0 |
Hemangioma/*metabolism/pathology | 2 | 40.0 |
DNA Replication | 5 | 1.0 |
Fibroblasts/pathology | 2 | 2.0 |
Fibrosarcoma/pathology | 2 | 11.0 |
Neovascularization, Pathologic/chemically induced | 2 | 100.0 |
Mathematics | 2 | 1.0 |
Neoplasms/*blood supply/*pathology | 4 | 66.0 |
Glucocorticoids/*pharmacology | 2 | 1.0 |
Chimeric Proteins | 2 | 2.0 |
Endothelium, Vascular/drug effects/*physiology | 8 | 15.0 |
Placenta/*chemistry | 7 | 20.0 |
Receptors, Mitogen/*analysis | 2 | 20.0 |
Muscle, Smooth, Vascular/cytology/*metabolism | 2 | 9.0 |
Erythropoietin/biosynthesis/*genetics | 2 | 15.0 |
Carrier Proteins/*genetics | 3 | 0.0 |
Dobutamine/pharmacology | 2 | 40.0 |
*Myocardial Ischemia | 2 | 66.0 |
Bone Marrow/*metabolism | 3 | 6.0 |
Leukocytes, Mononuclear/chemistry/metabolism | 2 | 25.0 |
Vascular Endothelial Growth Factor A/analysis/*metabolism | 3 | 100.0 |
Catechin/*pharmacology | 2 | 25.0 |
Tea/chemistry | 2 | 14.0 |
Chimeric Proteins/genetics/metabolism | 2 | 2.0 |
Dipeptides/pharmacology | 2 | 4.0 |
Thiophenes/pharmacology | 3 | 8.0 |
Cell Line, Tumor/metabolism | 2 | 16.0 |
Platelet-Derived Growth Factor/*metabolism | 2 | 8.0 |
Retina/*metabolism/pathology | 3 | 42.0 |
Retinal Vessels/metabolism/pathology | 4 | 80.0 |
Paclitaxel/*pharmacology | 3 | 4.0 |
Endometrial Neoplasms/*genetics | 2 | 4.0 |
Pregnancy Complications/*blood | 2 | 5.0 |
Thyroid Neoplasms/*blood | 2 | 12.0 |
Immunoassay/methods | 3 | 5.0 |
Ischemia/*pathology | 2 | 40.0 |
C-Reactive Protein/*metabolism | 3 | 0.0 |
Endothelial Growth Factors/*biosynthesis/*pharmacology | 2 | 100.0 |
Lymphokines/*biosynthesis/*pharmacology | 2 | 66.0 |
Plicamycin/pharmacology | 3 | 18.0 |
Endothelial Growth Factors/*chemistry | 3 | 100.0 |
Lymphokines/*chemistry | 3 | 27.0 |
Edema/*etiology/pathology | 2 | 100.0 |
Retinal Vessels/*pathology | 3 | 30.0 |
Ovarian Neoplasms/*chemistry | 2 | 15.0 |
Medulla Oblongata | 2 | 100.0 |
Culture Media, Serum-Free/chemistry/pharmacology | 2 | 100.0 |
Dendritic Cells/*drug effects/immunology | 2 | 14.0 |
Pigment Epithelium of Eye/cytology/drug effects/*metabolism | 2 | 18.0 |
Reperfusion | 2 | 18.0 |
Biopolymers | 2 | 1.0 |
Platelet-Derived Growth Factor/genetics/*physiology | 2 | 66.0 |
RNA, Antisense | 2 | 3.0 |
Pregnancy Proteins/*biosynthesis/genetics | 3 | 75.0 |
Muscle, Smooth, Vascular/*cytology/drug effects | 3 | 33.0 |
Endometrium/chemistry | 2 | 20.0 |
Peritoneal Cavity | 3 | 30.0 |
Mastectomy | 5 | 7.0 |
Cytokines/biosynthesis | 4 | 0.0 |
Osteoblasts/metabolism | 2 | 3.0 |
United States Food and Drug Administration | 2 | 15.0 |
Vascular Endothelial Growth Factor Receptor-2/immunology/*metabolism | 2 | 100.0 |
*Melanoma | 2 | 25.0 |
*Skin Neoplasms | 2 | 20.0 |
Vascular Endothelial Growth Factor Receptor-2/*genetics/metabolism | 3 | 75.0 |
Skin Neoplasms/*drug therapy | 2 | 10.0 |
Paclitaxel/*administration & dosage | 3 | 37.0 |
Antibodies, Monoclonal/administration & dosage | 2 | 6.0 |
Intercellular Adhesion Molecule-1/*blood | 2 | 3.0 |
Angiopoietin-1/*biosynthesis | 2 | 100.0 |
Antineoplastic Agents/administration & dosage/*pharmacology | 3 | 17.0 |
Vascular Endothelial Growth Factor A/*biosynthesis/drug effects | 4 | 100.0 |
Endothelium, Vascular/*cytology/drug effects/*physiology | 2 | 18.0 |
Oncogene Proteins/*metabolism | 3 | 3.0 |
Cell Differentiation/*genetics | 2 | 2.0 |
Adenosine/pharmacology | 2 | 8.0 |
Blood Pressure/*drug effects | 2 | 1.0 |
Ischemia/etiology/*metabolism | 2 | 100.0 |
Chromosomes, Human, Pair 6/*genetics | 2 | 1.0 |
Cosmids | 2 | 0.0 |
*Gene Therapy/adverse effects | 2 | 40.0 |
Tensile Strength | 2 | 10.0 |
Protein-Tyrosine Kinase/*genetics | 2 | 0.0 |
Antibodies, Viral/blood | 3 | 2.0 |
Vascular Endothelial Growth Factor A/*blood/*genetics | 2 | 100.0 |
Angiopoietin-1/genetics/metabolism | 3 | 100.0 |
Angiopoietin-2/genetics/metabolism | 2 | 100.0 |
Follicle Stimulating Hormone/pharmacology | 3 | 5.0 |
Superovulation | 2 | 33.0 |
Adenoviridae | 4 | 4.0 |
Isoenzymes/analysis | 2 | 3.0 |
Prostaglandin-Endoperoxide Synthase/analysis | 2 | 25.0 |
Calcium/*pharmacology | 2 | 2.0 |
Protein Engineering | 4 | 4.0 |
Beclomethasone/therapeutic use | 3 | 50.0 |
Inflammation/etiology | 2 | 5.0 |
Diabetes Mellitus, Type 2 | 2 | 33.0 |
Muscle, Smooth/cytology | 2 | 8.0 |
Acquired Immunodeficiency Syndrome/*complications | 2 | 1.0 |
Endometrial Neoplasms/*metabolism | 3 | 9.0 |
Antigens, CD31 | 3 | 8.0 |
Endothelial Growth Factors/*genetics/isolation & purification/*metabolism | 2 | 100.0 |
Lymphokines/*genetics/isolation & purification/*metabolism | 2 | 100.0 |
Receptor Protein-Tyrosine Kinases/isolation & purification/*metabolism | 2 | 50.0 |
Receptors, Growth Factor/isolation & purification/*metabolism | 2 | 100.0 |
Heparitin Sulfate/pharmacology | 3 | 23.0 |
Oligonucleotide Probes/genetics | 4 | 3.0 |
Antigens/analysis | 2 | 1.0 |
Carcinoma, Hepatocellular/blood supply/*metabolism/pathology | 2 | 100.0 |
Pregnancy Proteins/*genetics | 3 | 8.0 |
Protein Hybridization | 2 | 3.0 |
Vascular Endothelial Growth Factor A/drug effects/metabolism | 2 | 100.0 |
Platelet Aggregation Inhibitors/therapeutic use | 3 | 10.0 |
Repressor Proteins/*genetics | 2 | 0.0 |
Baculoviridae/genetics | 2 | 1.0 |
B-Lymphocytes/*metabolism | 2 | 1.0 |
Sequence Analysis | 2 | 0.0 |
Lectins/metabolism | 3 | 3.0 |
Vascular Endothelial Growth Factor A/biosynthesis/metabolism | 4 | 100.0 |
Cyclins/metabolism | 2 | 0.0 |
Patient Acceptance of Health Care | 2 | 8.0 |
Myocardium/metabolism/*pathology | 2 | 10.0 |
Colonic Neoplasms/*blood supply | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/complications | 2 | 4.0 |
Lung/blood supply/pathology | 2 | 100.0 |
Hematopoietic Stem Cells/*physiology | 2 | 1.0 |
Radiation, Ionizing | 2 | 1.0 |
Oligonucleotide Probes | 2 | 0.0 |
Endothelium | 2 | 28.0 |
Immunoglobulin G/genetics/metabolism | 2 | 25.0 |
Sulfonamides/*therapeutic use | 2 | 28.0 |
NF-kappa B/antagonists & inhibitors/metabolism | 2 | 6.0 |
Colonic Neoplasms/blood supply/metabolism/*pathology | 2 | 66.0 |
Melanoma/*pathology | 2 | 3.0 |
Thyroid Neoplasms/genetics/*metabolism | 2 | 20.0 |
Inflammation/complications | 2 | 40.0 |
Macrophages/*metabolism/physiology | 2 | 50.0 |
Extracellular Matrix Proteins/genetics/metabolism | 3 | 33.0 |
Proto-Oncogene Protein c-kit/*biosynthesis | 2 | 18.0 |
Protein p53/biosynthesis/genetics | 3 | 6.0 |
Receptor, erbB-2/*genetics | 2 | 5.0 |
Blood Donors | 2 | 0.0 |
Interleukin-10/*metabolism | 2 | 6.0 |
Angiopoietin-2/*blood | 3 | 100.0 |
Receptor, TIE-2/*blood | 3 | 100.0 |
Hyaluronic Acid/analysis | 2 | 22.0 |
*Enhancer Elements (Genetics) | 2 | 0.0 |
Drug Stability | 4 | 1.0 |
Growth Substances/pharmacology/*physiology | 2 | 14.0 |
Homozygote | 2 | 0.0 |
Fibroblasts/drug effects/*physiology | 2 | 16.0 |
Vascular Endothelial Growth Factor C/*genetics | 2 | 100.0 |
Extracellular Matrix Proteins/*blood | 2 | 50.0 |
Norpregnenes/*pharmacology | 2 | 20.0 |
Vascular Endothelial Growth Factors/*analysis | 3 | 100.0 |
Peptides/*physiology | 2 | 4.0 |
Retinal Diseases/metabolism | 2 | 50.0 |
Brain Neoplasms/*blood supply/*pathology | 3 | 100.0 |
Glioblastoma/*blood supply/*pathology | 2 | 100.0 |
Genetic Vectors/*administration & dosage/genetics | 2 | 12.0 |
Mitogen-Activated Protein Kinase Kinases/*metabolism | 2 | 3.0 |
Adenocarcinoma/blood/*complications/metabolism | 2 | 100.0 |
Lung Neoplasms/blood/*complications/metabolism | 2 | 100.0 |
Vascular Endothelial Growth Factor A/biosynthesis/*blood | 3 | 100.0 |
Growth Inhibitors/therapeutic use | 2 | 50.0 |
Pregnancy Proteins/*analysis | 2 | 1.0 |
Kidney/chemistry | 2 | 4.0 |
Vascular Endothelial Growth Factor Receptor-2/*analysis | 6 | 85.0 |
K562 Cells | 7 | 1.0 |
Vascular Endothelial Growth Factor A/*antagonists & inhibitors/*genetics | 2 | 100.0 |
Vascular Endothelial Growth Factor A/*analysis/physiology | 2 | 100.0 |
Placenta/blood supply/*metabolism/pathology | 2 | 66.0 |
Placenta Diseases/metabolism/pathology | 2 | 66.0 |
Receptor, IGF Type 1/*metabolism | 2 | 5.0 |
Neovascularization, Pathologic/drug therapy/metabolism | 3 | 100.0 |
Plant Extracts/pharmacology | 3 | 7.0 |
Receptor, erbB-2/*drug effects | 3 | 75.0 |
Caspases/antagonists & inhibitors | 2 | 4.0 |
Mesenchymal Stem Cells/*cytology | 2 | 25.0 |
Genes, fos | 2 | 1.0 |
Placenta/cytology/*metabolism | 2 | 11.0 |
Alternative Splicing/genetics | 2 | 1.0 |
Kidney/*metabolism | 2 | 1.0 |
Carcinoma, Ductal, Breast/*metabolism | 3 | 27.0 |
Ovarian Neoplasms/*enzymology/*pathology | 2 | 66.0 |
Breast Neoplasms/*drug therapy | 2 | 3.0 |
Angiopoietin-1/*physiology | 2 | 100.0 |
Pleural Effusion, Malignant/blood/*metabolism | 2 | 100.0 |
Tuberculosis, Pleural/blood/*metabolism | 2 | 100.0 |
Phytoestrogens | 2 | 7.0 |
Plant Preparations/*pharmacology | 2 | 28.0 |
Lipoproteins/blood | 2 | 0.0 |
Lymphokines/antagonists & inhibitors/*pharmacology | 3 | 100.0 |
Tissue Plasminogen Activator/biosynthesis | 2 | 13.0 |
Chemotaxis/physiology | 3 | 9.0 |
Cell Cycle Proteins/biosynthesis | 2 | 7.0 |
*Disease Outbreaks | 2 | 3.0 |
Integrins/metabolism | 5 | 3.0 |
Hydrogen Peroxide/*metabolism | 2 | 5.0 |
Cisplatin/pharmacology | 2 | 1.0 |
Anthracyclines/therapeutic use | 2 | 66.0 |
Antigens, CD45/metabolism | 2 | 2.0 |
Receptors, Interleukin-6/metabolism | 2 | 7.0 |
Adenocarcinoma/*blood/surgery | 2 | 66.0 |
Vascular Endothelial Growth Factor Receptor-1/physiology | 2 | 100.0 |
Retina/*cytology/metabolism | 2 | 40.0 |
*Cryopreservation | 2 | 3.0 |
RNA, Neoplasm/*analysis | 3 | 6.0 |
Angiopoietin-1/genetics | 3 | 100.0 |
Angiopoietin-2/*biosynthesis | 3 | 100.0 |
Carcinoma/*metabolism/mortality | 2 | 40.0 |
NIH 3T3 Cells | 6 | 2.0 |
Pre-Eclampsia/*blood/diagnosis | 3 | 75.0 |
Turkey | 2 | 1.0 |
Decidua/*physiology | 2 | 11.0 |
Vascular Endothelial Growth Factor Receptor-2/*genetics | 3 | 75.0 |
Agar/chemistry | 2 | 33.0 |
Receptors, Vascular Endothelial Growth Factor/*antagonists & inhibitors | 8 | 80.0 |
Neuropilin-1/*biosynthesis | 2 | 100.0 |
Pancreatic Neoplasms/*metabolism | 3 | 4.0 |
Tunicamycin/pharmacology | 3 | 3.0 |
Brain Edema/*etiology/*metabolism | 2 | 66.0 |
Ki-67 Antigen/*biosynthesis | 3 | 11.0 |
Uterine Neoplasms/*metabolism/pathology | 2 | 13.0 |
Receptor Protein-Tyrosine Kinases/drug effects/*metabolism | 2 | 33.0 |
Receptors, Growth Factor/drug effects/*metabolism | 2 | 100.0 |
Extracellular Matrix/drug effects/*metabolism | 2 | 20.0 |
Vascular Endothelial Growth Factors/*genetics | 2 | 100.0 |
*Hepatectomy | 2 | 5.0 |
Liver Regeneration | 2 | 4.0 |
Vascular Endothelial Growth Factor Receptor-1/genetics | 3 | 60.0 |
Adenocarcinoma/*metabolism/secretion | 2 | 100.0 |
Amino Acids/metabolism | 2 | 2.0 |
Breast Neoplasms/*metabolism/secretion | 2 | 100.0 |
CCAAT-Enhancer-Binding Proteins/biosynthesis | 2 | 50.0 |
DNA Damage/drug effects/physiology | 2 | 33.0 |
Glutamine/metabolism | 2 | 8.0 |
Heat-Shock Proteins/biosynthesis | 2 | 25.0 |
Interleukin-8/*biosynthesis/secretion | 2 | 66.0 |
Vascular Endothelial Growth Factors/*biosynthesis/secretion | 2 | 100.0 |
*Cerebrovascular Circulation | 2 | 5.0 |
RNA, Neoplasm/genetics/isolation & purification | 3 | 4.0 |
Leiomyosarcoma | 2 | 66.0 |
Vascular Endothelial Growth Factor D/*biosynthesis | 2 | 100.0 |
Ultrasonography, Doppler/methods | 2 | 33.0 |
Vascular Endothelial Growth Factor A/analysis/metabolism | 4 | 80.0 |
Crohn Disease/*metabolism | 3 | 20.0 |
Estrogen Receptor Modulators/*pharmacology | 3 | 12.0 |
Vascular Endothelial Growth Factor A/*blood/physiology | 3 | 100.0 |
Phosphopyruvate Hydratase/metabolism | 2 | 3.0 |
Vascular Endothelial Growth Factor A/*biosynthesis/*genetics/metabolism | 3 | 100.0 |
Endothelial Cells/cytology/*metabolism | 2 | 13.0 |
*Cell Survival | 2 | 5.0 |
DNA/genetics/isolation & purification | 2 | 0.0 |
Granulosa Cells/drug effects/*physiology | 2 | 33.0 |
Angiopoietin-1/biosynthesis/genetics | 2 | 100.0 |
Angiopoietin-2/biosynthesis/genetics | 2 | 100.0 |
Intercellular Signaling Peptides and Proteins/*secretion | 3 | 100.0 |
Prostaglandins/metabolism | 2 | 11.0 |
Receptors, Cytoplasmic and Nuclear/*metabolism | 2 | 1.0 |
Liver Neoplasms/pathology/*therapy | 2 | 28.0 |
Pulmonary Artery/*pathology | 2 | 33.0 |
Genistein/*pharmacology | 2 | 6.0 |
Blood Coagulation | 4 | 2.0 |
Kidney Failure, Chronic/*blood/physiopathology/*therapy | 2 | 50.0 |
Prednisone/administration & dosage | 2 | 2.0 |
Mitogen-Activated Protein Kinase 1/antagonists & inhibitors/*metabolism | 2 | 20.0 |
Vascular Endothelial Growth Factor A/antagonists & inhibitors/physiology | 2 | 100.0 |
Circular Dichroism | 2 | 0.0 |
Interleukin-10/blood | 2 | 2.0 |
Integrin alphaVbeta3/metabolism | 2 | 22.0 |
Angiogenesis Inhibitors | 3 | 27.0 |
Endothelium, Vascular/*cytology/pathology | 2 | 66.0 |
Colorectal Neoplasms/pathology | 2 | 14.0 |
Repressor Proteins/*metabolism | 2 | 1.0 |
Placenta/blood supply | 3 | 20.0 |
Matrix Metalloproteinases/*genetics/*metabolism | 2 | 25.0 |
*Implants, Experimental | 2 | 50.0 |
Testosterone/blood | 2 | 0.0 |
Leydig Cells/cytology/*physiology | 2 | 100.0 |
Vascular Endothelial Growth Factor B/metabolism | 2 | 100.0 |
Heart Transplantation | 2 | 5.0 |
Endothelium, Vascular/chemistry/*cytology/metabolism | 2 | 50.0 |
Heparin Lyase/pharmacology | 2 | 15.0 |
Endothelium, Vascular/growth & development | 2 | 100.0 |
Vascular Endothelial Growth Factor A/*administration & dosage/pharmacolog | 2 | 100.0 |
Transcription, Genetic/drug effects/physiology | 3 | 7.0 |
Umbilical Veins/chemistry/cytology/metabolism | 2 | 100.0 |
Bone Regeneration/*physiology | 2 | 100.0 |
Transforming Growth Factor beta/metabolism/secretion | 2 | 100.0 |
Kidney Glomerulus/metabolism/pathology | 2 | 16.0 |
Plasmids/administration & dosage/genetics | 3 | 37.0 |
Vascular Endothelial Growth Factor Receptor-1/analysis/*biosynthesis | 2 | 100.0 |
Vascular Endothelial Growth Factor Receptor-2/analysis/*biosynthesis | 2 | 100.0 |
Receptors, Vascular Endothelial Growth Factor/physiology | 4 | 100.0 |
Gelatinase B/*metabolism/pharmacology | 2 | 100.0 |
Multiple Myeloma/drug therapy/*pathology | 2 | 50.0 |
RNA, Small Interfering | 3 | 5.0 |
Pancreatic Neoplasms/blood supply/pathology/*therapy | 2 | 100.0 |
Heme Oxygenase (Decyclizing)/*biosynthesis/genetics | 2 | 100.0 |
Reperfusion Injury/metabolism | 2 | 28.0 |
Breast Neoplasms/*blood supply/*drug therapy | 2 | 100.0 |
Cell Cycle/*physiology | 2 | 0.0 |
Medical Records | 2 | 2.0 |
Retinal Vessels/pathology/*physiopathology | 2 | 100.0 |
Obesity/*blood | 2 | 2.0 |
Sodium Chloride/pharmacology | 2 | 2.0 |
Blood Circulation | 2 | 10.0 |
Vascular Diseases/therapy | 2 | 66.0 |
Membrane Proteins/*physiology | 2 | 1.0 |
Esophageal Neoplasms/*metabolism/*pathology | 2 | 50.0 |
Trans-Activators/genetics/metabolism | 3 | 1.0 |
Mitomycin/administration & dosage | 2 | 5.0 |
Thromboplastin/analysis | 2 | 7.0 |
Vascular Endothelial Growth Factor Receptor-1/blood | 4 | 100.0 |
Adenoma/*blood supply/chemistry/metabolism | 2 | 100.0 |
Trans-Activators/genetics/*metabolism | 4 | 1.0 |
Lung Neoplasms/*drug therapy | 2 | 4.0 |
*Placental Circulation | 2 | 66.0 |
Renin-Angiotensin System/drug effects | 2 | 3.0 |
Proto-Oncogene Protein c-kit/biosynthesis | 2 | 13.0 |
Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism | 2 | 9.0 |
Cell Line, Tumor/*metabolism | 2 | 100.0 |
Endothelial Cells/cytology/metabolism | 2 | 12.0 |
Glycoproteins/*metabolism | 2 | 1.0 |
Growth Substances/genetics | 3 | 4.0 |
alpha-Tocopherol/pharmacology | 2 | 18.0 |
Antigens, CD31/*biosynthesis/immunology | 2 | 100.0 |
Vascular Endothelial Growth Factor A/blood/genetics | 3 | 100.0 |
Gene Expression Regulation, Neoplastic/drug effects/physiology | 4 | 10.0 |
Receptor, IGF Type 1/metabolism | 3 | 9.0 |
Breast Neoplasms/chemistry/*metabolism | 2 | 18.0 |
Surgical Mesh | 3 | 75.0 |
Endothelial Cells/cytology/*drug effects/*metabolism | 2 | 100.0 |
Carcinoma, Renal Cell/*drug therapy | 2 | 28.0 |
Kidney Neoplasms/*drug therapy | 3 | 37.0 |
Angiopoietin-1/*biosynthesis/genetics | 2 | 100.0 |
Angiopoietin-2/*biosynthesis/genetics | 2 | 100.0 |
Xenograft Model Antitumor Assays/methods | 3 | 30.0 |
Antineoplastic Agents/administration & dosage | 2 | 6.0 |
Antineoplastic Agents, Phytogenic/therapeutic use | 2 | 14.0 |
Body Composition | 2 | 0.0 |
Osteogenesis/*physiology | 2 | 10.0 |
Stromal Cells/*physiology | 2 | 8.0 |
Bone Neoplasms/blood supply/pathology/*physiopathology | 2 | 100.0 |
Nerve Growth Factors/metabolism | 3 | 5.0 |
Spinal Cord/cytology/metabolism | 2 | 13.0 |
Mammaplasty | 2 | 28.0 |
Rana pipiens | 2 | 22.0 |
Vascular Endothelial Growth Factor Receptor-2/*biosynthesis/genetics | 2 | 100.0 |
*Nervous System | 2 | 18.0 |
*Nervous System Diseases | 2 | 18.0 |
*Neurology | 2 | 16.0 |
Platelet Aggregation | 2 | 1.0 |
Arterial Occlusive Diseases/etiology/*radiography/therapy | 2 | 9.0 |
Balloon Dilatation/methods | 2 | 8.0 |
Coronary Angiography/methods | 2 | 8.0 |
Coronary Vessels/pathology | 2 | 4.0 |
Arthritis, Rheumatoid/*complications/radiography | 2 | 10.0 |
Atlanto-Axial Joint/radiography | 2 | 10.0 |
*Cervical Vertebrae/radiography | 2 | 9.0 |
Dislocations/etiology/radiography | 2 | 10.0 |
Neck Pain/etiology | 2 | 10.0 |
Spinal Diseases/*etiology/radiography | 2 | 10.0 |
*Drug Approval | 2 | 28.0 |
Genome, Human | 2 | 0.0 |
Graft Survival/*drug effects/physiology | 2 | 66.0 |
Adenoviridae/*genetics/immunology | 2 | 18.0 |
Veins | 3 | 5.0 |
Cytokines/*biosynthesis/metabolism | 3 | 50.0 |
Vascular Endothelial Growth Factor A/blood/*physiology | 2 | 100.0 |
*Blood Pressure Monitoring, Ambulatory | 8 | 44.0 |
Cardiovascular Diseases/*diagnosis/*mortality/physiopathology | 8 | 80.0 |
Data Collection | 8 | 9.0 |
Ireland/epidemiology | 8 | 22.0 |
Methods | 8 | 3.0 |
Mortality | 8 | 25.0 |
Metalloproteases/*physiology | 4 | 66.0 |
Muscle, Skeletal/*blood supply/physiology | 4 | 66.0 |
Liver Neoplasms/*blood/drug therapy/secondary | 2 | 66.0 |
Neuropilin-1/*physiology | 3 | 60.0 |
Carcinoma, Squamous Cell/*genetics/metabolism | 2 | 7.0 |
Intercellular Signaling Peptides and Proteins/analysis/*genetics | 8 | 80.0 |
Cystadenocarcinoma, Serous/metabolism/pathology | 2 | 25.0 |
Vascular Endothelial Growth Factor Receptor-1/biosynthesis | 2 | 100.0 |
Intercellular Signaling Peptides and Proteins/pharmacology/*physiology | 4 | 40.0 |
Transforming Growth Factor beta/analysis/biosynthesis | 2 | 100.0 |
Vascular Endothelial Growth Factor A/analysis/biosynthesis | 2 | 100.0 |
Vascular Endothelial Growth Factor A/antagonists & inhibitors/*physiology | 2 | 100.0 |
Nerve Growth Factors/analysis | 2 | 16.0 |
Cyclin D1/*metabolism | 2 | 3.0 |
Intercellular Signaling Peptides and Proteins/blood/physiology | 2 | 66.0 |
POEMS Syndrome/diagnosis/*therapy | 2 | 100.0 |
*Proteins | 2 | 0.0 |
Heat-Shock Proteins/metabolism | 2 | 3.0 |
Intercellular Signaling Peptides and Proteins/biosynthesis/genetics | 7 | 63.0 |
Biocompatible Materials/*pharmacology | 2 | 28.0 |
Lipid Peroxidation | 2 | 1.0 |
Surgical Flaps/*physiology | 3 | 100.0 |
Plasmin/*metabolism | 2 | 7.0 |
Vascular Endothelial Growth Factor Receptor-3/metabolism | 2 | 66.0 |
Intercellular Signaling Peptides and Proteins/*immunology | 3 | 75.0 |
Phosphoric Monoester Hydrolases/*genetics/metabolism | 2 | 6.0 |
Indoles/*administration & dosage | 2 | 18.0 |
Pyrroles/*administration & dosage | 2 | 40.0 |
Mitogen-Activated Protein Kinases/*biosynthesis | 2 | 22.0 |
Intercellular Signaling Peptides and Proteins/genetics/*physiology | 2 | 40.0 |
Multiple Myeloma/blood/*diagnosis/mortality | 2 | 100.0 |
Bronchoalveolar Lavage Fluid/cytology | 2 | 1.0 |
Microsatellite Repeats/*genetics | 2 | 0.0 |
Intercellular Signaling Peptides and Proteins/secretion | 2 | 50.0 |
Colitis, Ulcerative/*metabolism | 2 | 11.0 |
Thiophenes/therapeutic use | 2 | 66.0 |
Enzyme Activation/drug effects/physiology | 2 | 3.0 |
Cyclooxygenase Inhibitors/therapeutic use | 2 | 18.0 |
Vascular Endothelial Growth Factor A/biosynthesis/genetics/*physiology | 2 | 100.0 |
Neuroglia/*physiology | 2 | 7.0 |
NADPH Oxidase/*metabolism | 2 | 4.0 |
Immune Sera/pharmacology | 2 | 2.0 |
Paclitaxel/administration & dosage | 2 | 7.0 |
Intercellular Signaling Peptides and Proteins/biosynthesis | 14 | 56.0 |
Monosaccharide Transport Proteins/biosynthesis | 2 | 40.0 |
Angiogenic Proteins/*blood | 2 | 100.0 |
Cysteine Endopeptidases/metabolism | 2 | 0.0 |
Polymers | 2 | 1.0 |
Stem Cells/*metabolism | 2 | 5.0 |
Synovial Membrane/blood supply/chemistry/pathology | 2 | 100.0 |
Collagen/*metabolism/pharmacology | 2 | 40.0 |
Neoplasm Proteins/*biosynthesis/genetics/physiology | 3 | 20.0 |
Polymorphism, Single Nucleotide/*genetics | 2 | 0.0 |
Ovarian Neoplasms/metabolism/*pathology | 2 | 12.0 |
Receptors, Vascular Endothelial Growth Factor/*physiology | 5 | 100.0 |
Agar/pharmacology | 2 | 20.0 |
Immunoglobulin G/blood | 2 | 0.0 |
Melanoma/*blood supply/metabolism/*pathology | 2 | 50.0 |
Skin Neoplasms/*blood supply/metabolism/*pathology | 2 | 100.0 |
Adenine/*analogs & derivatives/pharmacology | 2 | 13.0 |
Paclitaxel/pharmacology | 3 | 3.0 |
Administration, Cutaneous | 2 | 2.0 |
Vascular Endothelial Growth Factor Receptor-1/biosynthesis/genetics | 2 | 66.0 |
Vascular Endothelial Growth Factor Receptor-3/biosynthesis/genetics | 2 | 100.0 |
Skin Neoplasms/*pathology | 2 | 2.0 |
Peritoneal Neoplasms/secondary | 3 | 21.0 |
Microscopic Angioscopy | 2 | 100.0 |
Stomach Neoplasms/*blood supply/*chemistry/pathology | 2 | 100.0 |
Carcinoma, Renal Cell/*genetics/metabolism | 2 | 13.0 |
Kidney Neoplasms/*genetics/metabolism | 2 | 7.0 |
Drug Screening Assays, Antitumor/methods | 2 | 12.0 |
Plant Extracts/*pharmacology | 2 | 2.0 |
Paclitaxel/therapeutic use | 2 | 22.0 |
Carcinoma, Small Cell/*pathology | 2 | 15.0 |
Intercellular Signaling Peptides and Proteins/blood/*genetics | 2 | 66.0 |
Bone Marrow Cells/*drug effects/metabolism | 3 | 60.0 |
DNA, Antisense/*genetics | 2 | 15.0 |
Pterygium/*metabolism | 2 | 40.0 |
Synovial Membrane/cytology/metabolism | 2 | 22.0 |
Neoplasms/blood supply/drug therapy/pathology | 2 | 100.0 |
Alprostadil/*therapeutic use | 2 | 50.0 |
Intercellular Signaling Peptides and Proteins/analysis/*metabolism | 2 | 100.0 |
Recombinant Fusion Proteins/biosynthesis/physiology | 2 | 18.0 |
Intercellular Signaling Peptides and Proteins/metabolism/pharmacology | 4 | 80.0 |
Cyclins/analysis | 2 | 4.0 |
Breast/*metabolism | 2 | 3.0 |
Intercellular Signaling Peptides and Proteins/blood/*metabolism | 6 | 100.0 |
Serpins/genetics/*metabolism | 2 | 28.0 |
Nasal Mucosa/metabolism | 2 | 18.0 |
Neural Networks (Computer) | 2 | 8.0 |
Interleukin-10/*pharmacology | 2 | 2.0 |
Intercellular Signaling Peptides and Proteins/*blood/*genetics | 2 | 100.0 |
Platelet Factor 4/analysis | 2 | 2.0 |
Intercellular Signaling Peptides and Proteins/*analysis/genetics | 4 | 50.0 |
Response Elements/genetics | 2 | 1.0 |
Anti-Asthmatic Agents/therapeutic use | 2 | 33.0 |
Receptors, Somatostatin/metabolism | 2 | 11.0 |
Receptors, Endothelin/*antagonists & inhibitors | 2 | 15.0 |
Tumor Markers, Biological/blood/*metabolism | 3 | 37.0 |
Stromal Cells/*drug effects/metabolism | 3 | 60.0 |
Intercellular Signaling Peptides and Proteins/immunology/*pharmacology | 2 | 100.0 |
Receptors, Estrogen/*biosynthesis | 2 | 8.0 |
Heme Oxygenase (Decyclizing)/metabolism | 2 | 22.0 |
Recombinant Proteins/genetics/metabolism/pharmacology | 2 | 10.0 |
Intercellular Signaling Peptides and Proteins/*physiology | 7 | 26.0 |
Vascular Endothelial Growth Factor A/*antagonists & inhibitors/physiology | 2 | 100.0 |
Endometriosis/complications/*metabolism | 2 | 100.0 |
Retinal Vessels/*cytology | 2 | 100.0 |
Intercellular Signaling Peptides and Proteins/*genetics/*metabolism | 2 | 40.0 |
Prostatic Neoplasms/*drug therapy/pathology | 2 | 14.0 |
Intercellular Signaling Peptides and Proteins/immunology | 2 | 100.0 |
Monocyte Chemoattractant Protein-1/*biosynthesis | 2 | 25.0 |
Butyrates/*pharmacology | 2 | 4.0 |
Pancreatic Neoplasms/blood supply/metabolism/*pathology | 2 | 66.0 |
Lymphoma, Non-Hodgkin/*metabolism/pathology | 2 | 33.0 |
Receptors, Vascular Endothelial Growth Factor/biosynthesis/genetics | 2 | 100.0 |
Capillaries/physiopathology | 2 | 25.0 |
Ligation | 2 | 2.0 |
Cytarabine/administration & dosage | 2 | 2.0 |
Daunorubicin/administration & dosage | 2 | 5.0 |
Benzofurans/*pharmacology | 2 | 20.0 |
Phytotherapy | 2 | 7.0 |
Gene Expression Regulation/*drug effects/physiology | 2 | 11.0 |
Intercellular Signaling Peptides and Proteins/*biosynthesis/blood | 2 | 100.0 |
Hepatocyte Growth Factor/*physiology | 2 | 3.0 |
Heme Oxygenase (Decyclizing)/*genetics | 2 | 15.0 |
Intercellular Signaling Peptides and Proteins/genetics/pharmacology | 2 | 100.0 |
RNA, Catalytic/*therapeutic use | 2 | 50.0 |
Endothelial Growth Factors/antagonists & inhibitors/*pharmacology | 2 | 100.0 |
Finasteride/*pharmacology/therapeutic use | 2 | 66.0 |
Pleural Effusion/*metabolism/pathology | 2 | 100.0 |
Ovarian Neoplasms/*blood/pathology | 2 | 40.0 |
Angiogenesis Inhibitors/*blood | 2 | 100.0 |
Calcium Signaling/*physiology | 2 | 4.0 |
Carcinoma | 2 | 5.0 |
Tissue Inhibitor of Metalloproteinase-1/genetics/metabolism | 2 | 15.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
Colorectal Neoplasms/*drug therapy/mortality/pathology | 3 | 60.0 |
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage | 2 | 3.0 |
Chondrocytes/cytology/physiology | 2 | 25.0 |
Liver Neoplasms/metabolism/secondary | 2 | 14.0 |
Oxidants/metabolism | 2 | 11.0 |
Tissue Extracts/chemistry/*pharmacology | 2 | 100.0 |
*Vascular Endothelial Growth Factor B | 2 | 100.0 |
Intercellular Signaling Peptides and Proteins/metabolism/*physiology | 2 | 40.0 |
